--06-30 2022 Q3 0001001250 false 0001001250 2021-07-01 2022-03-31 0001001250 us-gaap:CommonClassAMember 2022-04-26 xbrli:shares 0001001250 us-gaap:CommonClassBMember 2022-04-26 0001001250 2022-01-01 2022-03-31 iso4217:USD 0001001250 2021-01-01 2021-03-31 0001001250 2020-07-01 2021-03-31 iso4217:USD xbrli:shares 0001001250 2022-03-31 0001001250 2021-06-30 0001001250 us-gaap:CommonClassAMember 2022-03-31 0001001250 us-gaap:CommonClassAMember 2021-06-30 0001001250 us-gaap:CommonClassBMember 2021-06-30 0001001250 us-gaap:CommonClassBMember 2022-03-31 0001001250 2020-06-30 0001001250 2021-03-31 0001001250 el:LargestCustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 xbrli:pure 0001001250 el:LargestCustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001001250 el:LargestCustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2022-03-31 0001001250 el:LargestCustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2021-03-31 0001001250 us-gaap:AccountsReceivableMember el:LargestCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-03-31 0001001250 us-gaap:AccountsReceivableMember el:LargestCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2022-03-31 0001001250 us-gaap:AccountsReceivableMember el:LargestCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-06-30 0001001250 us-gaap:AccountsReceivableMember el:LargestCustomerMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2021-06-30 0001001250 us-gaap:LandMember 2022-03-31 0001001250 us-gaap:LandMember 2021-06-30 0001001250 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2021-07-01 2022-03-31 0001001250 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2021-07-01 2022-03-31 0001001250 us-gaap:BuildingAndBuildingImprovementsMember 2022-03-31 0001001250 us-gaap:BuildingAndBuildingImprovementsMember 2021-06-30 0001001250 us-gaap:MachineryAndEquipmentMember srt:MinimumMember 2021-07-01 2022-03-31 0001001250 us-gaap:MachineryAndEquipmentMember srt:MaximumMember 2021-07-01 2022-03-31 0001001250 us-gaap:MachineryAndEquipmentMember 2022-03-31 0001001250 us-gaap:MachineryAndEquipmentMember 2021-06-30 0001001250 el:ComputerHardwareAndSoftwareMember srt:MinimumMember 2021-07-01 2022-03-31 0001001250 srt:MaximumMember el:ComputerHardwareAndSoftwareMember 2021-07-01 2022-03-31 0001001250 el:ComputerHardwareAndSoftwareMember 2022-03-31 0001001250 el:ComputerHardwareAndSoftwareMember 2021-06-30 0001001250 us-gaap:FurnitureAndFixturesMember srt:MinimumMember 2021-07-01 2022-03-31 0001001250 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2021-07-01 2022-03-31 0001001250 us-gaap:FurnitureAndFixturesMember 2022-03-31 0001001250 us-gaap:FurnitureAndFixturesMember 2021-06-30 0001001250 us-gaap:LeaseholdImprovementsMember 2022-03-31 0001001250 us-gaap:LeaseholdImprovementsMember 2021-06-30 0001001250 us-gaap:ConstructionInProgressMember 2022-03-31 0001001250 us-gaap:ConstructionInProgressMember 2021-06-30 0001001250 el:OtherAssetImpairmentChargesMember 2020-07-01 2021-03-31 0001001250 el:OtherAssetImpairmentChargesMember 2021-01-01 2021-03-31 0001001250 us-gaap:InternalRevenueServiceIRSMember el:FiscalYear2020And2019Member 2021-01-01 2021-03-31 0001001250 us-gaap:InternalRevenueServiceIRSMember el:FiscalYear2020And2019Member 2020-07-01 2021-03-31 0001001250 us-gaap:OtherNoncurrentLiabilitiesMember 2022-03-31 0001001250 us-gaap:OtherNoncurrentLiabilitiesMember 2021-06-30 0001001250 us-gaap:RetainedEarningsMember srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate201912Member 2021-06-30 0001001250 el:DECIEMMember 2021-05-18 2021-05-18 0001001250 el:DECIEMMember 2021-05-18 0001001250 el:DECIEMMember 2021-05-17 0001001250 el:DECIEMMember 2021-05-18 0001001250 el:DECIEM2021StockOptionPlanMember el:DECIEMMember us-gaap:EmployeeStockOptionMember 2021-05-18 0001001250 el:DECIEMMember el:DECIEMMember 2021-05-18 0001001250 el:DECIEMMember 2022-03-31 2022-03-31 0001001250 el:DECIEMMember el:DECIEMMember 2022-03-31 2022-03-31 0001001250 el:DECIEM2021StockOptionPlanMember el:DECIEMMember us-gaap:EmployeeStockOptionMember 2022-03-31 0001001250 el:DECIEM2021StockOptionPlanMember el:DECIEMMember us-gaap:EmployeeStockOptionMember 2022-03-31 2022-03-31 0001001250 el:DECIEMMember 2022-03-31 0001001250 el:DECIEMMember el:DECIEMMember 2022-03-31 0001001250 el:DECIEM2021StockOptionPlanMember el:DECIEMMember us-gaap:EmployeeStockOptionMember 2021-05-18 2021-05-18 0001001250 el:DECIEMMember 2021-05-01 2021-05-31 0001001250 us-gaap:CustomerListsMember el:DECIEMMember 2021-05-01 2021-05-31 0001001250 el:DECIEMMember us-gaap:CustomerListsMember srt:MinimumMember 2021-05-01 2021-05-31 0001001250 srt:MaximumMember el:DECIEMMember us-gaap:CustomerListsMember 2021-05-01 2021-05-31 0001001250 el:DECIEMMember us-gaap:TrademarksMember 2021-05-01 2021-05-31 0001001250 el:SkinCareMember 2021-06-30 0001001250 el:MakeupMember 2021-06-30 0001001250 el:FragranceMember 2021-06-30 0001001250 el:HairCareMember 2021-06-30 0001001250 el:SkinCareMember 2021-07-01 2022-03-31 0001001250 el:MakeupMember 2021-07-01 2022-03-31 0001001250 el:FragranceMember 2021-07-01 2022-03-31 0001001250 el:HairCareMember 2021-07-01 2022-03-31 0001001250 el:SkinCareMember 2022-03-31 0001001250 el:MakeupMember 2022-03-31 0001001250 el:FragranceMember 2022-03-31 0001001250 el:HairCareMember 2022-03-31 0001001250 el:CustomerListsAndOtherMember 2022-03-31 0001001250 el:CustomerListsAndOtherMember 2021-06-30 0001001250 us-gaap:LicensingAgreementsMember 2022-03-31 0001001250 us-gaap:LicensingAgreementsMember 2021-06-30 0001001250 us-gaap:TrademarksMember 2022-03-31 0001001250 us-gaap:TrademarksMember 2021-06-30 0001001250 srt:AmericasMember el:GLAMGLOWMember us-gaap:TrademarksMember el:SkinCareMember 2022-01-01 2022-03-31 0001001250 srt:AmericasMember el:GLAMGLOWMember us-gaap:TrademarksMember el:SkinCareMember 2022-03-31 0001001250 el:TooFacedMember us-gaap:TrademarksMember 2022-03-31 0001001250 el:DECIEMMember us-gaap:TrademarksMember 2022-03-31 0001001250 el:TooFacedMember us-gaap:TrademarksMember 2021-07-01 2022-03-31 0001001250 el:DECIEMMember us-gaap:TrademarksMember 2021-07-01 2022-03-31 0001001250 el:DrJartMember us-gaap:TrademarksMember 2021-07-01 2022-03-31 0001001250 srt:AmericasMember el:GLAMGLOWMember el:SkinCareMember 2021-07-01 2022-03-31 0001001250 srt:AmericasMember el:GLAMGLOWMember el:SkinCareMember 2022-03-31 0001001250 el:DrJartMember srt:AsiaPacificMember el:SkinCareMember 2021-07-01 2022-03-31 0001001250 el:DrJartMember srt:AsiaPacificMember el:SkinCareMember 2022-03-31 0001001250 el:GLAMGLOWAndDrJartMember el:SkinCareMember 2021-07-01 2022-03-31 0001001250 el:GLAMGLOWAndDrJartMember el:SkinCareMember 2022-03-31 0001001250 srt:AmericasMember el:GLAMGLOWMember us-gaap:TrademarksMember el:SkinCareMember 2020-11-01 2020-11-30 0001001250 srt:AmericasMember el:GLAMGLOWMember us-gaap:CustomerListsMember el:SkinCareMember 2020-11-01 2020-11-30 0001001250 srt:AmericasMember el:GLAMGLOWMember el:SkinCareMember 2020-11-01 2020-11-30 0001001250 srt:AmericasMember el:GLAMGLOWMember el:SkinCareMember 2021-03-31 0001001250 srt:AmericasMember el:GLAMGLOWMember us-gaap:TrademarksMember el:SkinCareMember 2021-03-31 0001001250 us-gaap:SalesReturnsAndAllowancesMember el:PCBAProgramMember 2022-01-01 2022-03-31 0001001250 us-gaap:CostOfSalesMember el:PCBAProgramMember 2022-01-01 2022-03-31 0001001250 us-gaap:RestructuringChargesMember el:PCBAProgramMember 2022-01-01 2022-03-31 0001001250 us-gaap:OtherOperatingIncomeExpenseMember el:PCBAProgramMember 2022-01-01 2022-03-31 0001001250 el:PCBAProgramMember 2022-01-01 2022-03-31 0001001250 us-gaap:SalesReturnsAndAllowancesMember el:PCBAProgramMember 2021-07-01 2022-03-31 0001001250 us-gaap:CostOfSalesMember el:PCBAProgramMember 2021-07-01 2022-03-31 0001001250 us-gaap:RestructuringChargesMember el:PCBAProgramMember 2021-07-01 2022-03-31 0001001250 us-gaap:OtherOperatingIncomeExpenseMember el:PCBAProgramMember 2021-07-01 2022-03-31 0001001250 el:PCBAProgramMember 2021-07-01 2022-03-31 0001001250 el:PCBAProgramMember 2020-08-20 2020-08-20 0001001250 srt:MinimumMember el:PCBAProgramMember 2021-07-01 2022-03-31 el:position 0001001250 srt:MaximumMember el:PCBAProgramMember 2021-07-01 2022-03-31 0001001250 srt:MinimumMember el:PCBAProgramMember 2020-08-20 2020-08-20 0001001250 srt:MaximumMember el:PCBAProgramMember 2020-08-20 2020-08-20 0001001250 srt:MinimumMember el:PCBAProgramMember 2020-08-20 0001001250 srt:MaximumMember el:PCBAProgramMember 2020-08-20 0001001250 us-gaap:SalesReturnsAndAllowancesMember el:PCBAProgramMember 2021-06-30 0001001250 us-gaap:CostOfSalesMember el:PCBAProgramMember 2021-06-30 0001001250 us-gaap:RestructuringChargesMember el:PCBAProgramMember 2021-06-30 0001001250 us-gaap:OtherOperatingIncomeExpenseMember el:PCBAProgramMember 2021-06-30 0001001250 el:PCBAProgramMember 2021-06-30 0001001250 us-gaap:SalesReturnsAndAllowancesMember el:PCBAProgramMember 2022-03-31 0001001250 us-gaap:CostOfSalesMember el:PCBAProgramMember 2022-03-31 0001001250 us-gaap:RestructuringChargesMember el:PCBAProgramMember 2022-03-31 0001001250 us-gaap:OtherOperatingIncomeExpenseMember el:PCBAProgramMember 2022-03-31 0001001250 el:PCBAProgramMember 2022-03-31 0001001250 us-gaap:RestructuringChargesMember us-gaap:EmployeeSeveranceMember el:PCBAProgramMember 2021-06-30 0001001250 us-gaap:RestructuringChargesMember el:ImpairmentInValueOfAssetsMember el:PCBAProgramMember 2021-06-30 0001001250 us-gaap:RestructuringChargesMember us-gaap:ContractTerminationMember el:PCBAProgramMember 2021-06-30 0001001250 us-gaap:RestructuringChargesMember us-gaap:OtherRestructuringMember el:PCBAProgramMember 2021-06-30 0001001250 us-gaap:RestructuringChargesMember us-gaap:EmployeeSeveranceMember el:PCBAProgramMember 2021-07-01 2022-03-31 0001001250 us-gaap:RestructuringChargesMember el:ImpairmentInValueOfAssetsMember el:PCBAProgramMember 2021-07-01 2022-03-31 0001001250 us-gaap:RestructuringChargesMember us-gaap:ContractTerminationMember el:PCBAProgramMember 2021-07-01 2022-03-31 0001001250 us-gaap:RestructuringChargesMember us-gaap:OtherRestructuringMember el:PCBAProgramMember 2021-07-01 2022-03-31 0001001250 us-gaap:RestructuringChargesMember us-gaap:EmployeeSeveranceMember el:PCBAProgramMember 2022-03-31 0001001250 us-gaap:RestructuringChargesMember el:ImpairmentInValueOfAssetsMember el:PCBAProgramMember 2022-03-31 0001001250 us-gaap:RestructuringChargesMember us-gaap:ContractTerminationMember el:PCBAProgramMember 2022-03-31 0001001250 us-gaap:RestructuringChargesMember us-gaap:OtherRestructuringMember el:PCBAProgramMember 2022-03-31 0001001250 el:RestructuringAndOtherChargesMember us-gaap:EmployeeSeveranceMember el:PCBAProgramMember 2021-06-30 0001001250 el:RestructuringAndOtherChargesMember el:ImpairmentInValueOfAssetsMember el:PCBAProgramMember 2021-06-30 0001001250 el:RestructuringAndOtherChargesMember us-gaap:ContractTerminationMember el:PCBAProgramMember 2021-06-30 0001001250 el:RestructuringAndOtherChargesMember us-gaap:OtherRestructuringMember el:PCBAProgramMember 2021-06-30 0001001250 el:RestructuringAndOtherChargesMember el:PCBAProgramMember 2021-06-30 0001001250 el:RestructuringAndOtherChargesMember us-gaap:EmployeeSeveranceMember el:PCBAProgramMember 2021-07-01 2022-03-31 0001001250 el:RestructuringAndOtherChargesMember el:ImpairmentInValueOfAssetsMember el:PCBAProgramMember 2021-07-01 2022-03-31 0001001250 el:RestructuringAndOtherChargesMember us-gaap:ContractTerminationMember el:PCBAProgramMember 2021-07-01 2022-03-31 0001001250 el:RestructuringAndOtherChargesMember us-gaap:OtherRestructuringMember el:PCBAProgramMember 2021-07-01 2022-03-31 0001001250 el:RestructuringAndOtherChargesMember el:PCBAProgramMember 2021-07-01 2022-03-31 0001001250 el:RestructuringAndOtherChargesMember us-gaap:EmployeeSeveranceMember el:PCBAProgramMember 2022-03-31 0001001250 el:RestructuringAndOtherChargesMember el:ImpairmentInValueOfAssetsMember el:PCBAProgramMember 2022-03-31 0001001250 el:RestructuringAndOtherChargesMember us-gaap:ContractTerminationMember el:PCBAProgramMember 2022-03-31 0001001250 el:RestructuringAndOtherChargesMember us-gaap:OtherRestructuringMember el:PCBAProgramMember 2022-03-31 0001001250 el:RestructuringAndOtherChargesMember el:PCBAProgramMember 2022-03-31 0001001250 el:PCBAProgramMember srt:ScenarioForecastMember 2021-07-01 2022-06-30 0001001250 el:PCBAProgramMember srt:ScenarioForecastMember 2022-07-01 2023-06-30 0001001250 el:PCBAProgramMember srt:ScenarioForecastMember 2023-07-01 2024-06-30 0001001250 us-gaap:SubsequentEventMember el:PCBAProgramMember 2022-04-26 0001001250 us-gaap:SalesReturnsAndAllowancesMember us-gaap:SubsequentEventMember el:PCBAProgramMember 2022-04-01 2022-04-26 0001001250 us-gaap:CostOfSalesMember us-gaap:SubsequentEventMember el:PCBAProgramMember 2022-04-01 2022-04-26 0001001250 us-gaap:RestructuringChargesMember us-gaap:SubsequentEventMember el:PCBAProgramMember 2022-04-01 2022-04-26 0001001250 us-gaap:OtherOperatingIncomeExpenseMember us-gaap:SubsequentEventMember el:PCBAProgramMember 2022-04-01 2022-04-26 0001001250 us-gaap:SubsequentEventMember el:PCBAProgramMember 2022-04-01 2022-04-26 0001001250 us-gaap:RestructuringChargesMember us-gaap:EmployeeSeveranceMember us-gaap:SubsequentEventMember el:PCBAProgramMember 2022-04-01 2022-04-26 0001001250 us-gaap:RestructuringChargesMember el:ImpairmentInValueOfAssetsMember us-gaap:SubsequentEventMember el:PCBAProgramMember 2022-04-01 2022-04-26 0001001250 us-gaap:RestructuringChargesMember us-gaap:ContractTerminationMember us-gaap:SubsequentEventMember el:PCBAProgramMember 2022-04-01 2022-04-26 0001001250 us-gaap:RestructuringChargesMember us-gaap:SubsequentEventMember us-gaap:OtherRestructuringMember el:PCBAProgramMember 2022-04-01 2022-04-26 0001001250 us-gaap:NondesignatedMember 2022-03-31 0001001250 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember el:ForeignCurrencyCashFlowHedgesMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-03-31 0001001250 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember el:ForeignCurrencyCashFlowHedgesMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-06-30 0001001250 el:ForeignCurrencyCashFlowHedgesMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccruedLiabilitiesMember 2022-03-31 0001001250 el:ForeignCurrencyCashFlowHedgesMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccruedLiabilitiesMember 2021-06-30 0001001250 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember 2022-03-31 0001001250 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember 2021-06-30 0001001250 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember us-gaap:AccruedLiabilitiesMember 2022-03-31 0001001250 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember us-gaap:AccruedLiabilitiesMember 2021-06-30 0001001250 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-03-31 0001001250 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-06-30 0001001250 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccruedLiabilitiesMember 2022-03-31 0001001250 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccruedLiabilitiesMember 2021-06-30 0001001250 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-03-31 0001001250 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-06-30 0001001250 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccruedLiabilitiesMember 2022-03-31 0001001250 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccruedLiabilitiesMember 2021-06-30 0001001250 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2022-03-31 0001001250 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2021-06-30 0001001250 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:AccruedLiabilitiesMember 2022-03-31 0001001250 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:AccruedLiabilitiesMember 2021-06-30 0001001250 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2022-01-01 2022-03-31 0001001250 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2021-01-01 2021-03-31 0001001250 us-gaap:ForeignExchangeForwardMember us-gaap:SalesMember us-gaap:CashFlowHedgingMember 2022-01-01 2022-03-31 0001001250 us-gaap:ForeignExchangeForwardMember us-gaap:SalesMember us-gaap:CashFlowHedgingMember 2021-01-01 2021-03-31 0001001250 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember 2022-01-01 2022-03-31 0001001250 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember 2021-01-01 2021-03-31 0001001250 us-gaap:InterestExpenseMember us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember 2022-01-01 2022-03-31 0001001250 us-gaap:InterestExpenseMember us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember 2021-01-01 2021-03-31 0001001250 us-gaap:CashFlowHedgingMember 2022-01-01 2022-03-31 0001001250 us-gaap:CashFlowHedgingMember 2021-01-01 2021-03-31 0001001250 us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember 2022-01-01 2022-03-31 0001001250 us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember 2021-01-01 2021-03-31 0001001250 us-gaap:NetInvestmentHedgingMember 2022-01-01 2022-03-31 0001001250 us-gaap:NetInvestmentHedgingMember 2021-01-01 2021-03-31 0001001250 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2021-07-01 2022-03-31 0001001250 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2020-07-01 2021-03-31 0001001250 us-gaap:ForeignExchangeForwardMember us-gaap:SalesMember us-gaap:CashFlowHedgingMember 2021-07-01 2022-03-31 0001001250 us-gaap:ForeignExchangeForwardMember us-gaap:SalesMember us-gaap:CashFlowHedgingMember 2020-07-01 2021-03-31 0001001250 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember 2021-07-01 2022-03-31 0001001250 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember 2020-07-01 2021-03-31 0001001250 us-gaap:InterestExpenseMember us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember 2021-07-01 2022-03-31 0001001250 us-gaap:InterestExpenseMember us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember 2020-07-01 2021-03-31 0001001250 us-gaap:CashFlowHedgingMember 2021-07-01 2022-03-31 0001001250 us-gaap:CashFlowHedgingMember 2020-07-01 2021-03-31 0001001250 us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember 2021-07-01 2022-03-31 0001001250 us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember 2020-07-01 2021-03-31 0001001250 us-gaap:NetInvestmentHedgingMember 2021-07-01 2022-03-31 0001001250 us-gaap:NetInvestmentHedgingMember 2020-07-01 2021-03-31 0001001250 us-gaap:InterestExpenseMember us-gaap:FairValueHedgingMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-01-01 2022-03-31 0001001250 us-gaap:InterestExpenseMember us-gaap:FairValueHedgingMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-01-01 2021-03-31 0001001250 us-gaap:InterestExpenseMember us-gaap:FairValueHedgingMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-07-01 2022-03-31 0001001250 us-gaap:InterestExpenseMember us-gaap:FairValueHedgingMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-07-01 2021-03-31 0001001250 us-gaap:ShortTermDebtMember us-gaap:FairValueHedgingMember 2022-03-31 0001001250 us-gaap:ShortTermDebtMember 2021-07-01 2022-03-31 0001001250 us-gaap:FairValueHedgingMember us-gaap:LongTermDebtMember 2022-03-31 0001001250 us-gaap:LongTermDebtMember 2021-07-01 2022-03-31 0001001250 us-gaap:DebtMember us-gaap:FairValueHedgingMember 2022-03-31 0001001250 us-gaap:DebtMember 2021-07-01 2022-03-31 0001001250 us-gaap:SalesMember 2022-01-01 2022-03-31 0001001250 us-gaap:InterestExpenseMember 2022-01-01 2022-03-31 0001001250 us-gaap:SalesMember 2021-01-01 2021-03-31 0001001250 us-gaap:InterestExpenseMember 2021-01-01 2021-03-31 0001001250 us-gaap:InterestExpenseMember us-gaap:FairValueHedgingMember us-gaap:InterestRateContractMember 2022-01-01 2022-03-31 0001001250 us-gaap:InterestExpenseMember us-gaap:FairValueHedgingMember us-gaap:InterestRateContractMember 2021-01-01 2021-03-31 0001001250 us-gaap:SalesMember 2021-07-01 2022-03-31 0001001250 us-gaap:InterestExpenseMember 2021-07-01 2022-03-31 0001001250 us-gaap:SalesMember 2020-07-01 2021-03-31 0001001250 us-gaap:InterestExpenseMember 2020-07-01 2021-03-31 0001001250 us-gaap:InterestExpenseMember us-gaap:FairValueHedgingMember us-gaap:InterestRateContractMember 2021-07-01 2022-03-31 0001001250 us-gaap:InterestExpenseMember us-gaap:FairValueHedgingMember us-gaap:InterestRateContractMember 2020-07-01 2021-03-31 0001001250 us-gaap:ForeignExchangeForwardMember us-gaap:OperatingExpenseMember us-gaap:NondesignatedMember 2022-01-01 2022-03-31 0001001250 us-gaap:ForeignExchangeForwardMember us-gaap:OperatingExpenseMember us-gaap:NondesignatedMember 2021-01-01 2021-03-31 0001001250 us-gaap:ForeignExchangeForwardMember us-gaap:OperatingExpenseMember us-gaap:NondesignatedMember 2021-07-01 2022-03-31 0001001250 us-gaap:ForeignExchangeForwardMember us-gaap:OperatingExpenseMember us-gaap:NondesignatedMember 2020-07-01 2021-03-31 0001001250 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2022-03-31 0001001250 us-gaap:CashFlowHedgingMember 2022-03-31 0001001250 us-gaap:CashFlowHedgingMember 2021-06-30 0001001250 el:SeniorNotesTwoThirtyFivePercentDue2022Member us-gaap:FairValueHedgingMember us-gaap:InterestRateSwapMember 2022-03-31 0001001250 us-gaap:FairValueHedgingMember el:SeniorNotesDueApril2030Member us-gaap:InterestRateSwapMember 2022-03-31 0001001250 us-gaap:FairValueHedgingMember el:SeniorNotesOneNinetyFivePercentDue2031Member us-gaap:InterestRateSwapMember 2022-03-31 0001001250 el:SeniorNotesTwoThirtyFivePercentDue2022Member us-gaap:FairValueHedgingMember us-gaap:InterestRateSwapMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-07-01 2022-03-31 0001001250 us-gaap:FairValueHedgingMember el:SeniorNotesOneNinetyFivePercentDue2031Member us-gaap:InterestRateSwapMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-07-01 2022-03-31 0001001250 us-gaap:FairValueHedgingMember el:SeniorNotesDueApril2030Member us-gaap:InterestRateSwapMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-07-01 2022-03-31 0001001250 us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember 2022-03-31 0001001250 us-gaap:DerivativeMember 2022-03-31 el:agency 0001001250 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001001250 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001001250 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001001250 us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001001250 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001001250 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001001250 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001001250 us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001001250 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2022-03-31 0001001250 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-03-31 0001001250 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-06-30 0001001250 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-06-30 0001001250 us-gaap:ForeignExchangeForwardMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2022-03-31 0001001250 us-gaap:ForeignExchangeForwardMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-03-31 0001001250 us-gaap:ForeignExchangeForwardMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-06-30 0001001250 us-gaap:ForeignExchangeForwardMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-06-30 0001001250 us-gaap:InterestRateContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2022-03-31 0001001250 us-gaap:InterestRateContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-03-31 0001001250 us-gaap:InterestRateContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-06-30 0001001250 us-gaap:InterestRateContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-06-30 0001001250 el:TrademarksAndCustomerListsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember el:GLAMGLOWMember 2021-07-01 2022-03-31 0001001250 el:TrademarksAndCustomerListsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember el:GLAMGLOWMember 2022-03-31 0001001250 el:DrJartMember el:TrademarksAndCustomerListsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2021-07-01 2022-03-31 0001001250 el:DrJartMember el:TrademarksAndCustomerListsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2022-03-31 0001001250 el:TrademarksAndCustomerListsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2021-07-01 2022-03-31 0001001250 el:TrademarksAndCustomerListsMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsNonrecurringMember 2022-03-31 0001001250 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2021-07-01 2022-03-31 0001001250 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsNonrecurringMember 2022-03-31 0001001250 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember el:GLAMGLOWMember 2020-07-01 2021-03-31 0001001250 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsNonrecurringMember el:GLAMGLOWMember 2021-03-31 0001001250 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember el:BeccaMember 2020-07-01 2021-03-31 0001001250 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsNonrecurringMember el:BeccaMember 2021-03-31 0001001250 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2020-07-01 2021-03-31 0001001250 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsNonrecurringMember 2021-03-31 0001001250 el:TrademarksAndCustomerListsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember el:GLAMGLOWMember 2020-07-01 2021-03-31 0001001250 el:TrademarksAndCustomerListsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember el:GLAMGLOWMember 2021-03-31 0001001250 el:TrademarksAndCustomerListsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember el:BeccaMember 2020-07-01 2021-03-31 0001001250 el:TrademarksAndCustomerListsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember el:BeccaMember 2021-03-31 0001001250 el:TrademarksAndCustomerListsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2020-07-01 2021-03-31 0001001250 el:TrademarksAndCustomerListsMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsNonrecurringMember 2021-03-31 0001001250 us-gaap:ForeignExchangeForwardMember srt:MaximumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-07-01 2022-03-31 0001001250 us-gaap:ForeignExchangeForwardMember el:SwapYieldCurveMember srt:MinimumMember 2021-07-01 2022-03-31 0001001250 us-gaap:FairValueInputsLevel3Member el:DeferredCompensationShareBasedArrangementsLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001001250 us-gaap:FairValueInputsLevel3Member el:DeferredCompensationShareBasedArrangementsLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2021-07-01 2022-03-31 0001001250 us-gaap:FairValueInputsLevel3Member el:DeferredCompensationShareBasedArrangementsLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001001250 2021-12-31 0001001250 2020-12-31 0001001250 2022-04-01 2022-03-31 0001001250 country:US us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-03-31 0001001250 country:US us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-03-31 0001001250 us-gaap:PensionPlansDefinedBenefitMember us-gaap:ForeignPlanMember 2022-01-01 2022-03-31 0001001250 us-gaap:PensionPlansDefinedBenefitMember us-gaap:ForeignPlanMember 2021-01-01 2021-03-31 0001001250 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-01-01 2022-03-31 0001001250 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-01-01 2021-03-31 0001001250 country:US us-gaap:PensionPlansDefinedBenefitMember 2021-07-01 2022-03-31 0001001250 country:US us-gaap:PensionPlansDefinedBenefitMember 2020-07-01 2021-03-31 0001001250 us-gaap:PensionPlansDefinedBenefitMember us-gaap:ForeignPlanMember 2021-07-01 2022-03-31 0001001250 us-gaap:PensionPlansDefinedBenefitMember us-gaap:ForeignPlanMember 2020-07-01 2021-03-31 0001001250 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-07-01 2022-03-31 0001001250 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-07-01 2021-03-31 0001001250 us-gaap:CommonClassAMember 2021-07-01 2022-03-31 0001001250 us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:CommonClassAMember us-gaap:RestrictedStockUnitsRSUMember 2021-07-01 2022-03-31 0001001250 us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:CommonClassAMember el:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVesting2023Member us-gaap:RestrictedStockUnitsRSUMember 2021-07-01 2022-03-31 0001001250 us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:CommonClassAMember us-gaap:RestrictedStockUnitsRSUMember el:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVesting2024Member 2021-07-01 2022-03-31 0001001250 el:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVesting2025Member us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:CommonClassAMember us-gaap:RestrictedStockUnitsRSUMember 2021-07-01 2022-03-31 0001001250 us-gaap:PerformanceSharesMember us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:CommonClassAMember 2021-07-01 2022-03-31 0001001250 us-gaap:PerformanceSharesMember us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:CommonClassAMember 2021-09-01 2021-09-30 0001001250 us-gaap:PerformanceSharesMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2020-07-01 2021-06-30 0001001250 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-01-01 2022-03-31 0001001250 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-07-01 2022-03-31 0001001250 el:DECIEM2021StockOptionPlanMember 2021-07-01 2022-03-31 0001001250 el:DECIEM2021StockOptionPlanMember us-gaap:EmployeeStockOptionMember 2022-03-31 0001001250 el:DECIEM2021StockOptionPlanMember us-gaap:EmployeeStockOptionMember 2021-06-30 0001001250 el:DECIEM2021StockOptionPlanMember el:DECIEMMember us-gaap:EmployeeStockOptionMember 2021-06-30 2021-06-30 0001001250 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001001250 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001001250 us-gaap:EmployeeStockOptionMember 2021-07-01 2022-03-31 0001001250 us-gaap:EmployeeStockOptionMember 2020-07-01 2021-03-31 0001001250 us-gaap:PerformanceSharesMember 2022-01-01 2022-03-31 0001001250 us-gaap:PerformanceSharesMember 2021-01-01 2021-03-31 0001001250 us-gaap:PerformanceSharesMember 2021-07-01 2022-03-31 0001001250 us-gaap:PerformanceSharesMember 2020-07-01 2021-03-31 0001001250 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0001001250 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001001250 us-gaap:RestrictedStockUnitsRSUMember 2021-07-01 2022-03-31 0001001250 us-gaap:RestrictedStockUnitsRSUMember 2020-07-01 2021-03-31 0001001250 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001001250 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001001250 us-gaap:EmployeeStockOptionMember 2021-07-01 2022-03-31 0001001250 us-gaap:EmployeeStockOptionMember 2020-07-01 2021-03-31 0001001250 el:RestrictedStockUnitsAndPerformanceSharesMember 2022-01-01 2022-03-31 0001001250 el:RestrictedStockUnitsAndPerformanceSharesMember 2021-01-01 2021-03-31 0001001250 el:RestrictedStockUnitsAndPerformanceSharesMember 2021-07-01 2022-03-31 0001001250 el:RestrictedStockUnitsAndPerformanceSharesMember 2020-07-01 2021-03-31 0001001250 el:ContingentlyIssuableShareMember 2021-07-01 2022-03-31 0001001250 el:ContingentlyIssuableShareMember 2020-07-01 2021-03-31 0001001250 us-gaap:CommonStockMember 2021-12-31 0001001250 us-gaap:CommonStockMember 2020-12-31 0001001250 us-gaap:CommonStockMember 2021-06-30 0001001250 us-gaap:CommonStockMember 2020-06-30 0001001250 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001001250 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001001250 us-gaap:CommonStockMember 2021-07-01 2022-03-31 0001001250 us-gaap:CommonStockMember 2020-07-01 2021-03-31 0001001250 us-gaap:CommonStockMember 2022-03-31 0001001250 us-gaap:CommonStockMember 2021-03-31 0001001250 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001001250 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001001250 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001001250 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001001250 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001001250 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001001250 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2022-03-31 0001001250 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2021-03-31 0001001250 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001001250 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001001250 us-gaap:RetainedEarningsMember 2021-12-31 0001001250 us-gaap:RetainedEarningsMember 2020-12-31 0001001250 us-gaap:RetainedEarningsMember 2021-06-30 0001001250 us-gaap:RetainedEarningsMember 2020-06-30 0001001250 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001001250 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001001250 us-gaap:RetainedEarningsMember 2021-07-01 2022-03-31 0001001250 us-gaap:RetainedEarningsMember 2020-07-01 2021-03-31 0001001250 us-gaap:RetainedEarningsMember srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2021-12-31 0001001250 us-gaap:RetainedEarningsMember srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2020-12-31 0001001250 us-gaap:RetainedEarningsMember srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2021-06-30 0001001250 us-gaap:RetainedEarningsMember srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2020-06-30 0001001250 us-gaap:RetainedEarningsMember 2022-03-31 0001001250 us-gaap:RetainedEarningsMember 2021-03-31 0001001250 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001001250 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001001250 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001001250 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001001250 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001001250 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001001250 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2022-03-31 0001001250 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2021-03-31 0001001250 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001001250 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001001250 us-gaap:TreasuryStockMember 2021-12-31 0001001250 us-gaap:TreasuryStockMember 2020-12-31 0001001250 us-gaap:TreasuryStockMember 2021-06-30 0001001250 us-gaap:TreasuryStockMember 2020-06-30 0001001250 us-gaap:TreasuryStockMember 2022-01-01 2022-03-31 0001001250 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0001001250 us-gaap:TreasuryStockMember 2021-07-01 2022-03-31 0001001250 us-gaap:TreasuryStockMember 2020-07-01 2021-03-31 0001001250 us-gaap:TreasuryStockMember 2022-03-31 0001001250 us-gaap:TreasuryStockMember 2021-03-31 0001001250 us-gaap:ParentMember 2022-03-31 0001001250 us-gaap:ParentMember 2021-03-31 0001001250 us-gaap:NoncontrollingInterestMember 2021-12-31 0001001250 us-gaap:NoncontrollingInterestMember 2020-12-31 0001001250 us-gaap:NoncontrollingInterestMember 2021-06-30 0001001250 us-gaap:NoncontrollingInterestMember 2020-06-30 0001001250 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0001001250 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0001001250 us-gaap:NoncontrollingInterestMember 2021-07-01 2022-03-31 0001001250 us-gaap:NoncontrollingInterestMember 2020-07-01 2021-03-31 0001001250 us-gaap:NoncontrollingInterestMember 2022-03-31 0001001250 us-gaap:NoncontrollingInterestMember 2021-03-31 0001001250 el:RedeemableNoncontrollingInterestMember 2021-12-31 0001001250 el:RedeemableNoncontrollingInterestMember 2020-12-31 0001001250 el:RedeemableNoncontrollingInterestMember 2021-06-30 0001001250 el:RedeemableNoncontrollingInterestMember 2020-06-30 0001001250 el:RedeemableNoncontrollingInterestMember 2022-01-01 2022-03-31 0001001250 el:RedeemableNoncontrollingInterestMember 2021-01-01 2021-03-31 0001001250 el:RedeemableNoncontrollingInterestMember 2021-07-01 2022-03-31 0001001250 el:RedeemableNoncontrollingInterestMember 2020-07-01 2021-03-31 0001001250 el:RedeemableNoncontrollingInterestMember 2022-03-31 0001001250 el:RedeemableNoncontrollingInterestMember 2021-03-31 0001001250 us-gaap:CommonClassBMember 2021-08-18 2021-08-18 0001001250 us-gaap:CommonClassBMember 2021-09-15 2021-09-15 0001001250 us-gaap:CommonClassAMember 2021-08-18 2021-08-18 0001001250 us-gaap:CommonClassAMember 2021-09-15 2021-09-15 0001001250 us-gaap:CommonClassBMember 2021-12-15 2021-12-15 0001001250 us-gaap:CommonClassBMember 2021-11-01 2021-11-01 0001001250 us-gaap:CommonClassAMember 2021-11-01 2021-11-01 0001001250 us-gaap:CommonClassAMember 2021-12-15 2021-12-15 0001001250 us-gaap:CommonClassBMember 2022-02-02 2022-02-02 0001001250 us-gaap:CommonClassAMember 2022-03-15 2022-03-15 0001001250 us-gaap:CommonClassBMember 2022-03-15 2022-03-15 0001001250 us-gaap:CommonClassAMember 2022-02-02 2022-02-02 0001001250 us-gaap:CommonClassBMember us-gaap:SubsequentEventMember 2022-05-02 2022-05-02 0001001250 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2022-05-02 2022-05-02 0001001250 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-06-30 0001001250 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-06-30 0001001250 us-gaap:AccumulatedTranslationAdjustmentMember 2021-06-30 0001001250 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-07-01 2022-03-31 0001001250 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-07-01 2022-03-31 0001001250 us-gaap:AccumulatedTranslationAdjustmentMember 2021-07-01 2022-03-31 0001001250 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-03-31 0001001250 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-03-31 0001001250 us-gaap:AccumulatedTranslationAdjustmentMember 2022-03-31 0001001250 us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-03-31 0001001250 us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-01-01 2021-03-31 0001001250 us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-07-01 2022-03-31 0001001250 us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-07-01 2021-03-31 0001001250 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember us-gaap:InterestRateContractMember 2022-01-01 2022-03-31 0001001250 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember us-gaap:InterestRateContractMember 2021-01-01 2021-03-31 0001001250 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember us-gaap:InterestRateContractMember 2021-07-01 2022-03-31 0001001250 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember us-gaap:InterestRateContractMember 2020-07-01 2021-03-31 0001001250 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-03-31 0001001250 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-01-01 2021-03-31 0001001250 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-07-01 2022-03-31 0001001250 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-07-01 2021-03-31 0001001250 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2022-01-01 2022-03-31 0001001250 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2021-01-01 2021-03-31 0001001250 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2021-07-01 2022-03-31 0001001250 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2020-07-01 2021-03-31 0001001250 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember 2022-01-01 2022-03-31 0001001250 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember 2021-01-01 2021-03-31 0001001250 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember 2021-07-01 2022-03-31 0001001250 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember 2020-07-01 2021-03-31 0001001250 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001001250 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001001250 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2021-07-01 2022-03-31 0001001250 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2020-07-01 2021-03-31 0001001250 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001001250 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001001250 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2021-07-01 2022-03-31 0001001250 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2020-07-01 2021-03-31 el:segment 0001001250 el:SkinCareMember 2022-01-01 2022-03-31 0001001250 el:SkinCareMember 2021-01-01 2021-03-31 0001001250 el:SkinCareMember 2020-07-01 2021-03-31 0001001250 el:MakeupMember 2022-01-01 2022-03-31 0001001250 el:MakeupMember 2021-01-01 2021-03-31 0001001250 el:MakeupMember 2020-07-01 2021-03-31 0001001250 el:FragranceMember 2022-01-01 2022-03-31 0001001250 el:FragranceMember 2021-01-01 2021-03-31 0001001250 el:FragranceMember 2020-07-01 2021-03-31 0001001250 el:HairCareMember 2022-01-01 2022-03-31 0001001250 el:HairCareMember 2021-01-01 2021-03-31 0001001250 el:HairCareMember 2020-07-01 2021-03-31 0001001250 us-gaap:ProductAndServiceOtherMember 2022-01-01 2022-03-31 0001001250 us-gaap:ProductAndServiceOtherMember 2021-01-01 2021-03-31 0001001250 us-gaap:ProductAndServiceOtherMember 2021-07-01 2022-03-31 0001001250 us-gaap:ProductAndServiceOtherMember 2020-07-01 2021-03-31 0001001250 us-gaap:SalesReturnsAndAllowancesMember 2022-01-01 2022-03-31 0001001250 us-gaap:SalesReturnsAndAllowancesMember 2021-01-01 2021-03-31 0001001250 us-gaap:SalesReturnsAndAllowancesMember 2021-07-01 2022-03-31 0001001250 us-gaap:SalesReturnsAndAllowancesMember 2020-07-01 2021-03-31 0001001250 srt:AmericasMember 2022-01-01 2022-03-31 0001001250 srt:AmericasMember 2021-01-01 2021-03-31 0001001250 srt:AmericasMember 2021-07-01 2022-03-31 0001001250 srt:AmericasMember 2020-07-01 2021-03-31 0001001250 us-gaap:EMEAMember 2022-01-01 2022-03-31 0001001250 us-gaap:EMEAMember 2021-01-01 2021-03-31 0001001250 us-gaap:EMEAMember 2021-07-01 2022-03-31 0001001250 us-gaap:EMEAMember 2020-07-01 2021-03-31 0001001250 srt:AsiaPacificMember 2022-01-01 2022-03-31 0001001250 srt:AsiaPacificMember 2021-01-01 2021-03-31 0001001250 srt:AsiaPacificMember 2021-07-01 2022-03-31 0001001250 srt:AsiaPacificMember 2020-07-01 2021-03-31
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________________________________________________________
FORM 10-Q
(Mark One)

☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2022
or

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to
Commission file number 1-14064
The Estée Lauder Companies Inc.
(Exact name of registrant as specified in its charter)

Delaware | 11-2408943
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.)
767 Fifth Avenue, New York, New York | 10153
(Address of principal executive offices) | (Zip Code)

212-572-4200
(Registrant’s telephone number, including area code)
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Class A Common Stock, $.01 par value | EL | New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer | ☒ | Accelerated filer | ☐
Non-accelerated filer | ☐ | Smaller reporting company | ☐
|  | Emerging growth company | ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
At April 26, 2022, 231,805,171 shares of the registrant’s Class A Common Stock, $.01 par value, and 125,542,029 shares of the registrant’s Class B Common Stock, $.01 par value, were outstanding.

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
INDEX

| Page
Part I. Financial Information |
Item 1. Financial Statements (Unaudited) |
Consolidated Statements of Earnings — Three and Nine Months Ended March 31, 2022 and 2021 | 2
Consolidated Statements of Comprehensive Income — Three and Nine Months Ended March 31, 2022 and 2021 | 3
Consolidated Balance Sheets — March 31, 2022 and June 30, 2021 (Audited) | 4
Consolidated Statements of Cash Flows — Nine Months Ended March 31, 2022 and 2021 | 5
Notes to Consolidated Financial Statements | 6
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations | 39
Item 3. Quantitative and Qualitative Disclosures About Market Risk | 68
Item 4. Controls and Procedures | 68
Part II. Other Information |
Item 1. Legal Proceedings | 68
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds | 69
Item 6. Exhibits | 69
Signatures | 70

Table of Contents
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements.
THE ESTÉE LAUDER COMPANIES INC.
CONSOLIDATED STATEMENTS OF EARNINGS
(Unaudited)

|  |  |  | Three Months Ended March 31 |  | Nine Months Ended March 31
(In millions, except per share data) |  |  |  |  |  | 2022 |  | 2021 |  | 2022 |  | 2021
Net sales |  |  |  |  |  | $ | 4,245 |  |  | $ | 3,864 |  |  | $ | 14,176 |  |  | $ | 12,279 |
Cost of sales |  |  |  |  |  | 994 |  |  | 939 |  |  | 3,274 |  |  | 2,848 |
Gross profit |  |  |  |  |  | 3,251 |  |  | 2,925 |  |  | 10,902 |  |  | 9,431 |
Operating expenses |  |  |  |  |  |  |  |  |  |  |  |
Selling, general and administrative |  |  |  |  |  | 2,275 |  |  | 2,145 |  |  | 7,554 |  |  | 6,761 |
Restructuring and other charges |  |  |  |  |  | 22 |  |  | 131 |  |  | 41 |  |  | 172 |
Goodwill impairment |  |  |  |  |  | — |  |  | — |  |  | — |  |  | 54 |
Impairment of other intangible and long-lived assets |  |  |  |  |  | 216 |  |  | 33 |  |  | 216 |  |  | 60 |
Total operating expenses |  |  |  |  |  | 2,513 |  |  | 2,309 |  |  | 7,811 |  |  | 7,047 |
Operating income |  |  |  |  |  | 738 |  |  | 616 |  |  | 3,091 |  |  | 2,384 |
Interest expense |  |  |  |  |  | 41 |  |  | 43 |  |  | 125 |  |  | 131 |
Interest income and investment income, net |  |  |  |  |  | 5 |  |  | 9 |  |  | 19 |  |  | 40 |
Other components of net periodic benefit cost |  |  |  |  |  | (1) |  |  | 2 |  |  | (2) |  |  | 12 |
Other income |  |  |  |  |  | — |  |  | — |  |  | 1 |  |  | — |
Earnings before income taxes |  |  |  |  |  | 703 |  |  | 580 |  |  | 2,988 |  |  | 2,281 |
Provision for income taxes |  |  |  |  |  | 130 |  |  | 122 |  |  | 630 |  |  | 421 |
Net earnings |  |  |  |  |  | 573 |  |  | 458 |  |  | 2,358 |  |  | 1,860 |
Net earnings attributable to noncontrolling interests |  |  |  |  |  | (3) |  |  | (2) |  |  | (8) |  |  | (8) |
Net earnings attributable to redeemable noncontrolling interest |  |  |  |  |  | (12) |  |  | — |  |  | (12) |  |  | — |
Net earnings attributable to The Estée Lauder Companies Inc. |  |  |  |  |  | $ | 558 |  |  | $ | 456 |  |  | $ | 2,338 |  |  | $ | 1,852 |
Net earnings attributable to The Estée Lauder Companies Inc. per common share |  |  |  |  |  |  |  |  |  |  |  |
Basic |  |  |  |  |  | $ | 1.55 |  |  | $ | 1.25 |  |  | $ | 6.48 |  |  | $ | 5.10 |
Diluted |  |  |  |  |  | $ | 1.53 |  |  | $ | 1.24 |  |  | $ | 6.39 |  |  | $ | 5.03 |
Weighted-average common shares outstanding |  |  |  |  |  |  |  |  |  |  |  |
Basic |  |  |  |  |  | 359.2 |  |  | 363.6 |  |  | 360.7 |  |  | 362.9 |
Diluted |  |  |  |  |  | 363.6 |  |  | 369.0 |  |  | 365.8 |  |  | 368.1 |

See notes to consolidated financial statements.
2

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited)

|  |  | Three Months Ended March 31 |  | Nine Months Ended March 31 |  |
(In millions) |  |  | 2022 |  | 2021 |  | 2022 |  | 2021 |  |  |  |
Net earnings |  |  | $ | 573 |  |  | $ | 458 |  |  | $ | 2,358 |  |  | $ | 1,860 |  |  |  |  |
Other comprehensive income (loss): |  |  |  |  |  |  |  |  |  |  |  |  |
Net cash flow hedge gain (loss) |  |  | 5 |  |  | 41 |  |  | 21 |  |  | (16) |  |  |  |  |
Retirement plan and other retiree benefit adjustments |  |  | 4 |  |  | 7 |  |  | 12 |  |  | 19 |  |  |  |  |
Translation adjustments |  |  | 28 |  |  | (121) |  |  | (173) |  |  | 170 |  |  |  |  |
Benefit (provision) for income taxes on components of other comprehensive income |  |  | (4) |  |  | (32) |  |  | (22) |  |  | 6 |  |  |  |  |
Total other comprehensive income (loss), net of tax |  |  | 33 |  |  | (105) |  |  | (162) |  |  | 179 |  |  |  |  |
Comprehensive income |  |  | 606 |  |  | 353 |  |  | 2,196 |  |  | 2,039 |  |  |  |  |
Comprehensive income attributable to noncontrolling interests: |  |  |  |  |  |  |  |  |  |  |  |  |
Net earnings |  |  | (3) |  |  | (2) |  |  | (8) |  |  | (8) |  |  |  |  |
Translation adjustments |  |  | 1 |  |  | 1 |  |  | 3 |  |  | (1) |  |  |  |  |
Total comprehensive income attributable to noncontrolling interests |  |  | (2) |  |  | (1) |  |  | (5) |  |  | (9) |  |  |  |  |
Comprehensive income attributable to redeemable noncontrolling interest: |  |  |  |  |  |  |  |  |  |  |  |  |
Net earnings |  |  | (12) |  |  | — |  |  | (12) |  |  | — |  |  |  |  |
Translation adjustments |  |  | (14) |  |  | — |  |  | 3 |  |  | — |  |  |  |  |
Total comprehensive income attributable to redeemable noncontrolling interest |  |  | (26) |  |  | — |  |  | (9) |  |  | — |  |  |  |  |
Comprehensive income attributable to The Estée Lauder Companies Inc. |  |  | $ | 578 |  |  | $ | 352 |  |  | $ | 2,182 |  |  | $ | 2,030 |  |  |  |  |

See notes to consolidated financial statements.
3

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
CONSOLIDATED BALANCE SHEETS

(In millions, except share data) |  | March 31 2022 |  | June 30 2021
|  | (Unaudited) |  |
ASSETS |  |  |  |
Current assets |  |  |  |
Cash and cash equivalents |  | $ | 3,836 |  |  | $ | 4,958 |
Accounts receivable, net |  | 2,209 |  |  | 1,702 |
Inventory and promotional merchandise |  | 2,830 |  |  | 2,505 |
Prepaid expenses and other current assets |  | 625 |  |  | 603 |
Total current assets |  | 9,500 |  |  | 9,768 |
Property, plant and equipment, net |  | 2,493 |  |  | 2,280 |
Other assets |  |  |  |
Operating lease right-of-use assets |  | 2,034 |  |  | 2,190 |
Goodwill |  | 2,591 |  |  | 2,616 |
Other intangible assets, net |  | 3,638 |  |  | 4,095 |
Other assets |  | 1,103 |  |  | 1,022 |
Total other assets |  | 9,366 |  |  | 9,923 |
Total assets |  | $ | 21,359 |  |  | $ | 21,971 |
LIABILITIES AND EQUITY |  |  |  |
Current liabilities |  |  |  |
Current debt |  | $ | 269 |  |  | $ | 32 |
Accounts payable |  | 1,470 |  |  | 1,692 |
Operating lease liabilities |  | 388 |  |  | 379 |
Other accrued liabilities |  | 3,287 |  |  | 3,195 |
Total current liabilities |  | 5,414 |  |  | 5,298 |
Noncurrent liabilities |  |  |  |
Long-term debt |  | 5,188 |  |  | 5,537 |
Long-term operating lease liabilities |  | 1,948 |  |  | 2,151 |
Other noncurrent liabilities |  | 1,758 |  |  | 2,037 |
Total noncurrent liabilities |  | 8,894 |  |  | 9,725 |
Contingencies |  |  |  |
Redeemable Noncontrolling Interest |  | 865 |  |  | 857 |
Equity |  |  |  |
Common stock, $.01 par value; Class A shares authorized: 1,300,000,000 at March 31, 2022 and June 30, 2021; shares issued: 467,516,898 at March 31, 2022 and 462,633,034 at June 30, 2021; Class B shares authorized: 304,000,000 at March 31, 2022 and June 30, 2021; shares issued and outstanding: 125,542,029 at March 31, 2022 and 128,242,029 at June 30, 2021 |  | 6 |  |  | 6 |
Paid-in capital |  | 5,746 |  |  | 5,335 |
Retained earnings |  | 14,076 |  |  | 12,244 |
Accumulated other comprehensive loss |  | (626) |  |  | (470) |
|  | 19,202 |  |  | 17,115 |
Less: Treasury stock, at cost; 235,234,161 Class A shares at March 31, 2022 and 229,115,665 Class A shares at June 30, 2021 |  | (13,052) |  |  | (11,058) |
Total stockholders’ equity – The Estée Lauder Companies Inc. |  | 6,150 |  |  | 6,057 |
Noncontrolling interests |  | 36 |  |  | 34 |
Total equity |  | 6,186 |  |  | 6,091 |
Total liabilities, redeemable noncontrolling interest and equity |  | $ | 21,359 |  |  | $ | 21,971 |

See notes to consolidated financial statements.
4

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

|  | Nine Months Ended March 31
(In millions) |  | 2022 |  | 2021
Cash flows from operating activities |  |  |  |
Net earnings |  | $ | 2,358 |  |  | $ | 1,860 |
Adjustments to reconcile net earnings to net cash flows from operating activities: |  |  |  |
Depreciation and amortization |  | 546 |  |  | 475 |
Deferred income taxes |  | (90) |  |  | (103) |
Non-cash stock-based compensation |  | 283 |  |  | 255 |
Net loss on disposal of property, plant and equipment |  | 6 |  |  | 19 |
Non-cash restructuring and other charges |  | 2 |  |  | 97 |
Pension and post-retirement benefit expense |  | 59 |  |  | 75 |
Pension and post-retirement benefit contributions |  | (30) |  |  | (35) |
Goodwill, other intangible and long-lived asset impairments |  | 216 |  |  | 114 |
Changes in fair value of contingent consideration |  | — |  |  | (2) |
Gain on previously held equity method investment |  | (1) |  |  | — |
Other non-cash items |  | (4) |  |  | (17) |
Changes in operating assets and liabilities: |  |  |  |
Increase in accounts receivable, net |  | (548) |  |  | (506) |
Decrease (increase) in inventory and promotional merchandise |  | (398) |  |  | 13 |
Increase in other assets, net |  | (61) |  |  | (122) |
Increase (decrease) in accounts payable |  | (199) |  |  | 55 |
Increase (decrease) in other accrued and noncurrent liabilities |  | (132) |  |  | 629 |
Decrease in operating lease assets and liabilities, net |  | (38) |  |  | (30) |
Net cash flows provided by operating activities |  | 1,969 |  |  | 2,777 |
Cash flows from investing activities |  |  |  |
Capital expenditures |  | (658) |  |  | (386) |
Proceeds from purchase price refund |  | — |  |  | 32 |
Payments for acquired businesses |  | (3) |  |  | (8) |
Purchases of investments |  | (10) |  |  | (40) |
Settlement of net investment hedges |  | 108 |  |  | (175) |
Net cash flows used for investing activities |  | (563) |  |  | (577) |
Cash flows from financing activities |  |  |  |
Repayments of current debt, net |  | (4) |  |  | (746) |
Proceeds from issuance of long-term debt, net |  | — |  |  | 596 |
Debt issuance costs |  | (1) |  |  | (4) |
Repayments and redemptions of long-term debt |  | (16) |  |  | (6) |
Net proceeds from stock-based compensation transactions |  | 127 |  |  | 180 |
Payments to acquire treasury stock |  | (1,998) |  |  | (316) |
Dividends paid to stockholders |  | (624) |  |  | (561) |
Payments to noncontrolling interest holders for dividends |  | — |  |  | (5) |
Net cash flows used for financing activities |  | (2,516) |  |  | (862) |
Effect of exchange rate changes on Cash and cash equivalents |  | (12) |  |  | 39 |
Net increase (decrease) in Cash and cash equivalents |  | (1,122) |  |  | 1,377 |
Cash and cash equivalents at beginning of period |  | 4,958 |  |  | 5,022 |
Cash and cash equivalents at end of period |  | $ | 3,836 |  |  | $ | 6,399 |

See notes to consolidated financial statements.
5

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The accompanying consolidated financial statements include the accounts of The Estée Lauder Companies Inc. and its subsidiaries (collectively, the “Company”). All significant intercompany balances and transactions have been eliminated.
The unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim consolidated financial statements furnished reflect all adjustments which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the full fiscal year. The interim consolidated financial statements should be read in conjunction with the consolidated financial statements and accompanying footnotes included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2021.
Certain prior year amounts in the notes to the consolidated financial statements have been reclassified to conform to current year presentation.
Management Estimates
The preparation of financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses reported in those financial statements. Descriptions of the Company’s significant accounting policies are discussed in the notes to consolidated financial statements in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2021. Management evaluates the related estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ significantly from those estimates and assumptions. Significant changes, if any, in those estimates and assumptions resulting from continuing changes in the economic environment, including those related to the impacts of the COVID-19 pandemic, will be reflected in the consolidated financial statements in future periods.
Currency Translation and Transactions
All assets and liabilities of foreign subsidiaries and affiliates are translated at period-end rates of exchange, while revenue and expenses are translated at monthly average rates of exchange for the period. Unrealized translation gains (losses), net of tax, reported as translation adjustments through other comprehensive income (loss) (“OCI”) attributable to The Estée Lauder Companies Inc. were $13 million and $(143) million, net of tax, during the three months ended March 31, 2022 and 2021, respectively, and $(182) million and $175 million, net of tax, during the nine months ended March 31, 2022 and 2021, respectively. For the Company’s subsidiaries operating in highly inflationary economies, the U.S. dollar is the functional currency. Remeasurement adjustments in financial statements in a highly inflationary economy and other transactional gains and losses are reflected in earnings. These subsidiaries are not material to the Company’s consolidated financial statements or liquidity.
The Company enters into foreign currency forward contracts and may enter into option contracts to hedge foreign currency transactions for periods consistent with its identified exposures. The Company also enters into foreign currency forward contracts to hedge a portion of its net investment in certain foreign operations, which are designated as net investment hedges. See Note 5 – Derivative Financial Instruments for further discussion. The Company categorizes these instruments as entered into for purposes other than trading.
The accompanying consolidated statements of earnings include net exchange gains (losses) on foreign currency transactions of $3 million and $(3) million during the three months ended March 31, 2022 and March 31, 2021, respectively, and $(15) million and $(5) million during the nine months ended March 31, 2022 and 2021, respectively.
6

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Concentration of Credit Risk
The Company is a worldwide manufacturer, marketer and seller of skin care, makeup, fragrance and hair care products. The Company’s sales subject to credit risk are made primarily to retailers in its travel retail business, department stores, specialty multi-brand retailers and perfumeries. The Company grants credit to qualified customers. As a result of the COVID-19 pandemic, the Company has enhanced its assessment of its customers' abilities to pay with a greater focus on factors affecting their liquidity and less on historical payment performance. While the Company does not believe it is exposed significantly to any undue concentration of credit risk at this time, it continues to monitor the extent of the impact of the COVID-19 pandemic on its customers' abilities, individually and collectively, to make timely payments.
The Company’s largest customer during the three and nine months ended March 31, 2022 sells products primarily in China travel retail. This customer accounted for $740 million or 17%, and $690 million, or 18%, of the Company's consolidated net sales for the three months ended March 31, 2022 and 2021, respectively, and $1,792 million, or 13%, and $1,898 million, or 15%, for the nine months ended March 31, 2022 and 2021, respectively. This customer accounted for $457 million, or 20%, and $179 million, or 10%, of the Company's accounts receivable at March 31, 2022 and June 30, 2021, respectively.
Inventory and Promotional Merchandise
Inventory and promotional merchandise consists of the following:

(In millions) |  | March 31, 2022 |  | June 30, 2021
Raw materials |  | $ | 778 |  |  | $ | 674 |
Work in process |  | 336 |  |  | 330 |
Finished goods |  | 1,454 |  |  | 1,213 |
Promotional merchandise |  | 262 |  |  | 288 |
|  | $ | 2,830 |  |  | $ | 2,505 |

Property, Plant and Equipment
Property, plant and equipment consists of the following:

(In millions) |  | March 31, 2022 |  | June 30, 2021
Assets (Useful Life) |  |  |  |
Land |  | $ | 56 |  |  | $ | 55 |
Buildings and improvements (10 to 40 years) |  | 496 |  |  | 256 |
Machinery and equipment (3 to 10 years) |  | 992 |  |  | 920 |
Computer hardware and software (4 to 10 years) |  | 1,428 |  |  | 1,303 |
Furniture and fixtures (5 to 10 years) |  | 129 |  |  | 125 |
Leasehold improvements |  | 2,307 |  |  | 2,312 |
Construction in progress |  | 589 |  |  | 647 |
|  | 5,997 |  |  | 5,618 |
Less accumulated depreciation and amortization |  | (3,504) |  |  | (3,338) |
|  | $ | 2,493 |  |  | $ | 2,280 |

Depreciation and amortization of property, plant and equipment was $140 million and $129 million during the three months ended March 31, 2022 and 2021, respectively, and $406 million and $380 million during the nine months ended March 31, 2022 and 2021, respectively. Depreciation and amortization related to the Company’s manufacturing process is included in Cost of sales, and all other depreciation and amortization is included in Selling, general and administrative expenses in the accompanying consolidated statements of earnings.
7

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Leases
The Company recognized $33 million of long-lived asset impairments, included in Impairments of other intangible and long-lived assets, in the accompanying consolidated statements of earnings for the three and nine months ended March 31, 2021. The fiscal 2021 impairments related to other assets (i.e. rights associated with commercial operating leases), operating lease right-of-use assets and the related property, plant and equipment in certain freestanding stores primarily in Europe. The impairments were due to the negative impacts of the COVID-19 pandemic. For the three and nine months ended March 31, 2022, the Company did not recognize any long-lived asset impairments.
Income Taxes
The effective rate for income taxes for the three and nine months ended March 31, 2022 and 2021 are as follows:

| Three Months Ended March 31 |  | Nine Months Ended March 31
| 2022 |  | 2021 |  | 2022 |  | 2021
Effective rate for income taxes | 18.5 | % |  | 21.0 | % |  | 21.1 | % |  | 18.5 | %
Basis-point change from the prior-year period | (250) |  |  |  |  | 260 |  |  |

The effective tax rate for the three and nine months ended March 31, 2021 included the retroactive impact relating to fiscal 2020 and 2019 of the U.S. government issuance of final global intangible low-taxed income (“GILTI”) tax regulations in July 2020 under the Tax Cuts and Jobs Act that provide for a high-tax exception to the GILTI tax. The impact of the final issuance of GILTI tax regulations with respect to fiscal 2020 and 2019 was recognized as a discrete item in the provision for income taxes in the second and third quarters of fiscal 2021 and resulted in reductions of 30 basis points and 220 basis points to the effective tax rates for the three and nine months ended March 31, 2021, respectively.
For the three months ended March 31, 2022, the decrease in the effective tax rate was primarily attributable to a lower effective tax rate on the Company's foreign operations, partially offset by a decrease in excess tax benefits associated with stock-based compensation arrangements.
For the nine months ended March 31, 2022, the increase in the effective tax rate was primarily attributable to a higher effective tax rate on the Company’s foreign operations, which includes the retroactive impact of the final GILTI tax regulations recognized in the prior period. Also contributing to the increase was a decrease in excess tax benefits associated with stock-based compensation arrangements.
As of March 31, 2022 and June 30, 2021, the gross amount of unrecognized tax benefits, exclusive of interest and penalties, totaled $63 million and $62 million, respectively. The total amount of unrecognized tax benefits at March 31, 2022 that, if recognized, would affect the effective tax rate was $53 million. The total gross interest and penalties accrued related to unrecognized tax benefits during the three and nine months ended March 31, 2022 in the accompanying consolidated statements of earnings was $1 million and $5 million, respectively. The total gross accrued interest and penalties in the accompanying consolidated balance sheets at March 31, 2022 and June 30, 2021, was $15 million and $14 million, respectively. On the basis of the information available as of March 31, 2022, the Company does not expect significant changes to the total amount of unrecognized tax benefits within the next twelve months.
During the fiscal 2022 first quarter, the Company formally concluded the compliance process with respect to its fiscal 2020 income tax return under the U.S. Internal Revenue Service (“IRS”) Compliance Assurance Program (“CAP”), which had no impact on the Company’s consolidated financial statements for the three and nine months ended March 31, 2022.
8

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Other Accrued and Noncurrent Liabilities
Other accrued liabilities consist of the following:

(In millions) |  | March 31, 2022 |  | June 30, 2021
Advertising, merchandising and sampling |  | $ | 322 |  |  | $ | 294 |
Employee compensation |  | 582 |  |  | 670 |
Deferred revenue |  | 313 |  |  | 322 |
Payroll and other non-income taxes |  | 321 |  |  | 359 |
Accrued income taxes |  | 299 |  |  | 237 |
Other |  | 1,450 |  |  | 1,313 |
|  | $ | 3,287 |  |  | $ | 3,195 |

At March 31, 2022 and June 30, 2021, total Other noncurrent liabilities of $1,758 million and $2,037 million included $744 million and $849 million of deferred tax liabilities, respectively.
Recently Adopted Accounting Standards
Income Taxes (ASU 2019-12 – Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes)
In December 2019, the Financial Accounting Standards Board (“FASB”) issued authoritative guidance that simplifies the accounting for income taxes by removing certain exceptions and making simplifications in other areas.
Effective for the Company – Fiscal 2022 first quarter.
Impact on consolidated financial statements – On July 1, 2021, the Company adopted this standard and recorded a cumulative adjustment of $121 million as an increase to its fiscal 2022 opening retained earnings balance to derecognize a deferred tax liability related to a previously held equity method investment that became a foreign subsidiary.
Recently Issued Accounting Standards
Reference Rate Reform (ASC Topic 848 “ASC 848”)
In March 2020, the FASB issued authoritative guidance to provide optional relief for companies preparing for the discontinuation of interest rates such as the London Interbank Offered Rate (“LIBOR”) and applies to lease and other contracts, hedging instruments, held-to-maturity debt securities and debt arrangements that reference LIBOR or another rate that is expected to be discontinued as a result of reference rate reform.
In January 2021, the FASB issued authoritative guidance that makes amendments to the new rules on accounting for reference rate reform. The amendments clarify that for all derivative instruments affected by the changes to interest rates used for discounting, margining or contract price alignment, regardless of whether they reference LIBOR or another rate expected to be discontinued as a result of reference rate reform, an entity may apply certain practical expedients in ASC 848.
Effective for the Company – This guidance can be applied for a limited time through December 31, 2022. The guidance will no longer be available to apply after December 31, 2022.
Impact on consolidated financial statements – The Company currently has an implementation team in place that is performing a comprehensive evaluation and assessing the impact of applying this guidance, which includes assessing the impact to business processes and internal controls over financial reporting and the related disclosure requirements. For treasury related arrangements, the Company references LIBOR in its interest rate swap agreements and LIBOR is also used for purposes of discounting certain foreign currency and interest rate forward contracts. The Company is currently evaluating the potential impact of modifying treasury related arrangements and applying the relevant ASC 848 optional practical expedients, as needed. For existing lease, debt arrangements and other contracts, the Company does not expect any qualifying contract modifications related to reference rate reform and therefore does not expect that the optional guidance in ASC 848 will need to be applied through December 31, 2022. The Company will continue to monitor new contracts that could potentially be eligible for contract modification relief through December 31, 2022.
9

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
No other recently issued accounting pronouncements are expected to have a material impact on the Company’s consolidated financial statements.
NOTE 2 – ACQUISITION OF BUSINESS
On May 18, 2021, the Company acquired additional shares in Deciem Beauty Group Inc. (“DECIEM”), a Toronto-based skin care company, for $1,092 million in cash, including proceeds from the issuance of debt. DECIEM is a multi-brand beauty company with a brand portfolio that includes The Ordinary and NIOD. This acquisition is expected to further strengthen the Company’s leadership position in prestige skin care, expand its global consumer reach and complement its business in the online and specialty-multi channels. The Company originally acquired a minority interest in DECIEM in June 2017. The minority interest was accounted for as an equity method investment, which had a carrying value of $65 million at the acquisition date. The acquisition of additional shares increased the Company's fully diluted equity interest from approximately 29% to approximately 76% and was considered a step acquisition. On a fully diluted basis, the DECIEM stock options, discussed below, approximated 4% of the total capital structure. Accordingly, for purposes of determining the consideration transferred, the Company excluded the DECIEM stock options, which resulted in an increase in the Company’s post-acquisition undiluted equity interest from approximately 30% to approximately 78% and the post-acquisition undiluted equity interest of the remaining noncontrolling interest holders of approximately 22%. The Company remeasured the previously held equity method investment to its fair value of $913 million, resulting in the recognition of a gain of $848 million. As part of the increase in the Company's investment, the Company was granted the right to purchase (“Call Option”), and granted the remaining investors a right to sell to the Company (“Put Option”), the remaining interests after a three-year period, with a purchase price based on the future performance of DECIEM (the “net Put (Call) Option”). As a result of this redemption feature, the Company recorded redeemable noncontrolling interest, at its acquisition‑date fair value, that is classified as mezzanine equity in the consolidated balance sheets at June 30, 2021. The accounting for the DECIEM business combination was finalized as of March 31, 2022.
A summary of the total consideration transferred, including immaterial measurement period adjustments as of March 31, 2022, is as follows:

(In millions) |  |  |  |  |  | March 31, 2022
Cash paid |  |  |  |  |  | $ | 1,095 |
Fair value of DECIEM stock options liability |  |  |  |  |  | 104 |
Fair value of net Put (Call) Option |  |  |  |  |  | 233 |
Total consideration for the acquired ownership interest (approximately 47.9%) |  |  |  |  |  | 1,432 |
Fair value of previously held equity method investment (approximately 30.5%) |  |  |  |  |  | 913 |
Fair value of redeemable noncontrolling interest (approximately 21.6%) |  |  |  |  |  | 647 |
Total consideration transferred (100%) |  |  |  |  |  | $ | 2,992 |

As part of the acquisition of additional shares, DECIEM stock options were issued in replacement of and exchange for certain vested and unvested stock options previously issued by DECIEM. The total fair value of the DECIEM stock options of $295 million was recorded as part of the total consideration transferred, comprising of $191 million of Cash paid for vested options settled as of the acquisition date and $104 million reported as a stock options liability on the Company's consolidated balance sheet as it is not an assumed liability of DECIEM and is expected to be settled in cash upon completion of the exercise of the Put (Call). The acquisition-date fair value of the DECIEM stock options liability was calculated by multiplying the acquisition-date fair value by the number of DECIEM stock options replaced the day after the acquisition date. The stock options replaced consist of vested and partially vested stock options. See Note 10 – Stock Programs for information relating to the DECIEM stock options.
The acquisition-date fair value of the previously held equity method investment was calculated by multiplying the gross-up of the total consideration for the acquired ownership interest of $2,992 million by the related effective previously held equity interest of approximately 30.5%.
The acquisition-date fair value of the redeemable noncontrolling interest includes the acquisition-date fair value of the net Put (Call) Option of $233 million. The remaining acquisition-date fair value of the redeemable noncontrolling interest of $647 million was calculated by multiplying the gross-up of the total consideration for the acquired ownership interest of $2,992 million by the related noncontrolling interest of approximately 21.6%.
10

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
The acquisition-date fair values of the DECIEM stock options and the net Put (Call) Option were calculated by incorporating significant assumptions including the starting equity value, revenue growth rates and EBITDA and the following key assumptions into the Monte Carlo Method:

|  | May 18, 2021
Risk-free rate |  | 0.50%
Term to mid of last twelve-month period |  | 2.54 years
Operating leverage adjustment |  | 0.45
Net sales discount rate |  | 3.30%
EBITDA discount rate |  | 6.80%
EBITDA volatility |  | 38.30%
Net sales volatility |  | 17.20%

The Company recorded a preliminary allocation of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their fair value at the acquisition date. The total consideration transferred includes the cash paid at closing, the fair value of its previously held equity method investment, the fair value of the redeemable noncontrolling interest, including the fair value of the net Put (Call) Option, and the fair value of the DECIEM stock options liability. The excess of the total consideration transferred over the fair value of the net tangible and intangible assets acquired was recorded as goodwill. To determine the acquisition date estimated fair value of intangible assets acquired, the Company applied the income approach, specifically the multi-period excess earnings method for customer relationships and the relief-from-royalty method for trademarks. The significant assumptions used in these approaches include revenue growth rates and profit margins, terminal values, weighted-average cost of capital used to discount future cash flows, and a customer attrition rate for customer relationships and royalty rates for trademarks. The final allocation of the total consideration transferred, including immaterial measurement period adjustments as of March 31, 2022, has been recorded as follows:

(In millions) |  | March 31, 2022
Cash |  | $ | 35 |
Accounts receivable |  | 64 |
Inventory |  | 190 |
Other current assets |  | 33 |
Property, plant and equipment |  | 40 |
Operating lease right-of-use assets |  | 40 |
Intangible assets |  | 1,917 |
Goodwill |  | 1,296 |
Deferred income taxes |  | 8 |
Total assets acquired |  | 3,623 |
Accounts payable |  | 21 |
Operating lease liabilities |  | 8 |
Other accrued liabilities |  | 78 |
Deferred income taxes |  | 479 |
Long-term operating lease liabilities |  | 45 |
Total liabilities assumed |  | 631 |
Total consideration transferred |  | $ | 2,992 |

11

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
The results of operations for DECIEM and acquisition-related costs were not material to the Company's consolidated statements of earnings for the three and nine months ended March 31, 2022. Pro forma results of operations for the fiscal 2021 periods reflecting the acquisition of DECIEM are not presented, as the impact on the Company’s consolidated financial results would not have been material.
NOTE 3 – GOODWILL AND OTHER INTANGIBLE ASSETS
As previously discussed in Note 2 – Acquisition of Business, in May 2021 the Company increased its investment in DECIEM, which resulted in the inclusion of additional goodwill of $1,296 million, amortizable intangible assets (customer lists) of $701 million with amortization periods of 7 years to 14 years, and non-amortizable intangible assets (trademarks) of $1,216 million. Goodwill associated with the acquisition is primarily attributable to the future revenue growth opportunities associated with sales growth in the skin care category, as well as the value associated with DECIEM's assembled workforce. As such, the goodwill has been allocated to the Company’s skin care product category. The goodwill recorded in connection with this acquisition is not deductible for tax purposes.
Goodwill
The following table presents goodwill by product category and the related change in the carrying amount:

(In millions) |  | Skin Care |  | Makeup |  | Fragrance |  | Hair Care |  | Total
Balance as of June 30, 2021 |  |  |  |  |  |  |  |  |  |
Goodwill |  | $ | 1,786 |  |  | $ | 1,214 |  |  | $ | 262 |  |  | $ | 355 |  |  | $ | 3,617 |
Accumulated impairments |  | (141) |  |  | (830) |  |  | (30) |  |  | — |  |  | (1,001) |
|  | 1,645 |  |  | 384 |  |  | 232 |  |  | 355 |  |  | 2,616 |
Goodwill measurement period adjustment |  | 13 |  |  | — |  |  | — |  |  | — |  |  | 13 |
Translation adjustments, goodwill |  | (34) |  |  | — |  |  | (6) |  |  | — |  |  | (40) |
Translation adjustments, accumulated impairments |  | 2 |  |  | — |  |  | — |  |  | — |  |  | 2 |
|  | (19) |  |  | — |  |  | (6) |  |  | — |  |  | (25) |
Balance as of March 31, 2022 |  |  |  |  |  |  |  |  |  |
Goodwill |  | 1,765 |  |  | 1,214 |  |  | 256 |  |  | 355 |  |  | 3,590 |
Accumulated impairments |  | (139) |  |  | (830) |  |  | (30) |  |  | — |  |  | (999) |
|  | $ | 1,626 |  |  | $ | 384 |  |  | $ | 226 |  |  | $ | 355 |  |  | $ | 2,591 |

Other Intangible Assets
Other intangible assets consist of the following:

|  | March 31, 2022 |  | June 30, 2021
(In millions) |  | Gross Carrying Value |  | Accumulated Amortization |  | Total Net Book Value |  | Gross Carrying Value |  | Accumulated Amortization |  | Total Net Book Value
Amortizable intangible assets: |  |  |  |  |  |  |  |  |  |  |  |
Customer lists and other |  | $ | 2,208 |  |  | $ | 660 |  |  | $ | 1,548 |  |  | $ | 2,273 |  |  | $ | 544 |  |  | $ | 1,729 |
License agreements |  | 43 |  |  | 43 |  |  | — |  |  | 43 |  |  | 43 |  |  | — |
|  | $ | 2,251 |  |  | $ | 703 |  |  | 1,548 |  |  | $ | 2,316 |  |  | $ | 587 |  |  | 1,729 |
Non-amortizable intangible assets: |  |  |  |  |  |  |  |  |  |  |  |
Trademarks and other |  |  |  |  |  | 2,090 |  |  |  |  |  |  | 2,366 |
Total intangible assets |  |  |  |  |  | $ | 3,638 |  |  |  |  |  |  | $ | 4,095 |

12

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
The aggregate amortization expense related to amortizable intangible assets was $38 million and $25 million for the three months ended March 31, 2022 and 2021, respectively, and $122 million and $77 million for the nine months ended March 31, 2022 and 2021, respectively.
The estimated aggregate amortization expense for the remainder of fiscal 2022 and for each of the next four fiscal years is as follows:

|  | Fiscal
(In millions) |  | 2022 |  | 2023 |  | 2024 |  | 2025 |  | 2026
Estimated aggregate amortization expense |  | $ | 39 |  |  | $ | 155 |  |  | $ | 154 |  |  | $ | 154 |  |  | $ | 154 |

Impairment Testing During the Nine Months Ended March 31, 2022
During the fiscal 2022 third quarter, given the lower-than-expected results from international expansion to areas that continue to be impacted by COVID-19, the Company made revisions to the internal forecasts relating to its GLAMGLOW reporting unit. The Company concluded that the changes in circumstances in the reporting unit triggered the need for an interim impairment review of its trademark intangible asset. As of March 31, 2022, the remaining carrying value of the trademark intangible asset was not recoverable and the Company recorded an impairment charge of $11 million reducing the carrying value to zero.
During the fiscal 2022 third quarter, given the lower-than-expected growth within key geographic regions and channels for Dr.Jart+ that continue to be impacted by the spread of COVID-19 variants and resurgence in cases and the potential future impacts relating to the uncertainty of the duration and severity of COVID-19 impacting the financial performance of the brand, the lower than expected growth in key retail channels for DECIEM, and the lower than expected results from international expansion to areas that continue to be impacted by COVID-19 for Too Faced, the Company made revisions to the internal forecasts relating to its Dr. Jart+, DECIEM and Too Faced reporting units.
The Company concluded that the changes in circumstances in the reporting units triggered the need for interim impairment reviews of their trademarks and goodwill. These changes in circumstances were also an indicator that the carrying amounts of Dr.Jart+’s, DECIEM’s and Too Faced’s long-lived assets, including customer lists, may not be recoverable. Accordingly, the Company performed interim impairment tests for the trademarks and a recoverability test for the long-lived assets as of February 28, 2022. The Company concluded that the carrying amounts of the long-lived assets were recoverable. For the Dr.Jart+ reporting unit, the Company also concluded that the carrying value of the trademark intangible asset exceeded its estimated fair value, which was determined utilizing the relief-from-royalty method to determine discounted projected future cash flows, and recorded an impairment charge. For the Too Faced and DECIEM reporting units, as the carrying values of the trademarks did not exceed their estimated fair values, which were determined utilizing the relief-from-royalty method to determine discounted projected future cash flows, the Company did not record impairment charges. As of March 31, 2022, the estimated fair values of Too Faced’s and DECIEM's trademarks exceeded their carrying values by 13% and 3%, respectively. For the Too Faced and DECIEM trademark intangible assets, if all other assumptions are held constant, an increase of 100 basis points and 50 basis points, respectively, in the weighted average cost of capital would result in an impairment charge. After adjusting the carrying values of the trademarks, the Company completed interim quantitative impairment tests for goodwill. As the estimated fair value of the Dr.Jart+, DECIEM and Too Faced reporting units were in excess of their carrying values, the Company concluded that the carrying amounts of the goodwill were recoverable and did not record a goodwill impairment charge related to these reporting units. The fair value of these reporting units were based upon an equal weighting of the income and market approaches, utilizing estimated cash flows and a terminal value, discounted at a rate of return that reflects the relative risk of the cash flows, as well as valuation multiples derived from comparable publicly traded companies that are applied to operating performance of the reporting units. The significant assumptions used in these approaches include revenue growth rates and profit margins, terminal values, weighted average cost of capital used to discount future cash flows and royalty rates for trademarks. The most significant unobservable input used to estimate the fair value of the Dr. Jart+ trademark intangible asset was the weighted-average cost of capital, which was 10.5%.
13

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
A summary of the impairment charges for the three and nine months ended March 31, 2022 and the remaining trademark and goodwill carrying values as of March 31, 2022, for each reporting unit, are as follows:

(In millions) |  |  |  | Impairment Charge |  | Carrying Value
Reporting Unit: |  | Geographic Region |  | Trademarks |  | Goodwill |  | Trademarks |  | Goodwill
GLAMGLOW |  | The Americas |  | $ | 11 |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Dr. Jart+ |  | Asia/Pacific |  | 205 |  |  | — |  |  | 486 |  |  | 332 |
Total |  |  |  | $ | 216 |  |  | $ | — |  |  | $ | 486 |  |  | $ | 332 |

The impairment charges for the three and nine months ended March 31, 2022 were reflected in the skin care product category.
Impairment Testing During the Nine Months Ended March 31, 2021
During November 2020, given the actual and the estimate of the potential future impacts relating to the uncertainty of the duration and severity of COVID-19 impacting the Company and lower than expected results from geographic expansion, the Company made further revisions to the internal forecasts relating to its GLAMGLOW reporting unit. The Company concluded that the changes in circumstances in this reporting unit triggered the need for an interim impairment review of its trademark and goodwill. These changes in circumstances were also an indicator that the carrying amounts of GLAMGLOW's long-lived assets, including customer lists, may not be recoverable. Accordingly, the Company performed an interim impairment test for the trademark and a recoverability test for the long-lived assets as of November 30, 2020. The Company concluded that the carrying value of the trademark for GLAMGLOW exceeded its estimated fair value, which was determined utilizing the relief-from-royalty method to determine discounted projected future cash flows, and recorded an impairment charge of $21 million. In addition, the Company concluded that the carrying value of the GLAMGLOW customer lists intangible asset was fully impaired and recorded an impairment charge of $6 million. The fair value of all other long-lived assets of GLAMGLOW exceeded their carrying values and were not impaired as of November 30, 2020. After adjusting the carrying values of the trademark and customer lists intangible assets, the Company completed an interim quantitative impairment test for goodwill and recorded a goodwill impairment charge of $54 million, reducing the carrying value of goodwill for the GLAMGLOW reporting unit to zero. The fair value of the GLAMGLOW reporting unit was based upon an equal weighting of the income and market approaches, utilizing estimated cash flows and a terminal value, discounted at a rate of return that reflects the relative risk of the cash flows, as well as valuation multiples derived from comparable publicly traded companies that are applied to operating performance of the reporting unit. The impairment charges for the nine months ended March 31, 2021 were reflected in the skin care product category and in the Americas region. As of March 31, 2021, the remaining carrying value of the trademark related to the GLAMGLOW reporting unit was $36 million.
NOTE 4 – CHARGES ASSOCIATED WITH RESTRUCTURING AND OTHER ACTIVITIES
Charges associated with the Post-COVID Business Acceleration Program for the three and nine months ended March 31, 2022 were as follows:

|  | Sales Returns (included in Net Sales) |  | Cost of Sales |  | Operating Expenses |  | Total
(In millions) |  |  |  | Restructuring Charges |  | Other Charges |
Three months ended March 31, 2022 |  | $ | 1 |  |  | $ | — |  |  | $ | 17 |  |  | $ | 1 |  |  | $ | 19 |
Nine months ended March 31, 2022 |  | $ | 3 |  |  | $ | (2) |  |  | $ | 24 |  |  | $ | 6 |  |  | $ | 31 |

Charges associated with restructuring and other activities are not allocated to the Company's product categories or geographic regions because they are centrally directed and controlled, are not included in internal measures of product category or geographic region performance and result from activities that are deemed Company-wide initiatives to redesign, resize and reorganize select areas of the business.
14

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Post-COVID Business Acceleration Program
On August 20, 2020, the Company announced a two-year restructuring program, Post-COVID Business Acceleration Program (the “PCBA Program”), designed to realign the Company's business to address the dramatic shifts to its distribution landscape and consumer behaviors in the wake of the COVID-19 pandemic. The PCBA Program is designed to help improve efficiency and effectiveness by rebalancing resources to growth areas of prestige beauty. It is expected to further strengthen the Company by building upon the foundational capabilities in which the Company has invested.
The PCBA Program’s main areas of focus include accelerating the shift to online with the realignment of the Company’s distribution network reflecting freestanding store and certain department store closures, with a focus on North America and Europe, the Middle East & Africa; the reduction in brick-and-mortar point of sale employees and related support staff; and the redesign of the Company’s regional branded marketing organizations, plus select opportunities in global brands and functions. This program is expected to position the Company to better execute its long-term strategy while strengthening its financial flexibility.
As of March 31, 2022, the Company estimates a net reduction over the duration of the PCBA Program in the range of 2,000 to 2,500 positions globally, including temporary and part-time employees. This reduction takes into account the elimination of some positions, retraining and redeployment of certain employees and investment in new positions in key areas. The Company also estimates the closure over the duration of the PCBA Program of approximately 10% to 15% of its freestanding stores globally, primarily in Europe, the Middle East & Africa and in North America.
The Company plans to approve specific initiatives under the PCBA Program through fiscal 2022 and expects to substantially complete those initiatives through fiscal 2023. The Company expects that the PCBA Program will result in related restructuring and other charges totaling between $400 million and $500 million, before taxes.
PCBA Program Approvals
Total PCBA Program cumulative charges (adjustments) approved by the Company through March 31, 2022 were:

|  | Sales Returns (included in Net Sales) |  | Cost of Sales |  | Operating Expenses |  | Total
(In millions) |  |  |  | Restructuring Charges |  | Other Charges |
Total Charges (Adjustments) Approved |  |  |  |  |  |  |  |  |  |
Cumulative through June 30, 2021 |  | $ | 42 |  |  | $ | (6) |  |  | $ | 257 |  |  | $ | 21 |  |  | $ | 314 |
Nine months ended March 31, 2022 |  | (19) |  |  | 9 |  |  | 5 |  |  | 2 |  |  | (3) |
Cumulative through March 31, 2022 |  | $ | 23 |  |  | $ | 3 |  |  | $ | 262 |  |  | $ | 23 |  |  | $ | 311 |

Included in the above table, cumulative PCBA Program restructuring initiatives approved by the Company through March 31, 2022 by major cost type were:

(In millions) |  | Employee- Related Costs |  | Asset- Related Costs |  | Contract Terminations |  | Other Exit Costs |  | Total
Restructuring Charges (Adjustments) Approved |  |  |  |  |  |  |  |  |  |
Cumulative through June 30, 2021 |  | $ | 132 |  |  | $ | 108 |  |  | $ | 13 |  |  | $ | 4 |  |  | $ | 257 |
Nine months ended March 31, 2022 |  | 3 |  |  | 4 |  |  | (1) |  |  | (1) |  |  | 5 |
Cumulative through March 31, 2022 |  | $ | 135 |  |  | $ | 112 |  |  | $ | 12 |  |  | $ | 3 |  |  | $ | 262 |

15

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Specific actions taken since the PCBA Program inception include:
•Optimize Distribution Network – To help restore profitability to pre-COVID-19 pandemic levels in certain areas of its distribution network and, as part of a broader initiative to be completed in phases, the Company has approved initiatives to close a number of underperforming freestanding stores, counters and other retail locations, mainly in certain affiliates across all geographic regions, including the Company's travel retail network. These anticipated closures reflect changing consumer behaviors including higher demand for online and omnichannel capabilities. These activities will result in a net reduction in workforce, inventory and other asset write-offs, product returns, and termination of contracts.
•Optimize Digital Organization and Other Go-To-Market Organizations – The Company approved initiatives to enhance its go-to-market capabilities and shift more resources to support online growth. These actions will result in a net reduction of the workforce, which includes position eliminations, the re-leveling of certain positions and an investment in new capabilities.
•Optimize Select Marketing, Brand and Global Functions – The Company has started to reduce its corporate office footprint and is moving toward the future of work in a post-COVID environment, by restructuring where and how its employees work and collaborate. These actions will result primarily in lease termination fees.
•Exit of the Global Distribution of BECCA Products – In reviewing the Company's brand portfolio to improve efficiency and the sustainability of long-term investments, the decision was made to exit the global distribution of BECCA products due to its limited distribution, the ongoing decline in product demand and the challenging environment caused by the COVID-19 pandemic. These activities resulted in charges for the impairment of goodwill and other intangible assets, product returns, termination of contracts, and employee severance. The Company expects to substantially complete these initiatives during fiscal 2022.
•Exit of Certain Designer Fragrance Licenses – In reviewing the Company’s brand portfolio of fragrances and to focus on investing its resources on alternative opportunities for long-term growth and value creation globally, the Company announced that it is not renewing its existing license agreements for Donna Karan New York, DKNY, Michael Kors, Tommy Hilfiger and Ermenegildo Zegna when they expire in June 2023. The Company expects to continue to sell products under these licenses through June 30, 2022. These actions resulted in, or are expected to result in, employee-related costs, asset write-offs, including charges for the impairment of goodwill, and consulting and legal fees.
PCBA Program Restructuring and Other Charges
Restructuring charges are comprised of the following:
Employee-Related Costs – Employee-related costs are primarily comprised of severance and other post-employment benefit costs, calculated based on salary levels, prior service and other statutory minimum benefits, if applicable.
Asset-Related Costs – Asset-related costs primarily consist of asset write-offs or accelerated depreciation related to long-lived assets in certain freestanding stores (including rights associated with commercial operating leases and operating lease right-of-use assets) that will be taken out of service prior to their existing useful life as a direct result of a restructuring initiative. These costs also include goodwill and other intangible asset impairment charges relating to the exit of the global distribution of BECCA products.
Contract Terminations – Costs related to contract terminations include continuing payments to a third party after the Company has ceased benefiting from the rights conveyed in the contract, or a payment made to terminate a contract prior to its expiration.
Other Exit Costs – Other exit costs related to restructuring activities generally include costs to relocate facilities or employees, recruiting to fill positions as a result of relocation of operations, and employee outplacement for separated employees.
16

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Other charges associated with restructuring activities are comprised of the following:
Sales Returns and Cost of Sales – Product returns (offset by the related cost of sales) and inventory write-offs or write-downs as a direct result of an approved restructuring initiative to exit certain businesses or locations will be recorded as a component of Net sales and/or Cost of sales when estimable and reasonably assured.
Other Charges – The Company approved other charges related to the design and implementation of approved initiatives, which are charged to Operating expenses as incurred and primarily include the following:
•Consulting and other professional services for organizational design of the future structures and processes as well as the implementation thereof;
•Temporary labor backfill;
•Costs to establish and maintain a PMO for the duration of the PCBA Program, including internal costs for employees dedicated solely to project management activities, and other PMO-related expenses incremental to the Company’s ongoing operations (e.g., rent and utilities); and
•Recruitment and training costs for new and reskilled employees to acquire and apply the capabilities needed to perform responsibilities as a direct result of an approved restructuring initiative.
The Company records approved charges associated with restructuring and other activities once the relevant accounting criteria have been met. Total cumulative charges recorded associated with restructuring and other activities for the PCBA Program were:

|  | Sales Returns (included in Net Sales) |  | Cost of Sales |  | Operating Expenses |  | Total
(In millions) |  |  |  | Restructuring Charges |  | Other Charges |
Total Charges (Adjustments) |  |  |  |  |  |  |  |  |  |
Cumulative through June 30, 2021 |  | $ | 14 |  |  | $ | 2 |  |  | $ | 201 |  |  | $ | 4 |  |  | $ | 221 |
Nine months ended March 31, 2022 |  | 3 |  |  | (2) |  |  | 24 |  |  | 6 |  |  | 31 |
Cumulative through March 31, 2022 |  | $ | 17 |  |  | $ | — |  |  | $ | 225 |  |  | $ | 10 |  |  | $ | 252 |

(In millions) |  | Employee- Related Costs |  | Asset- Related Costs |  | Contract Terminations |  | Other Exit Costs |  | Total
Restructuring Charges (Adjustments) |  |  |  |  |  |  |  |  |  |
Cumulative through June 30, 2021 |  | $ | 119 |  |  | $ | 75 |  |  | $ | 6 |  |  | $ | 1 |  |  | $ | 201 |
Nine months ended March 31, 2022 |  | 5 |  |  | 7 |  |  | 11 |  |  | 1 |  |  | 24 |
Cumulative through March 31, 2022 |  | $ | 124 |  |  | $ | 82 |  |  | $ | 17 |  |  | $ | 2 |  |  | $ | 225 |

17

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Changes in accrued restructuring charges for the nine months ended March 31, 2022 relating to the PCBA Program were:

(In millions) |  | Employee- Related Costs |  | Asset- Related Costs |  | Contract Terminations |  | Other Exit Costs |  | Total
Balance at June 30, 2021 |  | $ | 101 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 101 |
Charges |  | 5 |  |  | 7 |  |  | 11 |  |  | 1 |  |  | 24
Cash payments |  | (39) |  |  | — |  |  | (11) |  |  | (1) |  |  | (51) |
Non-cash asset write-offs |  | — |  |  | (7) |  |  | — |  |  | — |  |  | (7) |
Translation and other adjustments |  | (7) |  |  | — |  |  | — |  |  | — |  |  | (7) |
Balance at March 31, 2022 |  | $ | 60 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 60 |

Accrued restructuring charges at March 31, 2022 relating to the PCBA Program are expected to result in cash expenditures funded from cash provided by operations of approximately $23 million, $30 million and $7 million for the remainder of fiscal 2022 and for fiscal 2023 and 2024, respectively.
Between April 1, 2022 and April 26, 2022, the Company approved certain initiatives under the PCBA Program within areas of Optimize Distribution Network and Optimize Select Marketing, Brand and Global Functions. These initiatives pertain primarily to asset write-offs to close an underperforming freestanding store and the optimization of where and how employees work and collaborate.
Once the relevant accounting criteria have been met, the Company expects to record restructuring and other charges of approximately $50 million (before tax) in connection with these initiatives.
The following presents the restructuring initiatives approved from April 1, 2022 to April 26, 2022 by major cost type:

|  | Sales Returns (included in Net Sales) |  | Cost of Sales |  | Operating Expenses |  | Total
(In millions) |  |  |  | Restructuring Charges |  | Other Charges |
Approval Period |  |  |  |  |  |  |  |  |  |
April 1, 2022 - April 26, 2022 |  | $ | — |  |  | $ | — |  |  | $ | 50 |  |  | $ | — |  |  | $ | 50 |

Included in the above table, cumulative restructuring initiatives approved by the Company from April 1, 2022 to April 26, 2022 were:

(In millions) |  | Employee- Related Costs |  | Asset- Related Costs |  | Contract Terminations |  | Other Exit Costs |  | Total
Approval Period |  |  |  |  |  |  |  |  |  |
April 1, 2022 - April 26, 2022 |  | $ | — |  |  | $ | 34 |  |  | $ | 16 |  |  | $ | — |  |  | $ | 50 |

Leading Beauty Forward Program
The Company substantially completed initiatives approved under the Leading Beauty Program (the “LBF Program”) through fiscal 2021. Additional information about the LBF Program is included in the notes to consolidated financial statements in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2021.
18

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE 5 – DERIVATIVE FINANCIAL INSTRUMENTS
The Company addresses certain financial exposures through a controlled program of risk management that includes the use of derivative financial instruments. The Company enters into foreign currency forward contracts, and may enter into option contracts, to reduce the effects of fluctuating foreign currency exchange rates. In addition, the Company enters into interest rate derivatives to manage the effects of interest rate movements on the Company’s aggregate liability portfolio, including potential future debt issuances. The Company also enters into foreign currency forward contracts to hedge a portion of its net investment in certain foreign operations, which are designated as net investment hedges. The Company enters into the net investment hedges to offset the risk of changes in the U.S. dollar value of the Company’s investment in these foreign operations due to fluctuating foreign exchange rates. Time value is excluded from the effectiveness assessment and is recognized under a systematic and rational method over the life of the hedging instrument in Selling, general and administrative expenses. The net gain or loss on net investment hedges is recorded within translation adjustments, as a component of accumulated OCI (“AOCI”) on the Company’s consolidated balance sheets, until the sale or substantially complete liquidation of the underlying assets of the Company’s investment. The Company also enters into foreign currency forward contracts, and may use option contracts, not designated as hedging instruments, to mitigate the change in fair value of specific assets and liabilities on the consolidated balance sheets. At March 31, 2022, the notional amount of derivatives not designated as hedging instruments was $3,887 million. The Company does not utilize derivative financial instruments for trading or speculative purposes. Costs associated with entering into derivative financial instruments have not been material to the Company’s consolidated financial results.
For each derivative contract entered into, where the Company looks to obtain hedge accounting treatment, the Company formally and contemporaneously documents all relationships between hedging instruments and hedged items, as well as its risk-management objective and strategy for undertaking the hedge transaction, the nature of the risk being hedged, and how the hedging instruments’ effectiveness in offsetting the hedged risk will be assessed prospectively and retrospectively. This process includes linking all derivatives to specific assets and liabilities on the balance sheet or to specific firm commitments or forecasted transactions. At inception, the Company evaluates the effectiveness of hedge relationships quantitatively, and has elected to perform, after initial evaluation, qualitative effectiveness assessments of certain hedge relationships to support an ongoing expectation of high effectiveness, if effectiveness testing is required. If based on the qualitative assessment, it is determined that a derivative has ceased to be a highly effective hedge, the Company will perform a quantitative assessment to determine whether to discontinue hedge accounting with respect to that derivative prospectively.
The fair values of the Company’s derivative financial instruments included in the consolidated balance sheets are presented as follows:

|  | Asset Derivatives |  | Liability Derivatives
|  |  |  | Fair Value (1) |  |  |  | Fair Value (1)
(In millions) |  | Balance Sheet Location |  | March 31, 2022 |  | June 30, 2021 |  | Balance Sheet Location |  | March 31, 2022 |  | June 30, 2021
Derivatives Designated as Hedging Instruments: |  |  |  |  |  |  |  |  |  |  |  |
Foreign currency cash flow hedges |  | Prepaid expenses and other current assets |  | $ | 21 |  |  | $ | 12 |  |  | Other accrued liabilities |  | $ | 22 |  |  | $ | 20 |
Net investment hedges |  | Prepaid expenses and other current assets |  | 15 |  |  | 34 |  |  | Other accrued liabilities |  | — |  |  | — |
Interest rate-related derivatives |  | Prepaid expenses and other current assets |  | 10 |  |  | 15 |  |  | Other accrued liabilities |  | 71 |  |  | — |
Total Derivatives Designated as Hedging Instruments |  |  |  | 46 |  |  | 61 |  |  |  |  | 93 |  |  | 20 |
Derivatives Not Designated as Hedging Instruments: |  |  |  |  |  |  |  |  |  |  |  |
Foreign currency forward contracts |  | Prepaid expenses and other current assets |  | 23 |  |  | 6 |  |  | Other accrued liabilities |  | 25 |  |  | 36 |
Total derivatives |  |  |  | $ | 69 |  |  | $ | 67 |  |  |  |  | $ | 118 |  |  | $ | 56 |

(1)See Note 6 – Fair Value Measurements for further information about how the fair value of derivative assets and liabilities are determined.
19

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
The amounts of the gains and losses related to the Company’s derivative financial instruments designated as hedging instruments that are included in the assessment of effectiveness are as follows:

|  | Amount of Gain (Loss) Recognized in OCI on Derivatives |  | Location of Gain (Loss) Reclassified from AOCI into Earnings |  | Amount of Gain (Loss) Reclassified from AOCI into Earnings(1)
|  | Three Months Ended March 31 |  |  | Three Months Ended March 31
(In millions) |  | 2022 |  | 2021 |  |  | 2022 |  | 2021
Derivatives in Cash Flow Hedging Relationships: |  |  |  |  |  |  |  |  |  |
Foreign currency forward contracts |  | $ | (2) |  |  | $ | 22 |  |  | Net sales |  | $ | 3 |  |  | $ | (7) |
Interest rate-related derivatives |  | 10 |  |  | 11 |  |  | Interest expense |  | — |  |  | (1) |
|  | 8 |  |  | 33 |  |  |  |  | 3 |  |  | (8) |
Derivatives in Net Investment Hedging Relationships(2): |  |  |  |  |  |  |  |  |  |
Foreign currency forward contracts(3) |  | 17 |  |  | 125 |  |  |  |  | — |  |  | — |
Total derivatives |  | $ | 25 |  |  | $ | 158 |  |  |  |  | $ | 3 |  |  | $ | (8) |

(1)The amount reclassified into earnings as a result of the discontinuance of cash flow hedges because probable forecasted transactions will no longer occur by the end of the original time period was not material.
(2)During the three months ended March 31, 2022 and 2021, the gain recognized in earnings from net investment hedges related to the amount excluded from effectiveness testing was $3 million and $5 million, respectively.
(3)Included within translation adjustments as a component of AOCI on the Company’s consolidated balance sheets.

|  | Amount of Gain (Loss) Recognized in OCI on Derivatives |  | Location of Gain (Loss) Reclassified from AOCI into Earnings |  | Amount of Gain (Loss) Reclassified from AOCI into Earnings(1)
|  | Nine Months Ended March 31 |  |  | Nine Months Ended March 31
(In millions) |  | 2022 |  | 2021 |  |  | 2022 |  | 2021
Derivatives in Cash Flow Hedging Relationships: |  |  |  |  |  |  |  |  |  |
Foreign currency forward contracts |  | $ | 5 |  |  | $ | (43) |  |  | Net sales |  | $ | (5) |  |  | $ | (11) |
Interest rate-related derivatives |  | 10 |  |  | 14 |  |  | Interest expense |  | (1) |  |  | (2) |
|  | 15 |  |  | (29) |  |  |  |  | (6) |  |  | (13) |
Derivatives in Net Investment Hedging Relationships(2): |  |  |  |  |  |  |  |  |  |
Foreign currency forward contracts(3) |  | 87 |  |  | (17) |  |  |  |  | — |  |  | — |
Total derivatives |  | $ | 102 |  |  | $ | (46) |  |  |  |  | $ | (6) |  |  | $ | (13) |

(1)The amount reclassified into earnings as a result of the discontinuance of cash flow hedges because probable forecasted transactions will no longer occur by the end of the original time period was not material.
(2)During the nine months ended March 31, 2022 and 2021, the gain recognized in earnings from net investment hedges related to the amount excluded from effectiveness testing was $8 million and $15 million, respectively.
(3)Included within translation adjustments as a component of AOCI on the Company’s consolidated balance sheets.
20

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

|  |  |  | Amount of Gain (Loss) Recognized in Earnings on Derivatives (1) |  |  |  |
|  | Location of Gain (Loss) Recognized in Earnings on Derivatives |  |  |  |  |  |  |  |  |  |  |  |
|  |  | Three Months Ended March 31 |  | Nine Months Ended March 31 |  |
(In millions) |  |  | 2022 |  | 2021 |  | 2022 |  | 2021 |  |  |  |
Derivatives in Fair Value Hedging Relationships: |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest rate swap contracts |  | Interest expense |  | $ | (69) |  |  | $ | (18) |  |  | $ | (85) |  |  | $ | (23) |  |  |  |  |

(1)Changes in the fair value of the interest rate swap agreements are exactly offset by the change in the fair value of the underlying long-term debt.
Additional information regarding the cumulative amount of fair value hedging gain (loss) recognized in earnings for items designated and qualifying as hedged items in fair value hedges is as follows:

(In millions) |  |  |  |
Line Item in the Consolidated Balance Sheets in Which the Hedged Item is Included |  | Carrying Amount of the Hedged Liabilities |  | Cumulative Amount of Fair Value Hedging Gain (Loss) Included in the Carrying Amount of the Hedged Liability
|  | March 31, 2022 |  | March 31, 2022
Current debt |  | $ | 251 |  |  | $ | 1 |
Long-term debt |  | 921 |  |  | (71) |
Total debt |  | $ | 1,172 |  |  | $ | (70) |

21

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Additional information regarding the effects of fair value and cash flow hedging relationships for derivatives designated and qualifying as hedging instruments is as follows:

|  | Three Months Ended March 31
|  | 2022 |  | 2021
(In millions) |  | Net Sales |  | Interest Expense |  | Net Sales |  | Interest Expense
Total amounts of income and expense line items presented in the consolidated statements of earnings in which the effects of fair value and cash flow hedges are recorded |  | $ | 4,245 |  |  | $ | 41 |  |  | $ | 3,864 |  |  | $ | 43 |
The effects of fair value and cash flow hedging relationships: |  |  |  |  |  |  |  |
Gain (loss) on fair value hedge relationships – interest rate contracts: |  |  |  |  |  |  |  |
Hedged item |  | Not applicable |  | 69 |  |  | Not applicable |  | 18 |
Derivatives designated as hedging instruments |  | Not applicable |  | (69) |  |  | Not applicable |  | (18) |
Gain (loss) on cash flow hedge relationships – interest rate contracts: |  |  |  |  |  |  |  |
Amount of loss reclassified from AOCI into earnings |  | Not applicable |  | — |  |  | Not applicable |  | (1) |
Gain (loss) on cash flow hedge relationships – foreign currency forward contracts: |  |  |  |  |  |  |  |
Amount of gain reclassified from AOCI into earnings |  | 3 |  |  | Not applicable |  | (7) |  |  | Not applicable

22

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

|  | Nine Months Ended March 31
|  | 2022 |  | 2021
(In millions) |  | Net Sales |  | Interest Expense |  | Net Sales |  | Interest Expense
Total amounts of income and expense line items presented in the consolidated statements of earnings in which the effects of fair value and cash flow hedges are recorded |  | $ | 14,176 |  |  | $ | 125 |  |  | $ | 12,279 |  |  | $ | 131 |
The effects of fair value and cash flow hedging relationships: |  |  |  |  |  |  |  |
Gain (loss) on fair value hedge relationships – interest rate contracts: |  |  |  |  |  |  |  |
Hedged item |  | Not applicable |  | 85 |  |  | Not applicable |  | 23 |
Derivatives designated as hedging instruments |  | Not applicable |  | (85) |  |  | Not applicable |  | (23) |
Gain (loss) on cash flow hedge relationships – interest rate contracts: |  |  |  |  |  |  |  |
Amount of loss reclassified from AOCI into earnings |  | Not applicable |  | (1) |  |  | Not applicable |  | (2) |
Gain (loss) on cash flow hedge relationships – foreign currency forward contracts: |  |  |  |  |  |  |  |
Amount of gain reclassified from AOCI into earnings |  | (5) |  |  | Not applicable |  | (11) |  |  | Not applicable

The amount of gains and losses related to the Company’s derivative financial instruments not designated as hedging instruments are presented as follows:

|  |  |  | Amount of Gain (Loss) Recognized in Earnings on Derivatives |  |  |  |
|  | Location of Gain (Loss) Recognized in Earnings on Derivatives |  | Three Months Ended March 31 |  | Nine Months Ended March 31 |  |
(In millions) |  |  | 2022 |  | 2021 |  | 2022 |  | 2021 |  |  |  |
Derivatives Not Designated as Hedging Instruments: |  |  |  |  |  |  |  |  |  |  |  |  |  |
Foreign currency forward contracts |  | Selling, general and administrative |  | $ | 17 |  |  | $ | (97) |  |  | $ | (32) |  |  | $ | (34) |  |  |  |  |

23

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Cash Flow Hedges
The Company enters into foreign currency forward contracts, and may enter into foreign currency option contracts, to hedge anticipated transactions and receivables and payables denominated in foreign currencies, for periods consistent with the Company’s identified exposures. The purpose of the hedging activities is to minimize the effect of foreign exchange rate movements on the cash flows that the Company receives from foreign subsidiaries. The foreign currency forward contracts entered into to hedge anticipated transactions have been designated as cash flow hedges and have varying maturities through the end of December 2023. Hedge effectiveness of the foreign currency forward contracts is based on the forward method, which includes time value in the effectiveness assessment. At March 31, 2022, the Company had cash flow hedges outstanding with a notional amount totaling $1,563 million.
The Company may enter into interest rate forward contracts to hedge anticipated issuance of debt for periods consistent with the Company’s identified exposures. The purpose of the hedging activities is to minimize the effect of interest rate movements on the cost of debt issuance.
For hedge contracts that are no longer deemed highly effective, hedge accounting is discontinued and gains and losses in AOCI are reclassified to sales when the underlying forecasted transaction occurs. If it is probable that the forecasted transaction will no longer occur, then any gains or losses in AOCI are reclassified to current-period sales. As of March 31, 2022, the Company’s foreign currency cash flow hedges were highly effective.
The estimated net gain on the Company’s derivative instruments designated as cash flow hedges as of March 31, 2022 that is expected to be reclassified from AOCI into earnings, net of tax, within the next twelve months is $1 million. The accumulated net gain (loss) on derivative instruments in AOCI was $20 million and $(1) million as of March 31, 2022 and June 30, 2021, respectively.
Fair Value Hedges
The Company enters into interest rate derivative contracts to manage the exposure to interest rate fluctuations on its funded indebtedness. The Company has interest rate swap agreements, with notional amounts totaling $250 million, $700 million and $300 million to effectively convert the fixed rate interest on its 2022 Senior Notes, 2030 Senior Notes and 2031 Senior Notes, respectively, to variable interest rates based on three-month LIBOR plus a margin. These interest rate swap agreements are designated as fair value hedges of the related long-term debt, and the changes in the fair value of the interest rate swap agreements are exactly offset by the change in the fair value of the underlying long-term debt.
Net Investment Hedges
The Company enters into foreign currency forward contracts, designated as net investment hedges, to hedge a portion of its net investment in certain foreign operations. The net gain or loss on these contracts is recorded within translation adjustments, as a component of AOCI on the Company’s consolidated balance sheets. The purpose of the hedging activities is to minimize the effect of foreign exchange rate movements on the Company’s net investment in these foreign operations. The net investment hedge contracts have varying maturities through the end of July 2022. Hedge effectiveness of the net investment hedge contracts is based on the spot method. At March 31, 2022, the Company had net investment hedges outstanding with a notional amount totaling $1,372 million.
Credit Risk
As a matter of policy, the Company enters into derivative contracts only with counterparties that have a long-term credit rating of at least A- or higher by at least two nationally recognized rating agencies. The counterparties to these contracts are major financial institutions. Exposure to credit risk in the event of nonperformance by any of the counterparties is limited to the gross fair value of contracts in asset positions, which totaled $69 million at March 31, 2022. To manage this risk, the Company has strict counterparty credit guidelines that are continually monitored. Accordingly, management believes risk of loss under these hedging contracts is remote.
24

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE 6 – FAIR VALUE MEASUREMENTS
The Company records certain of its financial assets and liabilities at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability, in the principal or most advantageous market for the asset or liability, in an orderly transaction between market participants at the measurement date. The accounting for fair value measurements must be applied to nonfinancial assets and nonfinancial liabilities that require initial measurement or remeasurement at fair value, which principally consist of assets and liabilities acquired through business combinations and goodwill, indefinite-lived intangible assets and long-lived assets for the purposes of calculating potential impairment. The Company is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows:
Level 1: Inputs based on quoted market prices for identical assets or liabilities in active markets at the measurement date.
Level 2: Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
Level 3: Inputs reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. The inputs are unobservable in the market and significant to the instrument’s valuation.
The following table presents the Company’s hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2022:

(In millions) |  | Level 1 |  | Level 2 |  | Level 3 |  | Total
Assets: |  |  |  |  |  |  |  |
Money market funds |  | $ | 1,019 |  |  | $ | — |  |  | $ | — |  |  | $ | 1,019 |
Foreign currency forward contracts |  | — |  |  | 59 |  |  | — |  |  | 59 |
Interest rate-related derivatives |  | — |  |  | 10 |  |  | — |  |  | 10 |
Total |  | $ | 1,019 |  |  | $ | 69 |  |  | $ | — |  |  | $ | 1,088 |
Liabilities: |  |  |  |  |  |  |  |
Foreign currency forward contracts |  | $ | — |  |  | $ | 47 |  |  | $ | — |  |  | $ | 47 |
Interest rate-related derivatives |  | — |  |  | 71 |  |  | — |  |  | 71 |
DECIEM stock options |  | — |  |  | — |  |  | 74 |  |  | 74 |
Total |  | $ | — |  |  | $ | 118 |  |  | $ | 74 |  |  | $ | 192 |

25

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
The following table presents the Company’s hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2021:

(In millions) |  | Level 1 |  | Level 2 |  | Level 3 |  | Total
Assets: |  |  |  |  |  |  |  |
Money market funds |  | $ | 2,079 |  |  | $ | — |  |  | $ | — |  |  | $ | 2,079 |
Foreign currency forward contracts |  | — |  |  | 52 |  |  | — |  |  | 52 |
Interest rate-related derivatives |  | — |  |  | 15 |  |  | — |  |  | 15 |
Total |  | $ | 2,079 |  |  | $ | 67 |  |  | $ | — |  |  | $ | 2,146 |
Liabilities: |  |  |  |  |  |  |  |
Foreign currency forward contracts |  | $ | — |  |  | $ | 56 |  |  | $ | — |  |  | $ | 56 |
DECIEM stock options |  | — |  |  | — |  |  | 141 |  |  | 141 |
Total |  | $ | — |  |  | $ | 56 |  |  | $ | 141 |  |  | $ | 197 |

The estimated fair values of the Company’s financial instruments are as follows:

|  | March 31, 2022 |  | June 30, 2021
(In millions) |  | Carrying Amount |  | Fair Value |  | Carrying Amount |  | Fair Value
Nonderivatives |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 3,836 |  |  | $ | 3,836 |  |  | $ | 4,958 |  |  | $ | 4,958 |
Current and long-term debt |  | 5,457 |  |  | 5,607 |  |  | 5,569 |  |  | 6,262 |
DECIEM stock options |  | 74 |  |  | 74 |  |  | 141 |  |  | 141 |
Derivatives |  |  |  |  |  |  |  |
Foreign currency forward contracts – asset (liability), net |  | 12 |  |  | 12 |  |  | (4) |  |  | (4) |
Interest rate-related derivatives – asset (liability), net |  | (61) |  |  | (61) |  |  | 15 |  |  | 15 |

26

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
The following table presents the Company’s impairment charges for the nine months ended March 31, 2022 for certain of its nonfinancial assets measured at fair value on a nonrecurring basis, classified as Level 3, due to a change in circumstances that triggered an interim impairment test:

(In millions) |  | Impairment charges |  | Date of Fair Value Measurement |  | Fair Value(1)
Other intangible assets, net (trademarks) |  |  |  |  |  |
GLAMGLOW |  | $ | 11 |  |  | March 31, 2022 |  | $ | — |
Dr. Jart+ |  | 205 |  |  | February 28, 2022 |  | 486 |
Total |  | 216 |  |  |  |  | 486 |
Total |  | $ | 216 |  |  |  |  | $ | 486 |

(1)See Note 3 - Goodwill and Other Intangible Assets for discussion of the valuation techniques used to measure fair value, the description of the inputs and information used to develop those inputs.
The following table presents the Company’s impairment charges for the nine months ended March 31, 2021 for certain of its nonfinancial assets measured at fair value on a nonrecurring basis, classified as Level 3, due to a change in circumstances that triggered an interim impairment test:

(In millions) |  | Impairment charges |  | Date of Fair Value Measurement |  | Fair Value(1)
Goodwill |  |  |  |  |  |
GLAMGLOW |  | $ | 54 |  |  | November 30, 2020 |  | $ | — |
BECCA(2) |  | 13 |  |  | February 28, 2021 |  | — |
Total |  | 67 |  |  |  |  | — |
Other intangible assets, net (trademark and customer lists) |  |  |  |  |  |
GLAMGLOW |  | 27 |  |  | November 30, 2020 |  | 36 |
BECCA(2) |  | 34 |  |  | February 28, 2021 |  | — |
Total |  | 61 |  |  |  |  | 36 |
Long-lived assets |  | 33 |  |  | March 31, 2021 |  | 35 |
Total |  | $ | 161 |  |  |  |  | $ | 71 |

(1)See Note 3 - Goodwill and Other Intangible Assets for discussion of the valuation techniques used to measure fair value, the description of the inputs and information used to develop those inputs.
(2)See Note 4 – Charges Associated with Restructuring and Other Activities for further information relating to goodwill and other intangible asset impairment charges recorded in connection with the exit of the global distribution of BECCA products.
The following methods and assumptions were used to estimate the fair value of the Company’s financial instruments for which it is practicable to estimate that value:
Cash and cash equivalents – Cash and all highly-liquid securities with original maturities of three months or less are classified as cash and cash equivalents, primarily consisting of cash deposits in interest bearing accounts, time deposits and money market funds (classified within Level 1 of the valuation hierarchy). Cash deposits in interest bearing accounts and time deposits are carried at cost, which approximates fair value due to the short maturity of cash equivalent instruments.
27

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Foreign currency forward contracts – The fair values of the Company’s foreign currency forward contracts were determined using an industry-standard valuation model, which is based on an income approach. The significant observable inputs to the model, such as swap yield curves and currency spot and forward rates, were obtained from an independent pricing service. To determine the fair value of contracts under the model, the difference between the contract price and the current forward rate was discounted using LIBOR for contracts with maturities up to 12 months, and swap yield curves for contracts with maturities greater than 12 months.
Interest rate contracts – The fair values of the Company’s interest rate contracts were determined using an industry-standard valuation model, which is based on the income approach. The significant observable inputs to the model, such as treasury yield curves, swap yield curves and LIBOR forward rates, were obtained from independent pricing services.
Current and long-term debt – The fair value of the Company’s debt was estimated based on the current rates offered to the Company for debt with the same remaining maturities. To a lesser extent, debt also includes finance lease obligations for which the carrying amount approximates the fair value. The Company’s debt is classified within Level 2 of the valuation hierarchy.
DECIEM stock options – The stock option liability represents the employee stock options issued by DECIEM in replacement and exchange for certain vested and unvested DECIEM employee stock options previously issued by DECIEM, in connection with the Company's acquisition of DECIEM. The DECIEM stock options are subject to the terms and conditions of DECIEM's 2021 Stock Option Plan. The initial fair value of the DECIEM stock option liability was calculated using the acquisition date fair value multiplied by the number of options replaced (consisting of vested and partially vested stock options) on the day following the acquisition date. The acquisition date fair value was calculated using the Monte Carlo Method, which requires certain assumptions. Significant changes in the projected future operating results would result in a higher or lower fair value measurement. Changes to the discount rates or volatilities would have a lesser effect. These inputs are categorized as Level 3 of the valuation hierarchy. The DECIEM stock options are remeasured to fair value at each reporting date through the period when the options are exercised or repurchased (i.e., when they are settled), with an offsetting entry to compensation expense. See Note 2 – Acquisition of Business and Note 10 – Stock Programs for discussion.
Changes in the DECIEM stock option liability for the nine months ended March 31, 2022 are included in Selling, general and administrative expenses in the accompanying consolidated statements of earnings and were as follows:

(In millions) |  | Fair Value
DECIEM stock option liability as of June 30, 2021 |  | $ | 141 |
Changes in fair value, net of foreign currency remeasurements(1) |  | (58) |
Translation adjustments and other, net |  | (9) |
DECIEM stock option liability as of March 31, 2022 |  | $ | 74 |

(1)Amount includes expense attributable to graded vesting of stock options which is not material for the nine months ended March 31, 2022.
NOTE 7 – REVENUE RECOGNITION
The Company’s revenue recognition accounting policies are described in the notes to consolidated financial statements in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2021.
Accounts Receivable
Accounts receivable, net is stated net of the allowance for doubtful accounts and customer deductions totaling $36 million and $40 million as of March 31, 2022 and June 30, 2021, respectively. Payment terms are short-term in nature and are generally less than one year.
28

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Changes in the allowance for credit losses are as follows:

(In millions) |  | March 31, 2022
Balance at June 30, 2021 |  | $ | 20 |
Adjustment for expected credit losses |  | (2) |
Write-offs, net & other |  | (1) |
Balance at March 31, 2022 |  | $ | 17 |

The remaining balance of the allowance for doubtful accounts of $19 million, as of March 31, 2022, relates to non-credit losses, which are primarily due to customer deductions.
Deferred Revenue
Changes in deferred revenue during the period are as follows:

|  | Three Months Ended March 31 |  | Nine Months Ended March 31
(In millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021
Deferred revenue, beginning of period |  | $ | 421 |  |  | $ | 420 |  |  | $ | 371 |  |  | $ | 279 |
Revenue recognized that was included in the deferred revenue balance at the beginning of the period |  | (40) |  |  | (25) |  |  | (288) |  |  | (198) |
Revenue deferred (released) during the period |  | (13) |  |  | (30) |  |  | 285 |  |  | 278 |
Other |  | (4) |  |  | (4) |  |  | (4) |  |  | 2 |
Deferred revenue, end of period |  | $ | 364 |  |  | $ | 361 |  |  | $ | 364 |  |  | $ | 361 |

Transaction Price Allocated to the Remaining Performance Obligations
At March 31, 2022, the combined estimated revenue expected to be recognized in the next twelve months related to performance obligations for customer loyalty programs, gift with purchase promotions, purchase with purchase promotions and gift card liabilities that are unsatisfied (or partially unsatisfied) is $313 million. The remaining balance of deferred revenue at March 31, 2022 will be recognized beyond the next twelve months.
NOTE 8 – PENSION AND POST-RETIREMENT BENEFIT PLANS
The Company maintains pension plans covering substantially all of its full-time employees for its U.S. operations and a majority of its international operations. The Company also maintains post-retirement benefit plans that provide certain medical and dental benefits to eligible employees. Descriptions of these plans are included in the notes to consolidated financial statements in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2021.
The components of net periodic benefit cost for the three months ended March 31, 2022 and 2021 consisted of the following:

|  | Pension Plans |  | Other than Pension Plans
|  | U.S. |  | International |  | Post-retirement
(In millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021 |  | 2022 |  | 2021
Service cost |  | $ | 12 |  |  | $ | 12 |  |  | $ | 8 |  |  | $ | 9 |  |  | $ | 1 |  |  | $ | 2 |
Interest cost |  | 8 |  |  | 8 |  |  | 3 |  |  | 2 |  |  | 1 |  |  | 1 |
Expected return on plan assets |  | (14) |  |  | (14) |  |  | (4) |  |  | (4) |  |  | — |  |  | (1) |
Amortization of: |  |  |  |  |  |  |  |  |  |  |  |
Actuarial loss |  | 4 |  |  | 5 |  |  | — |  |  | 1 |  |  | — |  |  | — |
Prior service cost |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Settlements |  | — |  |  | — |  |  | — |  |  | 1 |  |  | — |  |  | — |
Special termination benefits |  | — |  |  | — |  |  | 1 |  |  | 1 |  |  | — |  |  | — |
Net periodic benefit cost |  | $ | 10 |  |  | $ | 11 |  |  | $ | 8 |  |  | $ | 10 |  |  | $ | 2 |  |  | $ | 2 |

29

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
The components of net periodic benefit cost for the nine months ended March 31, 2022 and 2021 consisted of the following:

|  | Pension Plans |  | Other than Pension Plans
|  | U.S. |  | International |  | Post-retirement
(In millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021 |  | 2022 |  | 2021
Service cost |  | $ | 35 |  |  | $ | 34 |  |  | $ | 24 |  |  | $ | 27 |  |  | $ | 2 |  |  | $ | 2 |
Interest cost |  | 23 |  |  | 23 |  |  | 8 |  |  | 7 |  |  | 4 |  |  | 4 |
Expected return on plan assets |  | (41) |  |  | (40) |  |  | (11) |  |  | (10) |  |  | (1) |  |  | (1) |
Amortization of: |  |  |  |  |  |  |  |  |  |  |  |
Actuarial loss |  | 11 |  |  | 15 |  |  | 1 |  |  | 3 |  |  | 1 |  |  | — |
Prior service cost |  | — |  |  | — |  |  | (1) |  |  | — |  |  | — |  |  | — |
Settlements |  | — |  |  | — |  |  | — |  |  | 1 |  |  | — |  |  | — |
Special termination benefits |  | — |  |  | — |  |  | 4 |  |  | 10 |  |  | — |  |  | — |
Net periodic benefit cost |  | $ | 28 |  |  | $ | 32 |  |  | $ | 25 |  |  | $ | 38 |  |  | $ | 6 |  |  | $ | 5 |

During the nine months ended March 31, 2022, the Company made contributions to its international pension plans totaling $17 million.
The amounts recognized in the consolidated balance sheets related to the Company’s pension and post-retirement benefit plans consist of the following:

(In millions) |  | March 31, 2022 |  | June 30, 2021
Other assets |  | $ | 142 |  |  | $ | 162 |
Other accrued liabilities |  | (28) |  |  | (28) |
Other noncurrent liabilities |  | (426) |  |  | (432) |
Funded status |  | (312) |  |  | (298) |
Accumulated other comprehensive loss |  | 229 |  |  | 242 |
Net amount recognized |  | $ | (83) |  |  | $ | (56) |

NOTE 9 – CONTINGENCIES
Legal Proceedings
The Company is involved, from time to time, in litigation and other legal proceedings incidental to its business, including employment, intellectual property, real estate, environmental, regulatory, advertising, trade relations, tax, privacy, and product liability matters (including asbestos-related claims). Management believes that the outcome of current litigation and legal proceedings will not have a material adverse effect upon the Company’s business, results of operations, financial condition or cash flows. However, management’s assessment of the Company’s current litigation and other legal proceedings could change in light of the discovery of facts with respect to legal actions or other proceedings pending against the Company not presently known to the Company or determinations by judges, juries or other finders of fact which are not in accord with management’s evaluation of the possible liability or outcome of such litigation or proceedings. Reasonably possible losses in addition to the amounts accrued for such litigation and legal proceedings are not material to the Company’s consolidated financial statements.
30

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE 10 – STOCK PROGRAMS
Additional information relating to the Company's stock programs and the DECIEM stock options are included in the notes to consolidated financial statements in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2021.
The Company's Stock Programs
Total net stock-based compensation expense is attributable to the granting of, and the remaining requisite service periods of stock options, restricted stock units (“RSUs”), performance share units (“PSUs”), long-term PSUs, including long-term price-vested units and share units. Compensation expense attributable to net stock-based compensation was $91 million and $86 million for the three months ended March 31, 2022 and 2021, respectively, and was $283 million and $255 million for the nine months ended March 31, 2022 and 2021, respectively.
Stock Options
During the nine months ended March 31, 2022, the Company granted stock options in respect of approximately 1.1 million shares of Class A Common Stock with an exercise price per share of $344.09 and a weighted-average grant date fair value per share of $85.56. The fair value of each option grant was estimated on the date of grant using the Black-Scholes option-pricing model. The aggregate intrinsic value of stock options exercised during the nine months ended March 31, 2022 was $248 million.
Restricted Stock Units
The Company granted RSUs in respect of approximately 0.7 million shares of Class A Common Stock during the nine months ended March 31, 2022 with a weighted-average grant date fair value per share of $340.18 that, at the time of grant, are scheduled to vest at 0.2 million, 0.2 million, and 0.3 million shares per year, in fiscal 2023, fiscal 2024 and fiscal 2025, respectively. Vesting of RSUs is generally subject to the continued employment or the retirement of the grantees. The RSUs are accompanied by dividend equivalent rights, payable upon settlement of the RSUs either in cash or shares (based on the terms of the particular award) and, as such, were generally valued at the closing market price of the Company’s Class A Common Stock on the date of grant.
Performance Share Units
During the nine months ended March 31, 2022, the Company granted PSUs with a target payout of approximately 0.1 million shares of Class A Common Stock with a grant date fair value per share of $344.06, which will be settled in stock subject to the achievement of the Company’s net sales and diluted net earnings per common share for the three fiscal years ending June 30, 2024, all subject to continued employment or the retirement of the grantees. For PSUs granted, no settlement will occur for results below the applicable minimum threshold. PSUs are accompanied by dividend equivalent rights that will be payable in cash upon settlement of the PSUs and, as such, were valued at the closing market value of the Company’s Class A Common Stock on the date of grant.
In September 2021, approximately 0.2 million shares of the Company’s Class A Common Stock were issued, and related accrued dividends were paid, relative to the target goals set at the time of the issuance, in settlement of 0.2 million PSUs with a performance period ended June 30, 2021.
DECIEM Stock Options
The DECIEM stock options are liability-classified awards as they are expected to be settled in cash and are remeasured to fair value at each reporting date through date of settlement. Total stock-based compensation expense is attributable to the exchange or replacement of and the remaining requisite service period of stock options. Due to a reduction in the fair value of the DECIEM stock options, the total stock option expense for the three and nine months ended March 31, 2022 resulted in income of $60 million and $58 million, respectively, net of foreign currency remeasurements. There were no DECIEM stock options exercised during the nine months ended March 31, 2022.
31

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
The initial fair value of the DECIEM stock option liability was calculated using the acquisition date fair value multiplied by the number of options replaced (consisting of vested and partially vested stock options) on the day following the acquisition date. As discussed in Note 2 – Acquisition of Business, DECIEM stock options, with total fair value of $295 million, were reported as part of the total consideration transferred. The DECIEM stock options are reported as a stock option liability of $74 million and $141 million in Other noncurrent liabilities in the accompanying consolidated balance sheets at March 31, 2022 and June 30, 2021, respectively. The fair value of the stock options were calculated using the following key assumptions into the Monte Carlo Method:

|  | March 31, 2022 |  | June 30, 2021 |  | May 18, 2021
Risk-free rate |  | 1.80% |  | 0.50% |  | 0.50%
Term to mid of last twelve-month period |  | 1.67 years |  | 2.42 years |  | 2.54 years
Operating leverage adjustment |  | 0.45 |  | 0.45 |  | 0.45
Net sales discount rate |  | 5.00% |  | 3.40% |  | 3.30%
EBITDA discount rate |  | 8.90% |  | 6.90% |  | 6.80%
EBITDA volatility |  | 34.00% |  | 37.70% |  | 38.30%
Net sales volatility |  | 15.30% |  | 17.00% |  | 17.20%

NOTE 11 – NET EARNINGS ATTRIBUTABLE TO THE ESTÉE LAUDER COMPANIES INC. PER COMMON SHARE
Net earnings attributable to The Estée Lauder Companies Inc. per common share (“basic EPS”) is computed by dividing net earnings attributable to The Estée Lauder Companies Inc. by the weighted-average number of common shares outstanding and shares underlying PSUs and RSUs where the vesting conditions have been met. Net earnings attributable to The Estée Lauder Companies Inc. per common share assuming dilution (“diluted EPS”) is computed by reflecting potential dilution from stock-based awards.
A reconciliation between the numerator and denominator of the basic and diluted EPS computations is as follows:

|  |  |  | Three Months Ended March 31 |  | Nine Months Ended March 31
(In millions, except per share data) |  |  |  |  |  | 2022 |  | 2021 |  | 2022 |  | 2021
Numerator: |  |  |  |  |  |  |  |  |  |  |  |
Net earnings attributable to The Estée Lauder Companies Inc. |  |  |  |  |  | $ | 558 |  |  | $ | 456 |  |  | $ | 2,338 |  |  | $ | 1,852 |
Denominator: |  |  |  |  |  |  |  |  |  |  |  |
Weighted-average common shares outstanding – Basic |  |  |  |  |  | 359.2 |  |  | 363.6 |  |  | 360.7 |  |  | 362.9 |
Effect of dilutive stock options |  |  |  |  |  | 3.5 |  | 4.1 |  | 3.9 |  | 3.9
Effect of PSUs |  |  |  |  |  | 0.2 |  | 0.2 |  | 0.2 |  | 0.2
Effect of RSUs |  |  |  |  |  | 0.7 |  | 1.1 |  | 1.0 |  | 1.1
Weighted-average common shares outstanding – Diluted |  |  |  |  |  | 363.6 |  |  | 369.0 |  |  | 365.8 |  |  | 368.1 |
Net earnings attributable to The Estée Lauder Companies Inc. per common share: |  |  |  |  |  |  |  |  |  |  |  |
Basic |  |  |  |  |  | $ | 1.55 |  |  | $ | 1.25 |  |  | $ | 6.48 |  |  | $ | 5.10 |
Diluted |  |  |  |  |  | $ | 1.53 |  |  | $ | 1.24 |  |  | $ | 6.39 |  |  | $ | 5.03 |

32

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
The shares of Class A Common Stock underlying stock options, RSUs and PSUs that were excluded in the computation of diluted EPS because their inclusion would be anti-dilutive were as follows:

| Three Months Ended March 31 |  | Nine Months Ended March 31
(In millions) | 2022 |  | 2021 |  | 2022 |  | 2021
Stock options | 1.0 |  | — |  | 0.8 |  | 0.9
RSUs and PSUs | — |  | — |  | 0.1 |  | 0.1

As of March 31, 2022 and 2021, 0.7 million and 0.9 million shares, respectively, of Class A Common Stock underlying PSUs have been excluded from the calculation of diluted EPS because the number of shares ultimately issued is contingent on the achievement of certain performance targets of the Company, as discussed in Note 10 – Stock Programs.
33

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE 12 – EQUITY AND REDEEMABLE NONCONTROLLING INTEREST
Total Stockholders’ Equity – The Estée Lauder Companies Inc.

|  |  |  | Three Months Ended March 31 |  | Nine Months Ended March 31
(In millions) |  |  |  |  |  | 2022 |  | 2021 |  | 2022 |  | 2021
Common stock, beginning of the period |  |  |  |  |  | $ | 6 |  |  | $ | 6 |  |  | $ | 6 |  |  | $ | 6 |
Stock-based compensation |  |  |  |  |  | — |  |  | — |  |  | — |  |  | — |
Common stock, end of the period |  |  |  |  |  | 6 |  |  | 6 |  |  | 6 |  |  | 6 |
Paid-in capital, beginning of the period |  |  |  |  |  | 5,605 |  |  | 5,068 |  |  | 5,335 |  |  | 4,790 |
Common stock dividends |  |  |  |  |  | 2 |  |  | 1 |  |  | 3 |  |  | 2 |
Stock-based compensation |  |  |  |  |  | 139 |  |  | 162 |  |  | 408 |  |  | 439 |
Paid-in capital, end of the period |  |  |  |  |  | 5,746 |  |  | 5,231 |  |  | 5,746 |  |  | 5,231 |
Retained earnings, beginning of the period |  |  |  |  |  | 13,735 |  |  | 11,159 |  |  | 12,244 |  |  | 10,134 |
Common stock dividends |  |  |  |  |  | (217) |  |  | (195) |  |  | (627) |  |  | (563) |
Net earnings attributable to The Estée Lauder Companies Inc. |  |  |  |  |  | 558 |  |  | 456 |  |  | 2,338 |  |  | 1,852 |
Cumulative effect of adoption of new accounting standards |  |  |  |  |  | — |  |  | — |  |  | 121 |  |  | (3) |
Retained earnings, end of the period |  |  |  |  |  | 14,076 |  |  | 11,420 |  |  | 14,076 |  |  | 11,420 |
Accumulated other comprehensive loss, beginning of the period |  |  |  |  |  | (646) |  |  | (383) |  |  | (470) |  |  | (665) |
Other comprehensive income (loss) attributable to The Estée Lauder Companies Inc. |  |  |  |  |  | 20 |  |  | (104) |  |  | (156) |  |  | 178 |
Accumulated other comprehensive loss, end of the period |  |  |  |  |  | (626) |  |  | (487) |  |  | (626) |  |  | (487) |
Treasury stock, beginning of the period |  |  |  |  |  | (12,482) |  |  | (10,429) |  |  | (11,058) |  |  | (10,330) |
Acquisition of treasury stock |  |  |  |  |  | (568) |  |  | (212) |  |  | (1,850) |  |  | (212) |
Stock-based compensation |  |  |  |  |  | (2) |  |  | (1) |  |  | (144) |  |  | (100) |
Treasury stock, end of the period |  |  |  |  |  | (13,052) |  |  | (10,642) |  |  | (13,052) |  |  | (10,642) |
Total stockholders’ equity – The Estée Lauder Companies Inc. |  |  |  |  |  | 6,150 |  |  | 5,528 |  |  | 6,150 |  |  | 5,528 |
Noncontrolling interests, beginning of the period |  |  |  |  |  | 34 |  |  | 35 |  |  | 34 |  |  | 27 |
Net earnings attributable to noncontrolling interests |  |  |  |  |  | 3 |  |  | 2 |  |  | 8 |  |  | 8 |
Distribution to noncontrolling interest holders |  |  |  |  |  | — |  |  | (6) |  |  | — |  |  | (6) |
Translation adjustments and other, net |  |  |  |  |  | (1) |  |  | (1) |  |  | (6) |  |  | 1 |
Noncontrolling interests, end of the period |  |  |  |  |  | 36 |  |  | 30 |  |  | 36 |  |  | 30 |
Total equity |  |  |  |  |  | $ | 6,186 |  |  | $ | 5,558 |  |  | $ | 6,186 |  |  | $ | 5,558 |
Redeemable noncontrolling interest, beginning of the period |  |  |  |  |  | $ | 840 |  |  | $ | — |  |  | $ | 857 |  |  | $ | — |
Net earnings attributable to redeemable noncontrolling interest |  |  |  |  |  | 12 |  |  | — |  |  | 12 |  |  | — |
Translation adjustments |  |  |  |  |  | 14 |  |  | — |  |  | (3) |  |  | — |
Adjustment of redeemable noncontrolling interest to redemption value |  |  |  |  |  | (1) |  |  | — |  |  | (1) |  |  | — |
Redeemable noncontrolling interest, end of the period |  |  |  |  |  | $ | 865 |  |  | $ | — |  |  | $ | 865 |  |  | $ | — |
Cash dividends declared per common share |  |  |  |  |  | $ | .60 |  |  | $ | .53 |  |  | $ | 1.73 |  |  | $ | 1.54 |

34

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
The following is a summary of quarterly cash dividends declared per share on the Company’s Class A and Class B Common Stock during the nine months ended March 31, 2022:

Date Declared |  | Record Date |  | Payable Date |  | Amount per Share
August 18, 2021 |  | August 31, 2021 |  | September 15, 2021 |  | $ | .53 |
November 1, 2021 |  | November 30, 2021 |  | December 15, 2021 |  | $ | .60 |
February 2, 2022 |  | February 28, 2022 |  | March 15, 2022 |  | $ | .60 |

On May 2, 2022, a dividend was declared in the amount of $.60 per share on the Company’s Class A and Class B Common Stock. The dividend is payable in cash on June 15, 2022 to stockholders of record at the close of business on May 31, 2022.
Common Stock
During the nine months ended March 31, 2022, the Company purchased approximately 6.2 million shares of its Class A Common Stock for $1,998 million.
During the nine months ended March 31, 2022, 2.7 million shares of the Company’s Class B Common Stock were converted into the same amount of shares of the Company’s Class A Common Stock.
Accumulated Other Comprehensive Income
The following table represents changes in AOCI, net of tax, by component for the nine months ended March 31, 2022:

(In millions) |  | Net Cash Flow Hedge Gain (Loss) |  | Amounts Included in Net Periodic Benefit Cost |  | Translation Adjustments |  | Total
Balance at June 30, 2021 |  | $ | (2) |  |  | $ | (179) |  |  | $ | (289) |  |  | $ | (470) |
OCI before reclassifications |  | 12 |  |  | 1 |  | (1) | (182) |  | (2) | (169) |
Amounts reclassified to Net earnings |  | 4 |  |  | 9 |  |  | — |  |  | 13 |
Net current-period OCI |  | 16 |  |  | 10 |  |  | (182) |  |  | (156) |
Balance at March 31, 2022 |  | $ | 14 |  |  | $ | (169) |  |  | $ | (471) |  |  | $ | (626) |

(1)Consists of foreign currency translation losses.
(2)See Note 5 – Derivative Financial Instruments for gains (losses) relating to net investment hedges.
35

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
The following table represents the effects of reclassification adjustments from AOCI into net earnings for the three and nine months ended March 31, 2022 and 2021:

|  | Amount Reclassified from AOCI |  |  |  |  |  | Affected Line Item in Consolidated Statements of Earnings
|  | Three Months Ended March 31 |  | Nine Months Ended March 31 |  |  |
(In millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021 |  |  |  |  |
Gain (Loss) on Cash Flow Hedges |  |  |  |  |  |  |  |  |  |  |  |  |  |
Foreign currency forward contracts |  | $ | 3 |  |  | $ | (7) |  |  | $ | (5) |  |  | $ | (11) |  |  |  |  |  |  | Net sales
Interest rate-related derivatives |  | — |  |  | (1) |  |  | (1) |  |  | (2) |  |  |  |  |  |  | Interest expense
|  | 3 |  |  | (8) |  |  | (6) |  |  | (13) |  |  |  |  |  |  |
Benefit for deferred taxes |  | — |  |  | 2 |  |  | 2 |  |  | 3 |  |  |  |  |  |  | Provision for income taxes
|  | 3 |  |  | (6) |  |  | (4) |  |  | (10) |  |  |  |  |  |  | Net earnings
Retirement Plan and Other Retiree Benefit Adjustments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amortization of prior service cost |  | — |  |  | — |  |  | 1 |  |  | — |  |  |  |  |  |  | Other components of net periodic benefit cost (1)
Amortization of actuarial loss |  | (4) |  |  | (6) |  |  | (13) |  |  | (18) |  |  |  |  |  |  | Other components of net periodic benefit cost (1)
Settlements |  | — |  |  | (1) |  |  | — |  |  | (1) |  |  |  |  |  |  | Other components of net periodic benefit cost (1)
|  | (4) |  |  | (7) |  |  | (12) |  |  | (19) |  |  |  |  |  |  |
Benefit for deferred taxes |  | 1 |  |  | 3 |  |  | 3 |  |  | 5 |  |  |  |  |  |  | Provision for income taxes
|  | (3) |  |  | (4) |  |  | (9) |  |  | (14) |  |  |  |  |  |  | Net earnings
Total reclassification adjustments, net |  | $ | — |  |  | $ | (10) |  |  | $ | (13) |  |  | $ | (24) |  |  |  |  |  |  | Net earnings

(1)See Note 8 – Pension and Post-Retirement Benefit Plans for additional information.
NOTE 13 – STATEMENT OF CASH FLOWS
Supplemental cash flow information for the nine months ended March 31, 2022 and 2021 is as follows:

(In millions) |  | 2022 |  | 2021
Cash: |  |  |  |
Cash paid during the period for interest |  | $ | 110 |  |  | $ | 108 |
Cash paid during the period for income taxes |  | $ | 626 |  |  | $ | 435 |
Non-cash investing and financing activities: |  |  |  |
Property, plant and equipment accrued but unpaid |  | $ | 110 |  |  | $ | 68 |
Financing lease modifications |  | $ | (13) |  |  | $ | — |
Right-of-use assets obtained in exchange for new/modified operating lease liabilities |  | $ | 179 |  |  | $ | 167 |

36

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE 14 – SEGMENT DATA AND RELATED INFORMATION
Reportable operating segments include components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker (the “Chief Executive”) in deciding how to allocate resources and in assessing performance. Although the Company operates in one business segment, beauty products, management also evaluates performance on a product category basis. Product category performance is measured based upon net sales before returns associated with restructuring and other activities, and operating income (loss) before charges associated with restructuring and other activities. Returns and charges associated with restructuring and other activities are not allocated to the Company's product categories or geographic regions because they are centrally directed and controlled, are not included in internal measures of product category or geographic region performance and result from activities that are deemed Company-wide initiatives to redesign, resize and reorganize select areas of the business.
The accounting policies for the Company’s reportable segments are substantially the same as those for the consolidated financial statements, as described in the notes to consolidated financial statements in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2021. The assets and liabilities of the Company are managed centrally and are reported internally in the same manner as the consolidated financial statements; thus, no additional information is produced for the Chief Executive or included herein. There has been no significant variance in the total or long-lived asset values associated with the Company’s segment data since June 30, 2021.
37

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

|  |  |  | Three Months Ended March 31 |  | Nine Months Ended March 31
(In millions) |  |  |  |  |  | 2022 |  | 2021 |  | 2022 |  | 2021
PRODUCT CATEGORY DATA |  |  |  |  |  |  |  |  |  |  |  |
Net sales: |  |  |  |  |  |  |  |  |  |  |  |
Skin Care |  |  |  |  |  | $ | 2,395 |  |  | $ | 2,259 |  |  | $ | 8,003 |  |  | $ | 7,113 |
Makeup |  |  |  |  |  | 1,114 |  |  | 1,018 |  |  | 3,674 |  |  | 3,243 |
Fragrance |  |  |  |  |  | 579 |  |  | 454 |  |  | 1,987 |  |  | 1,478 |
Hair Care |  |  |  |  |  | 147 |  |  | 128 |  |  | 475 |  |  | 418 |
Other |  |  |  |  |  | 11 |  |  | 15 |  |  | 40 |  |  | 37 |
|  |  |  |  |  | 4,246 |  |  | 3,874 |  |  | 14,179 |  |  | 12,289 |
Returns associated with restructuring and other activities |  |  |  |  |  | (1) |  |  | (10) |  |  | (3) |  |  | (10) |
Net sales |  |  |  |  |  | $ | 4,245 |  |  | $ | 3,864 |  |  | $ | 14,176 |  |  | $ | 12,279 |
Operating income (loss) before charges associated with restructuring and other activities: |  |  |  |  |  |  |  |  |  |  |  |
Skin Care |  |  |  |  |  | $ | 667 |  |  | $ | 804 |  |  | $ | 2,466 |  |  | $ | 2,453 |
Makeup |  |  |  |  |  | 7 |  |  | (72) |  |  | 228 |  |  | (115) |
Fragrance |  |  |  |  |  | 105 |  |  | 47 |  |  | 446 |  |  | 248 |
Hair Care |  |  |  |  |  | (18) |  |  | (17) |  |  | (8) |  |  | (10) |
Other |  |  |  |  |  | — |  |  | (1) |  |  | 3 |  |  | (1) |
|  |  |  |  |  | 761 |  |  | 761 |  |  | 3,135 |  |  | 2,575 |
Reconciliation: |  |  |  |  |  |  |  |  |  |  |  |
Charges associated with restructuring and other activities |  |  |  |  |  | (23) |  |  | (145) |  |  | (44) |  |  | (191) |
Interest expense |  |  |  |  |  | (41) |  |  | (43) |  |  | (125) |  |  | (131) |
Interest income and investment income, net |  |  |  |  |  | 5 |  |  | 9 |  |  | 19 |  |  | 40 |
Other components of net periodic benefit cost |  |  |  |  |  | 1 |  |  | (2) |  |  | 2 |  |  | (12) |
Other income |  |  |  |  |  | — |  |  | — |  |  | 1 |  |  | — |
Earnings before income taxes |  |  |  |  |  | $ | 703 |  |  | $ | 580 |  |  | $ | 2,988 |  |  | $ | 2,281 |
GEOGRAPHIC DATA(1) |  |  |  |  |  |  |  |  |  |  |  |
Net sales: |  |  |  |  |  |  |  |  |  |  |  |
The Americas |  |  |  |  |  | $ | 1,053 |  |  | $ | 916 |  |  | $ | 3,547 |  |  | $ | 2,837 |
Europe, the Middle East & Africa |  |  |  |  |  | 1,990 |  |  | 1,706 |  |  | 6,201 |  |  | 5,276 |
Asia/Pacific |  |  |  |  |  | 1,203 |  |  | 1,252 |  |  | 4,431 |  |  | 4,176 |
|  |  |  |  |  | 4,246 |  |  | 3,874 |  |  | 14,179 |  |  | 12,289 |
Returns associated with restructuring and other activities |  |  |  |  |  | (1) |  |  | (10) |  |  | (3) |  |  | (10) |
Net sales |  |  |  |  |  | $ | 4,245 |  |  | $ | 3,864 |  |  | $ | 14,176 |  |  | $ | 12,279 |
Operating income: |  |  |  |  |  |  |  |  |  |  |  |
The Americas |  |  |  |  |  | $ | 408 |  |  | $ | 155 |  |  | $ | 1,044 |  |  | $ | 256 |
Europe, the Middle East & Africa |  |  |  |  |  | 281 |  |  | 361 |  |  | 1,366 |  |  | 1,429 |
Asia/Pacific |  |  |  |  |  | 72 |  |  | 245 |  |  | 725 |  |  | 890 |
|  |  |  |  |  | 761 |  |  | 761 |  |  | 3,135 |  |  | 2,575 |
Charges associated with restructuring and other activities |  |  |  |  |  | (23) |  |  | (145) |  |  | (44) |  |  | (191) |
Operating income |  |  |  |  |  | $ | 738 |  |  | $ | 616 |  |  | $ | 3,091 |  |  | $ | 2,384 |

(1) The net sales from the Company’s travel retail business are included in the Europe, the Middle East & Africa region, with the exception of net sales of Dr.Jart+ in the travel retail channel that are reflected in Korea in the Asia/Pacific region.
Operating income attributable to the travel retail sales included in Europe, the Middle East & Africa is included in that region and in The Americas.
38

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
RESULTS OF OPERATIONS
We manufacture, market and sell beauty products including those in the skin care, makeup, fragrance and hair care categories, which are distributed in approximately 150 countries and territories. The following table is a comparative summary of operating results for the three and nine months ended March 31, 2022 and 2021, and reflects the basis of presentation described in Notes to Consolidated Financial Statements, Note 1 – Summary of Significant Accounting Policies for all periods presented. Products and services that do not meet our definition of skin care, makeup, fragrance and hair care have been included in the “other” category.

|  | Three Months Ended March 31 |  | Nine Months Ended March 31 |  |
(In millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021 |  |  |  |
NET SALES |  |  |  |  |  |  |  |  |  |  |  |
By Product Category: |  |  |  |  |  |  |  |  |  |  |  |
Skin Care |  | $ | 2,395 |  |  | $ | 2,259 |  |  | $ | 8,003 |  |  | $ | 7,113 |  |  |  |  |
Makeup |  | 1,114 |  |  | 1,018 |  |  | 3,674 |  |  | 3,243 |  |  |  |  |
Fragrance |  | 579 |  |  | 454 |  |  | 1,987 |  |  | 1,478 |  |  |  |  |
Hair Care |  | 147 |  |  | 128 |  |  | 475 |  |  | 418 |  |  |  |  |
Other |  | 11 |  |  | 15 |  |  | 40 |  |  | 37 |  |  |  |  |
|  | 4,246 |  |  | 3,874 |  |  | 14,179 |  |  | 12,289 |  |  |  |  |
Returns associated with restructuring and other activities |  | (1) |  |  | (10) |  |  | (3) |  |  | (10) |  |  |  |  |
Net sales |  | $ | 4,245 |  |  | $ | 3,864 |  |  | $ | 14,176 |  |  | $ | 12,279 |  |  |  |  |
By Region(1): |  |  |  |  |  |  |  |  |  |  |  |
The Americas |  | $ | 1,053 |  |  | $ | 916 |  |  | $ | 3,547 |  |  | $ | 2,837 |  |  |  |  |
Europe, the Middle East & Africa |  | 1,990 |  |  | 1,706 |  |  | 6,201 |  |  | 5,276 |  |  |  |  |
Asia/Pacific |  | 1,203 |  |  | 1,252 |  |  | 4,431 |  |  | 4,176 |  |  |  |  |
|  | 4,246 |  |  | 3,874 |  |  | 14,179 |  |  | 12,289 |  |  |  |  |
Returns associated with restructuring and other activities |  | (1) |  |  | (10) |  |  | (3) |  |  | (10) |  |  |  |  |
Net sales |  | $ | 4,245 |  |  | $ | 3,864 |  |  | $ | 14,176 |  |  | $ | 12,279 |  |  |  |  |
OPERATING INCOME (LOSS) |  |  |  |  |  |  |  |  |  |  |  |
By Product Category: |  |  |  |  |  |  |  |  |  |  |  |
Skin Care |  | $ | 667 |  |  | $ | 804 |  |  | $ | 2,466 |  |  | $ | 2,453 |  |  |  |  |
Makeup |  | 7 |  |  | (72) |  |  | 228 |  |  | (115) |  |  |  |  |
Fragrance |  | 105 |  |  | 47 |  |  | 446 |  |  | 248 |  |  |  |  |
Hair Care |  | (18) |  |  | (17) |  |  | (8) |  |  | (10) |  |  |  |  |
Other |  | — |  |  | (1) |  |  | 3 |  |  | (1) |  |  |  |  |
|  | 761 |  |  | 761 |  |  | 3,135 |  |  | 2,575 |  |  |  |  |
Charges associated with restructuring and other activities |  | (23) |  |  | (145) |  |  | (44) |  |  | (191) |  |  |  |  |
Operating income |  | $ | 738 |  |  | $ | 616 |  |  | $ | 3,091 |  |  | $ | 2,384 |  |  |  |  |
By Region(1): |  |  |  |  |  |  |  |  |  |  |  |
The Americas |  | $ | 408 |  |  | $ | 155 |  |  | $ | 1,044 |  |  | $ | 256 |  |  |  |  |
Europe, the Middle East & Africa |  | 281 |  |  | 361 |  |  | 1,366 |  |  | 1,429 |  |  |  |  |
Asia/Pacific |  | 72 |  |  | 245 |  |  | 725 |  |  | 890 |  |  |  |  |
|  | 761 |  |  | 761 |  |  | 3,135 |  |  | 2,575 |  |  |  |  |
Charges associated with restructuring and other activities |  | (23) |  |  | (145) |  |  | (44) |  |  | (191) |  |  |  |  |
Operating income |  | $ | 738 |  |  | $ | 616 |  |  | $ | 3,091 |  |  | $ | 2,384 |  |  |  |  |

(1) The net sales from our travel retail business are included in the Europe, the Middle East & Africa region, with the exception of net sales of Dr.Jart+ in the travel retail channel that are reflected in Korea in the Asia/Pacific region.
Operating income attributable to the travel retail sales included in Europe, the Middle East & Africa is included in that region and in The Americas.
39

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
The following table presents certain consolidated earnings data as a percentage of net sales:

|  | Three Months Ended March 31 |  | Nine Months Ended March 31 |  |
|  | 2022 |  | 2021 |  | 2022 |  | 2021 |  |  |  |
Net sales |  | 100.0 | % |  | 100.0 | % |  | 100.0 | % |  | 100.0 | % |  |  |  |
Cost of sales |  | 23.4 |  |  | 24.3 |  |  | 23.1 |  |  | 23.2 |  |  |  |  |
Gross profit |  | 76.6 |  |  | 75.7 |  |  | 76.9 |  |  | 76.8 |  |  |  |  |
Operating expenses: |  |  |  |  |  |  |  |  |  |  |  |
Selling, general and administrative |  | 53.6 |  |  | 55.5 |  |  | 53.3 |  |  | 55.1 |  |  |  |  |
Restructuring and other charges |  | 0.5 |  |  | 3.4 |  |  | 0.3 |  |  | 1.4 |  |  |  |  |
Goodwill impairment |  | — |  |  | — |  |  | — |  |  | 0.4 |  |  |  |  |
Impairment of other intangible and long-lived assets |  | 5.1 |  |  | 0.9 |  |  | 1.5 |  |  | 0.5 |  |  |  |  |
Total operating expenses |  | 59.2 |  |  | 59.8 |  |  | 55.1 |  |  | 57.4 |  |  |  |  |
Operating income |  | 17.4 |  |  | 15.9 |  |  | 21.8 |  |  | 19.4 |  |  |  |  |
Interest expense |  | 1.0 |  |  | 1.1 |  |  | 0.9 |  |  | 1.1 |  |  |  |  |
Interest income and investment income, net |  | 0.1 |  |  | 0.2 |  |  | 0.1 |  |  | 0.3 |  |  |  |  |
Other components of net periodic benefit cost |  | — |  |  | 0.1 |  |  | — |  |  | 0.1 |  |  |  |  |
Other income |  | — |  |  | — |  |  | — |  |  | — |  |  |  |  |
Earnings before income taxes |  | 16.6 |  |  | 15.0 |  |  | 21.1 |  |  | 18.6 |  |  |  |  |
Provision for income taxes |  | (3.1) |  |  | (3.2) |  |  | (4.4) |  |  | (3.4) |  |  |  |  |
Net earnings |  | 13.5 |  |  | 11.9 |  |  | 16.6 |  |  | 15.1 |  |  |  |  |
Net earnings attributable to noncontrolling interests |  | (0.1) |  |  | (0.1) |  |  | (0.1) |  |  | (0.1) |  |  |  |  |
Net earnings attributable to redeemable noncontrolling interest |  | (0.3) |  |  | — |  |  | (0.1) |  |  | — |  |  |  |  |
Net earnings attributable to The Estée Lauder Companies Inc. |  | 13.1 | % |  | 11.8 | % |  | 16.5 | % |  | 15.1 | % |  |  |  |

Not adjusted for differences caused by rounding
We continually introduce new products, support new and established products through advertising, merchandising and sampling and phase out existing products that no longer meet the needs of our consumers or our objectives. The economics of developing, producing, launching, supporting and discontinuing products impact our sales and operating performance each period. The introduction of new products may have some cannibalizing effect on sales of existing products, which we take into account in our business planning.
Non-GAAP Financial Measures
We use certain non-GAAP financial measures, among other financial measures, to evaluate our operating performance, which represent the manner in which we conduct and view our business. Management believes that excluding certain items that are not comparable from period to period helps investors and others compare operating performance between periods. While we consider the non-GAAP measures useful in analyzing our results, they are not intended to replace, or act as a substitute for, any presentation included in the consolidated financial statements prepared in conformity with U.S. GAAP. See Reconciliations of Non-GAAP Financial Measures beginning on page 58 for reconciliations between non-GAAP financial measures and the most directly comparable U.S. GAAP measures.
40

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
We operate on a global basis, with the majority of our net sales generated outside the United States. Accordingly, fluctuations in foreign currency exchange rates can affect our results of operations. Therefore, we present certain net sales, operating results and diluted net earnings per common share information excluding the effect of foreign currency rate fluctuations to provide a framework for assessing the performance of our underlying business outside the United States. Constant currency information compares results between periods as if exchange rates had remained constant period-over-period. We calculate constant currency information by translating current-period results using prior-year period monthly average foreign currency exchange rates and adjusting for the period-over-period impact of foreign currency cash flow hedging activities.
Overview
COVID-19 Business Update
The COVID-19 pandemic continued to disrupt our operating environment globally, primarily impacting retail traffic, travel, supply chain, inventory levels and other logistics during the three months ended March 31, 2022. The resurgence of COVID-19 cases in many Chinese provinces led to restrictions late in the fiscal 2022 third quarter to prevent further spread of the virus. Consequently, retail traffic, travel, and distribution capabilities were temporarily curtailed. Our distribution facilities in Shanghai operated with limited capacity to fulfill brick-and-mortar and online orders beginning in mid-March 2022.
Retail Impact
While most brick-and-mortar retail stores globally that sell our products, whether operated by us or our customers, were open during much of the third quarter of fiscal 2022, there were intermittent closures, primarily in mainland China, which had regional lockdowns. Globally, in areas where stores were open, consumer traffic has not recovered to the pre-pandemic levels.
International passenger traffic remained soft globally. However, passenger traffic in Europe, the Middle East & Africa and The Americas improved, although it remained significantly below pre-pandemic levels. The improvement was due to the partial lifting of COVID-19-related restrictions. In Asia/Pacific, traffic in Hainan was negatively impacted by fewer visitors due to intermittent domestic travel restrictions.
Consumer Preferences
The continuance of COVID-19 pandemic-related closures of offices, retail stores and other businesses and the significant decline in social gatherings have influenced consumer preferences and practices. While the demand for makeup has improved significantly in areas where restrictions have been lifted, it continues to be the only category that remains below the pre-pandemic period, given fewer makeup usage occasions and ongoing mask wearing, while skin care, fragrance and hair care have all grown from pre-pandemic levels.
Supply Chain
The COVID-19 pandemic has contributed to global supply chain disruptions, including manufacturing and transportation delays, due to closures, employee absences, port congestion, labor and container shortages, and shipment delays. As a result, we expect higher costs to negatively impact cost of sales and operating expenses for the remainder of fiscal 2022. We expect to mitigate some of the impact to our business and our costs through strategic price increases, product mix, timing of shipments, inventory levels, use of air freight and less congested ports, and cost savings in other areas. Toward the end of the third quarter of fiscal 2022, we began to experience challenges in logistics in China due to restrictions attributable to the COVID-19 pandemic.
41

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
Business Update
We are a leader in prestige beauty, which combines the repeat purchase and relative affordability of consumer goods with high quality products and services. Within prestige beauty, we are well diversified by product category, geography, brand, product sub-category, channel, consumer segment and price point. This diversification allows us to leverage consumer analytics and insights with agility by deploying our brands to fast growing and profitable opportunities. These analytics and insights, combined with our creativity, inform our innovation to provide a broad, locally-relevant and inclusive range of prestige products allowing us to compete effectively for a greater share of a consumer's beauty routine. Elements of our strategy are described in the Overview on pages 31-34 of our Annual Report on Form 10-K for the year ended June 30, 2021, as well as below.
During the third quarter of fiscal 2022, net sales increased 10%, reflecting early stages of a recovery in The Americas and in Europe, the Middle East & Africa as compared to a more difficult environment in the prior-year period. The net sales increase includes incremental net sales attributable to the increase in our ownership of DECIEM in the fiscal 2021 fourth quarter.
•Our skin care net sales benefited from the recent launch of The Hydrating Infused Emulsion from La Mer, as well as initial shipments of the brand's The Treatment Lotion and continued strength in its Crème de la Mer moisturizer. Incremental net sales attributable to the increase in our ownership of DECIEM in the fiscal 2021 fourth quarter also contributed to growth.
•The COVID-19 pandemic has generally resulted in more limited social and business activities and consumers overall wore less makeup. As restrictions lift and stores reopen in particular locations, we generally see demand for makeup products increasing. During the third quarter of fiscal 2022, net sales in makeup grew double digits in part due to this, and was also driven by strong activations, expanded consumer reach and the launch of MACStack mascara from M·A·C, increases in Estée Lauder foundation products, as well as a strong performance from Clinique. Our brands generated interest in makeup through virtual marketing efforts such as classes, virtual try-on technology and greater emphasis on social media platforms.
•Our fragrance net sales rose sharply as consumers gravitated to high-end and artisanal offerings from Jo Malone London, Tom Ford Beauty, and Le Labo.
•Our hair care net sales also grew double digits, reflecting increases from both Aveda and Bumble and bumble as brick-and-mortar channels recover, online growth continues and new products launch.
In September 2021, we announced that we are not renewing our existing license agreements for Donna Karan New York, DKNY, Michael Kors, Tommy Hilfiger and Ermenegildo Zegna when they expire in June 2023. We expect to continue to sell products under these licenses through June 30, 2022.
Our global distribution capability and operations allow us to focus on targeted expanded consumer reach wherever consumer demographics and trends are the most attractive. Our regional organizations, and the expertise of our people there, enable our brands to be more locally and culturally relevant in both product assortment and communications. We are evolving the way we connect with our consumers in stores, online and where they travel, including by expanding our digital and social media presence and the engagement of global and local influencers to amplify brand or product stories. We tailor implementation of our strategy by market to drive consumer engagement and embrace cultural diversity. We continuously strive to strengthen our presence in large, image-building core markets, while broadening our presence in emerging markets.
•The increase in net sales during the fiscal 2022 third quarter was led by Europe, the Middle East & Africa, which benefited from ongoing increases in our travel retail business, partly relating to the increase in traffic as a result of the easing of travel restrictions, which varied by location. In addition, brick-and-mortar retail reopened across the region, driving growth in department stores and freestanding retail stores.
•Net sales rose in The Americas, primarily reflecting the recovery of brick-and-mortar stores, targeted expanded consumer reach and incremental net sales attributable to the increase in our ownership of DECIEM in the fiscal 2021 fourth quarter.
•Net sales decreased in Asia/Pacific, reflecting tighter COVID-19 restrictions in Greater China, partially offset by a progression towards recovery across other markets in the region.
As a result of the invasion of Ukraine, we suspended all our business investments and initiatives and commercial activity in Russia and Ukraine in early March 2022. This included the temporary closure of our owned and authorized freestanding stores and our own brand sites, as well as the suspension of shipments to our retailers in Russia and Ukraine.
42

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
As the safety of our employees remains a top priority, we continue to take significant steps to support our employees in Ukraine, including the continuance of compensation, maintenance of regular communication and offering relocation assistance, and continue to provide compensation and support to our employees in Russia. We are monitoring the effects of this conflict, including risks that may affect our business, and expect that we will adjust our plans accordingly as the situation progresses.
For the three and nine months ended March 31, 2022, the results of operations related to Russia and Ukraine were not material to our consolidated financial statements.
Outlook
The COVID-19 pandemic continues to disrupt business for us, retailers and other companies with which we do business. There have been, and are likely to continue to be, intermittent store closures and supply chain disruptions. We are mindful that these trends may continue to impact the pace of recovery. The continued curtailment in international travel is also affecting our travel retail business in most of the world, which had been historically one of our fastest growth areas. We expect to invest in areas to support the recovery, including advertising, online, research and development and supply chain, to drive growth in areas of opportunity and help nurture emerging trends in the rest of the business. In addition to impacting net sales and profitability, these and other challenges may adversely impact the goodwill and other intangible assets associated with our brands, as well as long-lived assets (i.e. potentially resulting in impairments).
We believe that the best way to increase long-term stockholder value is to continue providing superior products and services in the most efficient and effective manner while recognizing shifts in consumers’ behaviors and shopping practices. Accordingly, our long-term strategy has numerous initiatives across geographic regions, product categories, brands, channels of distribution and functions designed to grow our sales, provide cost efficiencies, leverage our strengths and make us more productive and profitable. We plan to build upon and leverage our history of outstanding creativity and innovation, high quality products and services, and engaging communications while investing for long-term sustainable growth.
We continue to monitor the effects of the global macroeconomic environment, including increasing inflationary pressures; supply chain disruptions; social and political issues; regulatory matters, including the imposition of tariffs; geopolitical tensions; and global security issues. For example, we continue to monitor the geopolitical tensions between the United States and China, which could have a material adverse effect on our business. We are also mindful of inflationary pressures on our cost base and are monitoring the impact on consumer preferences.
The invasion of Ukraine has negatively impacted our operations in both Russia and Ukraine. In fiscal 2021, our operations in Ukraine and Russia accounted for approximately 1% of consolidated net sales. In March 2022, we announced a suspension of all our business investments and initiatives and commercial activity in Russia. Future impacts on our business, including sanctions and counter-sanctions, are difficult to predict due to the high level of uncertainty as to how these developments will evolve. On a broader perspective, there could be additional negative impacts to our net sales, earnings, assets and cash flows should these matters continue or escalate; such impacts could include economic challenges in other countries because of inflationary pressures or other consequences. Please refer to Risk Factors in Part I, Item 1A of the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2021, for a more complete discussion of the risks we encounter in our business and industry.
The uncertainty around the timing, speed and duration of the recovery from the adverse impacts of the COVID-19 pandemic, including the impacts on our business of the ongoing restrictions in China, will continue to affect our ability to grow sales profitably. We believe we can, to some extent, offset the impact of more ordinary challenges by continually developing and pursuing a diversified strategy with multiple engines of growth and by accelerating initiatives focused on areas of strength, discipline and agility, and by executing upon our Post-COVID Business Acceleration Program. As the current situation continues to progress, if economic and social conditions or the degree of uncertainty or volatility worsen, or the adverse conditions previously described are further prolonged, there could be a further negative effect on consumer confidence, demand, spending and willingness or ability to travel and, as a result, on our business. We are continuing to monitor these and other risks that may affect our business.
Post-COVID Business Acceleration Program
Information about our restructuring initiative, the Post-COVID Business Acceleration Program, is described in Notes to Consolidated Financial Statements, Note 4 – Charges Associated with Restructuring and Other Activities herein, as well as, in Notes to Consolidated Financial Statements, Note 8 – Charges Associated with Restructuring and Other Activities and in the Overview on page 33 of our Annual Report on Form 10-K for the year ended June 30, 2021.
43

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
Goodwill and Other Intangible Asset Impairments
During the fiscal 2022 third quarter, given the lower-than-expected results from international expansion to areas that continue to be impacted by COVID-19, we made revisions to the internal forecasts relating to our GLAMGLOW reporting unit. We concluded that the changes in circumstances in the reporting unit triggered the need for an interim impairment review of its trademark intangible asset. As of March 31, 2022, the remaining carrying value of the trademark intangible asset was not recoverable and we recorded an impairment charge of $11 million reducing the carrying value to zero.
During the fiscal 2022 third quarter, given the lower-than-expected growth within key geographic regions and channels for Dr.Jart+ that continue to be impacted by the spread of COVID-19 variants and resurgence in cases and the potential future impacts relating to the uncertainty of the duration and severity of COVID-19 impacting the financial performance of the brand, the lower than expected growth in key retail channels for DECIEM, and the lower than expected results from international expansion to areas that continue to be impacted by COVID-19 for Too Faced, we made revisions to the internal forecasts relating to its Dr. Jart+, DECIEM and Too Faced reporting units.
We concluded that the changes in circumstances in the reporting units triggered the need for interim impairment reviews of their trademarks and goodwill. These changes in circumstances were also an indicator that the carrying amounts of Dr.Jart+’s, DECIEM’s and Too Faced’s long-lived assets, including customer lists, may not be recoverable. Accordingly, we performed interim impairment tests for the trademarks and a recoverability test for the long-lived assets as of February 28, 2022. We concluded that the carrying amounts of the long-lived assets were recoverable. For the Dr.Jart+ reporting unit, we also concluded that the carrying value of the trademark intangible asset exceeded its estimated fair value, which was determined utilizing the relief-from-royalty method to determine discounted projected future cash flows, and recorded an impairment charge. For the Too Faced and DECIEM reporting units, as the carrying values of the trademarks did not exceed their estimated fair values, which were determined utilizing the relief-from-royalty method to determine discounted projected future cash flows, we did not record impairment charges. As of March 31, 2022, the estimated fair values of Too Faced’s and DECIEM's trademarks exceeded their carrying values by 13% and 3%, respectively. For the Too Faced and DECIEM trademark intangible assets, if all other assumptions are held constant, an increase of 100 basis points and 50 basis points, respectively, in the weighted average cost of capital would result in an impairment charge. After adjusting the carrying values of the trademarks, we completed interim quantitative impairment tests for goodwill. As the estimated fair value of the Dr.Jart+, DECIEM and Too Faced reporting units were in excess of their carrying values, we concluded that the carrying amounts of the goodwill were recoverable and did not record a goodwill impairment charge related to these reporting units. The fair value of these reporting units were based upon an equal weighting of the income and market approaches, utilizing estimated cash flows and a terminal value, discounted at a rate of return that reflects the relative risk of the cash flows, as well as valuation multiples derived from comparable publicly traded companies that are applied to operating performance of the reporting units. The significant assumptions used in these approaches include revenue growth rates and profit margins, terminal values, weighted average cost of capital used to discount future cash flows and royalty rates for trademarks. The most significant unobservable input used to estimate the fair value of the Dr. Jart+ trademark intangible asset was the weighted-average cost of capital, which was 10.5%.
A summary of the impairment charges for the three and nine months ended March 31, 2022 and the remaining trademark and goodwill carrying values as of March 31, 2022, for each reporting unit, are as follows:

(In millions) |  |  |  | Impairment Charge |  | Carrying Value
Reporting Unit: |  | Geographic Region |  | Trademarks |  | Goodwill |  | Trademarks |  | Goodwill
GLAMGLOW |  | The Americas |  | $ | 11 |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Dr. Jart+ |  | Asia/Pacific |  | 205 |  |  | — |  |  | 486 |  |  | 332 |
Total |  |  |  | $ | 216 |  |  | $ | — |  |  | $ | 486 |  |  | $ | 332 |

44

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
The impairment charges for the three and nine months ended March 31, 2022 were reflected in the skin care product category.
The fair value of the Dr. Jart+ trademark was equal to its carrying value subsequent to the impairment charge taken as of March 31, 2022. The key assumptions used to determine the estimated fair value of the reporting unit are primarily predicated on the estimated future impacts of COVID-19, the success of future new product launches, the achievement of distribution expansion plans, and the realization of cost reduction and other efficiency efforts. If such plans do not materialize, or if there are further challenges in the business environments in which the reporting unit operates, resulting changes in the key assumptions could have negative impacts on the estimated fair value of the reporting unit and it is possible we could recognize additional impairment charges in the future.
NET SALES

|  |  |  | Three Months Ended March 31 |  | Nine Months Ended March 31
($ in millions) |  |  |  |  |  | 2022 |  | 2021 |  | 2022 |  | 2021
As Reported: |  |  |  |  |  |  |  |  |  |  |  |
Net sales |  |  |  |  |  | $ | 4,245 |  |  | $ | 3,864 |  |  | $ | 14,176 |  |  | $ | 12,279 |
$ Change from prior-year period |  |  |  |  |  | 381 |  |  |  |  | 1,897 |  |  |
% Change from prior-year period |  |  |  |  |  | 10 | % |  |  |  | 15 | % |  |
Non-GAAP Financial Measure(1): |  |  |  |  |  |  |  |  |  |  |  |
% Change from prior-year period in constant currency |  |  |  |  |  | 11 | % |  |  |  | 15 | % |  |

(1)See “Reconciliations of Non-GAAP Financial Measures” beginning on page 58 for reconciliations between non-GAAP financial measures and the most directly comparable U.S. GAAP measures.
Reported net sales increased for the three and nine months ended March 31, 2022, driven by higher net sales from every major product category and in Europe, the Middle East & Africa and The Americas primarily reflecting (i) the continued progression towards brick-and-mortar and travel recovery compared to the prior-year challenges, which included widespread store closures, lower retail traffic, travel restrictions and quarantines, stemming from the COVID-19 pandemic; (ii) the continued success of hero product franchises; (iii) successful performance for holiday and key shopping moments (iv) new product launches; and (v) targeted expanded consumer reach.
Reported net sales in Asia/Pacific decreased and increased for the three and nine months ended March 31, 2022, respectively. For the three months ended March 31, 2022, net sales decreased due to a resurgence of COVID-19 cases across many Chinese provinces which led to restrictions to further prevent the spread of the virus. For the nine months ended March 31, 2022, net sales increased, led by mainland China and Korea.
For the three and nine months ended March 31, 2022, reported net sales increased from every major product category. Skin care net sales increased in both periods, led by La Mer and benefited from incremental net sales attributable to the increase in our ownership of DECIEM in the fiscal 2021 fourth quarter. Fragrance net sales grew double-digits, led by Jo Malone London, Tom Ford Beauty and Le Labo. The net sales increases from Estée Lauder and M·A·C drove the increases in the makeup net sales. Hair care net sales increased in both periods, due to higher net sales from Aveda and Bumble and bumble.
For the three and nine months ended March 31, 2022, reported net sales grew double-digits in Europe, the Middle East & Africa and The Americas and benefited from incremental net sales attributable to the increase in our ownership of DECIEM in the fiscal 2021 fourth quarter. Net sales increased in Europe, the Middle East & Africa, reflecting recovery across the region, led by our travel retail business and the United Kingdom. The increases in net sales in The Americas reflected higher net sales throughout the region.
The total net sales increases were impacted by approximately $53 million of unfavorable and $31 million of favorable foreign currency translation for the three and nine months ended March 31, 2022, respectively.
45

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
Returns associated with restructuring and other activities are not allocated to our product categories or geographic regions because they result from activities that are deemed a Company-wide initiative to redesign, resize and reorganize select corporate functions and go-to-market structures. Accordingly, the following discussions of Net sales by Product Categories and Geographic Regions exclude the impact of returns associated with restructuring and other activities for the three and nine months ended March 31, 2022 of $1 million and $3 million, respectively.
Product Categories
Skin Care

|  | Three Months Ended March 31 |  | Nine Months Ended March 31
($ in millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021
As Reported: |  |  |  |  |  |  |  |
Net sales |  | $ | 2,395 |  |  | $ | 2,259 |  |  | $ | 8,003 |  |  | $ | 7,113 |
$ Change from prior-year period |  | 136 |  |  |  |  | 890 |  |  |
% Change from prior-year period |  | 6 | % |  |  |  | 13 | % |  |
Non-GAAP Financial Measure(1): |  |  |  |  |  |  |  |
% Change from prior-year period in constant currency |  | 7 | % |  |  |  | 12 | % |  |

(1)See “Reconciliations of Non-GAAP Financial Measures” beginning on page 58 for reconciliations between non-GAAP financial measures and the most directly comparable U.S. GAAP measures.
Reported skin care net sales increased for the three months ended March 31, 2022, reflecting higher net sales from La Mer and incremental net sales attributable to the increase in our ownership of DECIEM in the fiscal 2021 fourth quarter of approximately $269 million, combined. Net sales from La Mer increased, led by our travel retail business and mainland China, primarily reflecting continued success of hero products, such as Crème de la Mer and the Genaissance de la Mer line of products, the current-year launch of The Hydrating Infused Emulsion, the fiscal 2022 third-quarter launch of the new upgraded The Treatment Lotion and targeted expanded consumer reach.
Partially offsetting the increase in skin care net sales for the three months ended March 31, 2022, were lower net sales from Estée Lauder and Origins of approximately $157 million, combined. The decreases in net sales from Estée Lauder and Origins reflected lower traffic in Asia due to the resurgence of COVID-19 cases in many Chinese provinces, which led to restrictions to prevent further spread of the virus. Net sales from Estée Lauder also declined due to lower net sales from the Advanced Night Repair product franchise primarily due to the prior-period launch of Advanced Night Repair Synchronized Multi-Recovery Complex.
Reported skin care net sales increased for the nine months ended March 31, 2022, reflecting higher net sales from La Mer and Clinique, as well as incremental net sales attributable to the increase in our ownership of DECIEM in the fiscal 2021 fourth quarter of approximately $869 million, combined. Net sales from La Mer increased, as discussed above. Clinique net sales increased, primarily driven by our travel retail business and North America, reflecting the continued success of existing products, such as the Take The Day Off line of products and Even Better Clinical Radical Dark Spot Corrector + Interrupter.
Partially offsetting the increase in skin care net sales for the nine months ended March 31, 2022, were lower net sales from Estée Lauder and Origins of approximately $197 million, combined, as discussed above.
The skin care net sales increases were impacted by approximately $16 million of unfavorable and $57 million of favorable foreign currency translation for the three and nine months ended March 31, 2022, respectively.
46

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
Makeup

|  |  | Three Months Ended March 31 |  | Nine Months Ended March 31
($ in millions) |  |  | 2022 |  | 2021 |  | 2022 |  | 2021
As Reported: |  |  |  |  |  |  |  |  |
Net sales |  |  | $ | 1,114 |  |  | $ | 1,018 |  |  | $ | 3,674 |  |  | $ | 3,243 |
$ Change from prior-year period |  |  | 96 |  |  |  |  | 431 |  |  |
% Change from prior-year period |  |  | 9 | % |  |  |  | 13 | % |  |
Non-GAAP Financial Measure(1): |  |  |  |  |  |  |  |  |
% Change from prior-year period in constant currency |  |  | 11 | % |  |  |  | 14 | % |  |

(1)See “Reconciliations of Non-GAAP Financial Measures” beginning on page 58 for reconciliations between non-GAAP financial measures and the most directly comparable U.S. GAAP measures.
Reported makeup net sales increased for the three months ended March 31, 2022, led by higher net sales from M·A·C, Estée Lauder and Clinique, of approximately $109 million, combined. The continued progression towards recovery in makeup, including increased usage occasions compared to the prior-year period, led to the increase in makeup net sales in The Americas and Europe, the Middle East & Africa. The increase in net sales from M·A·C was primarily driven by the continued success of hero products, such as Studio Fix, the fiscal 2022 third quarter launch of MACStack mascara and successful social media campaigns during key shopping moments. Net sales from Estée Lauder increased, primarily due to the continued success of existing products, such as the Double Wear and Futurist product franchises and new product launches, such as the current-year launches of Double Wear Sheer Long-Wear Makeup. Net sales for Clinique increased, primarily reflecting continued success from Even Better Makeup and successful performance in the lip, concealer and eye subcategories.
Reported makeup net sales increased for the nine months ended March 31, 2022, led by higher net sales from Estée Lauder and M·A·C of approximately $303 million, combined, as noted above. The net sales increase from M·A·C also benefited from the continued success of existing products, such as Ruby's Crew and Re-Think Pink in the lip subcategory and Magic Extension in the mascara subcategory, as well as the success of the fiscal 2022 third quarter launch of MACStack mascara.
The makeup net sales increases were impacted by approximately $19 million and $14 million of unfavorable foreign currency translation for the three and nine months ended March 31, 2022, respectively.
Fragrance

|  | Three Months Ended March 31 |  | Nine Months Ended March 31
($ in millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021
As Reported: |  |  |  |  |  |  |  |
Net sales |  | $ | 579 |  |  | $ | 454 |  |  | $ | 1,987 |  |  | $ | 1,478 |
$ Change from prior-year period |  | 125 |  |  |  |  | 509 |  |  |
% Change from prior-year period |  | 28 | % |  |  |  | 34 | % |  |
Non-GAAP Financial Measure(1): |  |  |  |  |  |  |  |
% Change from prior-year period in constant currency |  | 31 | % |  |  |  | 35 | % |  |

(1)See “Reconciliations of Non-GAAP Financial Measures” beginning on page 58 for reconciliations between non-GAAP financial measures and the most directly comparable U.S. GAAP measures.
47

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
Reported fragrance net sales increased for the three months ended March 31, 2022, primarily driven by Jo Malone London, Tom Ford Beauty, Le Labo and Estée Lauder of approximately $107 million, combined. Fragrance net sales grew in every geographic region, reflecting continued growth in luxury fragrances, the brick-and-mortar and travel recovery in various parts of the world due to more store openings, increased retail traffic, successful performance during holiday and key shopping moments, and the easing of travel restrictions compared to the prior-year period. The increase in net sales from Jo Malone London reflected the fiscal 2022 third quarter launches of House of Roses and Mediterranean Blossoms and continued growth of the home and bath & body subcategories. Net sales increased from Tom Ford Beauty, also benefiting from the continued success of Private Blend and Signature fragrances and the fiscal 2022 third quarter product launches of Costa Azzurra parfum, Rose de Chine and Rose d'Amalfi. Net sales from Le Labo increased, also reflecting the continued success of hero product franchises, current-year product launches and targeted expanded consumer reach. The increase in net sales from Estée Lauder was primarily due to the continued success of the Beautiful Magnolia line of products.
Reported fragrance net sales increased for the nine months ended March 31, 2022, primarily driven by Jo Malone London, Tom Ford Beauty and Le Labo of approximately $378 million, combined, and grew double digits in every geographic region, as discussed above. The increases in net sales from Jo Malone London reflected the continued success of our hero products, current-year launches and continued growth of the home and bath & body subcategories. Net sales increased from Tom Ford Beauty, reflecting the continued success of Private Blend and Signature fragrances, current-year product launches and the diversification of product offerings by region. Net sales from Le Labo increased, as discussed above.
The fragrance net sales increases were impacted by approximately $14 million and $8 million of unfavorable foreign currency translation for the three and nine months ended March 31, 2022, respectively.
Hair Care

|  | Three Months Ended March 31 |  | Nine Months Ended March 31
($ in millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021
As Reported: |  |  |  |  |  |  |  |
Net sales |  | $ | 147 |  |  | $ | 128 |  |  | $ | 475 |  |  | $ | 418 |
$ Change from prior-year period |  | 19 |  |  |  |  | 57 |  |  |
% Change from prior-year period |  | 15 | % |  |  |  | 14 | % |  |
Non-GAAP Financial Measure(1): |  |  |  |  |  |  |  |
% Change from prior-year period in constant currency |  | 17 | % |  |  |  | 14 | % |  |

(1)See “Reconciliations of Non-GAAP Financial Measures” beginning on page 58 for reconciliations between non-GAAP financial measures and the most directly comparable U.S. GAAP measures.
Reported hair care net sales increased for the three and nine months ended March 31, 2022, reflecting higher net sales from Aveda and Bumble and bumble, combined, of approximately $18 million and $49 million, respectively, primarily due to the continued progression towards salon and retail store recovery in North America. Net sales from Aveda increased in both periods, reflecting the continued success of existing product franchises and the fiscal 2022 third quarter relaunch of Full Spectrum Semi-Permanent Treatment Hair Color. The increases in net sales from Bumble and bumble also reflected the success of hero products, the fiscal 2022 third quarter product launches of Bb. Thickening Plumping Mask and Bb. Thickening Go Big Plumping Treatment, and targeted expanded consumer reach.
Geographic Regions
We strategically time our new product launches by geographic market, which may account for differences in regional sales growth.
48

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
The Americas

|  | Three Months Ended March 31 |  | Nine Months Ended March 31
($ in millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021
As Reported: |  |  |  |  |  |  |  |
Net sales |  | $ | 1,053 |  |  | $ | 916 |  |  | $ | 3,547 |  |  | $ | 2,837 |
$ Change from prior-year period |  | 137 |  |  |  |  | 710 |  |  |
% Change from prior-year period |  | 15 | % |  |  |  | 25 | % |  |
Non-GAAP Financial Measure(1): |  |  |  |  |  |  |  |
% Change from prior-year period in constant currency |  | 14 | % |  |  |  | 25 | % |  |

(1)See “Reconciliations of Non-GAAP Financial Measures” beginning on page 58 for reconciliations between non-GAAP financial measures and the most directly comparable U.S. GAAP measures.
Reported net sales in The Americas increased for the three and nine months ended March 31, 2022 in every country and product category, reflecting the brick-and-mortar and makeup recovery from the prior-year challenges that included store closures, lower retail traffic, fewer makeup usage occasions and quarantines, stemming from the COVID-19 pandemic. The net sales increases were led by higher net sales in North America of approximately $125 million and $658 million, respectively, also benefiting from incremental net sales attributable to the increase in our ownership of DECIEM in the fiscal 2021 fourth quarter, higher net sales from many of our brands, led by M·A·C and Clinique, and targeted expanded consumer reach.
Net sales in The Americas were impacted by approximately $6 million and $13 million of favorable foreign currency translation for the three and nine months ended March 31, 2022, respectively.
Europe, the Middle East & Africa

|  | Three Months Ended March 31 |  | Nine Months Ended March 31
($ in millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021
As Reported: |  |  |  |  |  |  |  |
Net sales |  | $ | 1,990 |  |  | $ | 1,706 |  |  | $ | 6,201 |  |  | $ | 5,276 |
$ Change from prior-year period |  | 284 |  |  |  |  | 925 |  |  |
% Change from prior-year period |  | 17 | % |  |  |  | 18 | % |  |
Non-GAAP Financial Measure(1): |  |  |  |  |  |  |  |
% Change from prior-year period in constant currency |  | 19 | % |  |  |  | 18 | % |  |

(1)See “Reconciliations of Non-GAAP Financial Measures” beginning on page 58 for reconciliations between non-GAAP financial measures and the most directly comparable U.S. GAAP measures.
Reported net sales for the three and nine months ended March 31, 2022 increased in Europe, the Middle East & Africa, reflecting continued recovery across the region, primarily due to store openings, increased retail traffic, and the easing of travel restrictions compared to the prior year, led by our travel retail business and the United Kingdom, combined, of approximately $271 million and $712 million, respectively. Despite the fiscal 2022 third quarter resurgence in COVID-19 cases in many Chinese provinces, which led to restrictions to prevent further spread of the virus and the curtailment of travel, net sales increased in our travel retail business, reflecting continued strength of our brands with the Chinese consumer, the easing of travel restrictions in Europe, the Middle East & Africa and The Americas, and continued success of hero product franchises from La Mer and Jo Malone London. These benefits were partially offset by lower net sales from Estée Lauder products, primarily reflecting lower net sales from the Advanced Night Repair product franchise primarily due to the prior-period launch of Advanced Night Repair Synchronized Multi-Recovery Complex. Net sales in the United Kingdom increased, primarily reflecting brick-and-mortar recovery, as noted above, and benefiting from the growth in makeup and fragrance. The increases in net sales in the United Kingdom also reflected incremental net sales attributable to the increase in our ownership of DECIEM in the fiscal 2021 fourth quarter.
49

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
Net sales in Europe, the Middle East & Africa were impacted by approximately $47 million and $45 million of unfavorable foreign currency translation for the three and nine months ended March 31, 2022, respectively.
Asia/Pacific

|  | Three Months Ended March 31 |  | Nine Months Ended March 31
($ in millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021
As Reported: |  |  |  |  |  |  |  |
Net sales |  | $ | 1,203 |  |  | $ | 1,252 |  |  | $ | 4,431 |  |  | $ | 4,176 |
$ Change from prior-year period |  | (49) |  |  |  |  | 255 |  |  |
% Change from prior-year period |  | (4) | % |  |  |  | 6 | % |  |
Non-GAAP Financial Measure(1): |  |  |  |  |  |  |  |
% Change from prior-year period in constant currency |  | (3) | % |  |  |  | 5 | % |  |

(1)See “Reconciliations of Non-GAAP Financial Measures” beginning on page 58 for reconciliations between non-GAAP financial measures and the most directly comparable U.S. GAAP measures.
Reported net sales decreased in Asia/Pacific for the three months ended March 31, 2022, primarily driven by lower results in mainland China and Hong Kong of approximately $54 million, combined, due to the resurgence of COVID-19 cases toward the end of the fiscal 2022 third quarter that led to restrictions to prevent further spread of the virus. These restrictions resulted in limited capacity in our Shanghai distribution facilities and the temporary curtailment of retail traffic, travel and other distribution capabilities.
Reported net sales increased in Asia/Pacific for the nine months ended March 31, 2022, reflecting higher net sales in mainland China, despite the resurgence in COVID-19 cases in many Chinese provinces toward the end of the fiscal 2022 third quarter, and Korea of approximately $257 million, combined. Net sales in mainland China increased, primarily due to the continued success of hero products franchises from Estée Lauder, La Mer and Jo Malone London, reflecting continued growth in skin care and strong momentum in fragrance, successful performance during holiday and key shopping moments, new product launches, and the current-year launch on a new third-party online platform. Net sales increased in Korea, despite the challenging brick-and-mortar retail environment, primarily reflecting the continued success of hero product franchises from Jo Malone London and strong momentum in fragrance.
Net sales in Asia/Pacific were impacted by approximately $11 million of unfavorable and $64 million of favorable foreign currency translation for the three and nine months ended March 31, 2022, respectively.
GROSS MARGIN
Gross margin increased to 76.6% and 76.9% for the three and nine months ended March 31, 2022, respectively, as compared with 75.7% and 76.8% in the prior-year periods.

|  | Favorable (Unfavorable) Basis Points |  |
|  | March 31, 2022 |  |
|  | Three Months Ended |  | Nine Months Ended |  |
Mix of business |  | (30) |  |  | (35) |  |  |
Obsolescence charges |  | 65 |  |  | (5) |  |  |
Manufacturing costs and other |  | (25) |  |  | (10) |  |  |
Foreign exchange transactions |  | 60 |  |  | 50 |  |  |
Subtotal |  | 70 |  |  | — |  |  |
Charges associated with restructuring and other activities |  | 20 |  |  | 10 |  |  |
Total |  | 90 |  |  | 10 |  |  |

50

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
The increase in gross margin for the three months ended March 31, 2022 reflected favorable obsolescence charges due to a higher level of destruction in the prior-year period, the favorable impact from transactional foreign exchange due to the strengthening of the U.S. Dollar and the favorable impact from under-absorption of manufacturing overhead costs in the prior-year period, partially offset by higher inbound transportation costs driven by global supply chain disruptions as discussed above and an unfavorable impact from our mix of business. The unfavorable impact from our mix of business was primarily driven by the change in category mix, primarily due to the increase in makeup and fragrance net sales, and higher costs from new skin care products, partially offset by strategic price increases.
The increase in gross margin for the nine months ended March 31, 2022 reflected a favorable transactional foreign exchange impact due to the strengthening of the U.S. Dollar, partially offset by an unfavorable impact from our mix of business. The unfavorable impact from our mix of business was primarily due to lower gross margins on DECIEM products, change in category mix primarily due to the increase in makeup and fragrance net sales and higher costs from new products and product sets, partially offset by strategic price increases.
OPERATING EXPENSES
Operating expenses as a percentage of net sales was 59.2% and 55.1% for the three and nine months ended March 31, 2022, respectively, as compared with 59.8% and 57.4% in the prior-year periods.

|  | Favorable (Unfavorable) Basis Points |  |
|  | March 31, 2022 |  |
|  | Three Months Ended |  | Nine Months Ended |  |
General and administrative expenses |  | 90 |  |  | 70 |  |  |
Advertising, merchandising, sampling and product development |  | 10 |  |  | 30 |  |  |
Selling |  | 20 |  |  | 70 |  |  |
Stock-based compensation |  | — |  |  | 10 |  |  |
Store operating costs |  | 10 |  |  | 10 |  |  |
Shipping |  | (80) |  |  | (50) |  |  |
Foreign exchange transactions |  | (10) |  |  | (10) |  |  |
Subtotal |  | 40 |  |  | 130 |  |  |
Charges associated with restructuring and other activities |  | 290 |  |  | 110 |  |  |
Goodwill, other intangible and long-lived asset impairments |  | (420) |  |  | (60) |  |  |
Acquisition-related stock compensation income |  | 150 |  |  | 50 |  |  |
Total |  | 60 |  |  | 230 |  |  |

The favorable change in operating expense margin for the three months ended March 31, 2022, was driven by income related to the change in fair value of acquisition-related stock options of $60 million relating to the increase in our investment in DECIEM during the fiscal 2021 fourth quarter, disciplined general and administrative expense management and the increase in net sales. Partially offsetting these favorable changes were the year-over-year impact of other intangible and long-lived asset impairments of $183 million, as well as higher shipping costs due to the increase in net sales volume and increased shipping rates.
The favorable change in operating expense margin for the nine months ended March 31, 2022, was driven by the increase in net sales, disciplined general and administrative expense management, the favorable impact from selling expenses, primarily due to the shift in channel mix to online, travel retail and specialty-multi, and income related to the change in fair value of acquisition-related stock options of $58 million relating to the increase in our investment in DECIEM during the fiscal 2021 fourth quarter. Partially offsetting these favorable changes in operating expense margin were the year-over-year impact of goodwill, other intangible and long-lived asset impairments of $102 million and higher shipping costs as discussed above.
51

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
OPERATING RESULTS

|  | Three Months Ended March 31 |  | Nine Months Ended March 31
($ in millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021
As Reported: |  |  |  |  |  |  |  |
Operating income |  | $ | 738 |  |  | $ | 616 |  |  | $ | 3,091 |  |  | $ | 2,384 |
$ Change from prior-year period |  | 122 |  |  |  |  | 707 |  |  |
% Change from prior-year period |  | 20 | % |  |  |  | 30 | % |  |
Operating margin |  | 17.4 | % |  | 15.9 | % |  | 21.8 | % |  | 19.4 | %
Non-GAAP Financial Measure(1): |  |  |  |  |  |  |  |
% Change in operating income from the prior-year period adjusting for the impact of charges associated with restructuring and other activities, goodwill, other intangible and long-lived asset impairments, the change in fair value of acquisition-related stock options and changes in fair value of contingent consideration |  | 15 | % |  |  |  | 23 | % |  |

(1)See “Reconciliations of Non-GAAP Financial Measures” beginning on page 58 for reconciliations between non-GAAP financial measures and the most directly comparable U.S. GAAP measures.
The increase in reported operating margin for the three and nine months ended March 31, 2022 from the prior-year period was primarily driven by the favorable changes in operating expense margin and gross margin, discussed above, partially offset by the year-over-year impact of goodwill, other intangible and long-lived asset impairments of $183 million and $102 million, respectively.
Charges associated with restructuring and other activities are not allocated to our product categories or geographic regions because they are centrally directed and controlled, are not included in internal measures of product category or geographic region performance and result from activities that are deemed Company-wide initiatives to redesign, resize and reorganize select areas of the business. Accordingly, the following discussions of Operating income by Product Categories and Geographic Regions exclude the impact of charges associated with restructuring and other activities.
Product Categories
Skin Care

|  | Three Months Ended March 31 |  | Nine Months Ended March 31
($ in millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021
As Reported: |  |  |  |  |  |  |  |
Operating income |  | $ | 667 |  |  | $ | 804 |  |  | $ | 2,466 |  |  | $ | 2,453 |
$ Change from prior-year period |  | (137) |  |  |  |  | 13 |  |  |
% Change from prior-year period |  | (17) | % |  |  |  | 1 | % |  |
Non-GAAP Financial Measure(1): |  |  |  |  |  |  |  |
% Change in operating income from the prior-year period adjusting for the impact of goodwill, other intangible and long-lived asset impairments and the change in fair value of acquisition-related stock options |  | 3 | % |  |  |  | 4 | % |  |

(1)See “Reconciliations of Non-GAAP Financial Measures” beginning on page 58 for reconciliations between non-GAAP financial measures and the most directly comparable U.S. GAAP measures.
52

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
Reported skin care operating income decreased for the three months ended March 31, 2022, reflecting the current year impact of other intangible asset impairments related to Dr.Jart+ and GLAMGLOW of approximately $216 million, combined, as well as lower results from Estée Lauder. The decrease in operating income from Estée Lauder was primarily due to the decrease in net sales.
Partially offsetting the decreases in operating income for the three months ended March 31, 2022 were higher results from La Mer primarily due to the increase in net sales, as well as $58 million of income related to the change in fair value of acquisition-related stock options relating to the increase in our investment in DECIEM during the fiscal 2021 fourth quarter.
Reported skin care operating income increased for the nine months ended March 31, 2022, reflecting higher results from La Mer, Bobbi Brown and Clinique of approximately $355 million, combined, and $56 million of income related to the change in fair value of acquisition-related stock options relating to the increase in our investment in DECIEM during the fiscal 2021 fourth quarter. The higher results for La Mer reflected the increase in net sales, partially offset by the increase in cost of sales primarily due to higher costs for promotional items and higher advertising and promotional activities primarily to support holiday and key shopping moments and new product launches. Operating income from Clinique increased, primarily due to higher net sales, partially offset by higher advertising and promotional activities primarily to support holiday and key shopping moments and new product launches.
Partially offsetting the increases in operating income for the nine months ended March 31, 2022 were the unfavorable year-over-year impact of goodwill and other intangible asset impairments related to Dr.Jart+ and GLAMGLOW of approximately $135 million, combined, as well as lower results from Estée Lauder. The decrease in operating income from Estée Lauder was primarily due to the decrease in net sales, the increase in cost of sales primarily due to higher costs for promotional items and higher advertising and promotional activities to support hero products, holiday and key shopping moments and new product launches.
Makeup

|  | Three Months Ended March 31 |  | Nine Months Ended March 31
($ in millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021
As Reported: |  |  |  |  |  |  |  |
Operating income (loss) |  | $ | 7 |  |  | $ | (72) |  |  | $ | 228 |  |  | $ | (115) |
$ Change from prior-year period |  | 79 |  |  |  |  | 343 |  |  |
% Change from prior-year period |  | 100+% |  |  |  | 100+% |  |
Non-GAAP Financial Measure(1): |  |  |  |  |  |  |  |
% Change in operating income from the prior-year period adjusting for the impact of long-lived asset impairments |  | 100+% |  |  |  | 100+ |  |

(1)See “Reconciliations of Non-GAAP Financial Measures” beginning on page 58 for reconciliations between non-GAAP financial measures and the most directly comparable U.S. GAAP measures.
Reported makeup operating income increased for the three months ended March 31, 2022, reflecting higher results from M·A·C, Clinique, Estée Lauder and La Mer of approximately $69 million, combined, and the favorable year-over-year impact of long-lived asset impairments of $24 million. Operating income from M·A·C increased due to the increase in net sales, partially offset by higher advertising and promotional activities to support new product launches and higher selling costs due to the brick-and-mortar recovery, including more stores being open and increased retail traffic compared to the prior year. The higher results from Clinique were primarily due to the increases in net sales, partially offset by higher selling costs due to the brick-and-mortar recovery and higher shipping costs. Operating income for Estée Lauder increased primarily due to the increase in net sales, partially offset by higher advertising and promotional activities relating to strategic investments to support the makeup recovery and digital advertising and social media spending. Operating income from La Mer increased primarily due to an increase in net sales, partially offset by higher cost of sales, due, in part to an increase in promotional items.
53

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
Reported makeup operating income increased for the nine months ended March 31, 2022, primarily driven by higher results from Estée Lauder and M·A·C of approximately $179 million, combined, reflecting the increases in net sales, partially offset by higher advertising and promotional activities as discussed above.
Fragrance

|  | Three Months Ended March 31 |  | Nine Months Ended March 31
($ in millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021
As Reported: |  |  |  |  |  |  |  |
Operating income |  | $ | 105 |  |  | $ | 47 |  |  | $ | 446 |  |  | $ | 248 |
$ Change from prior-year period |  | 58 |  |  |  |  | 198 |  |  |
% Change from prior-year period |  | 100+% |  |  |  | 80 | % |  |
Non-GAAP Financial Measure(1): |  |  |  |  |  |  |  |
% Change in operating income from the prior-year period adjusting for long-lived asset impairments and changes in fair value of contingent consideration |  | 88 | % |  |  |  | 75 | % |  |

(1)See “Reconciliations of Non-GAAP Financial Measures” beginning on page 58 for reconciliations between non-GAAP financial measures and the most directly comparable U.S. GAAP measures.
Reported fragrance operating income increased for the three and nine months ended March 31, 2022, primarily driven by higher results from Jo Malone London, Tom Ford Beauty and Le Labo, combined, of approximately $46 million and $171 million, respectively, as well as the favorable year-over-year impact of long-lived asset impairments of $9 million. In both periods, the higher results from Jo Malone London primarily reflected the increase in net sales, partially offset by higher cost of sales given the growth of the home subcategory and the increase in promotional items and the increase in selling costs resulting from the brick-and-mortar recovery. Also partially offsetting the increase in net sales from Jo Malone London for the nine months ended March 31, 2022, were higher advertising and promotional activities primarily to support in-store promotions given the increase in brick-and-mortar traffic and new product launches. Operating results from Tom Ford Beauty increased in both periods, primarily due to higher net sales, partially offset by higher cost of sales due, in part, to the increase in promotional items and the increase in advertising and promotional activities to support strategic investments in digital advertising and social media spending (including costs associated with influencers), hero product franchises, and new product launches. The increases in operating income from Le Labo, in both periods, was primarily driven by the increase in net sales.
Hair Care

|  | Three Months Ended March 31 |  | Nine Months Ended March 31
($ in millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021
As Reported: |  |  |  |  |  |  |  |
Operating loss |  | $ | (18) |  |  | $ | (17) |  |  | $ | (8) |  |  | $ | (10) |
$ Change from prior-year period |  | (1) |  |  |  |  | 2 |  |  |
% Change from prior-year period |  | (6) | % |  |  |  | 20 | % |  |

Reported hair care operating income decreased for the three months ended March 31, 2022, primarily driven by increased operating expenses to support the salon and retail story recovery, partially offset by increases in operating results from Bumble and bumble and Aveda, primarily due to the increases in net sales.
Reported hair care operating income increased for the nine months ended March 31, 2022, primarily driven by higher results from Bumble and bumble, primarily due to the increase in net sales.
54

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
Geographic Regions
The Americas

|  | Three Months Ended March 31 |  | Nine Months Ended March 31
($ in millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021
As Reported: |  |  |  |  |  |  |  |
Operating income |  | $ | 408 |  |  | $ | 155 |  |  | $ | 1,044 |  |  | $ | 256 |
$ Change from prior-year period |  | 253 |  |  |  |  | 788 |  |  |
% Change from prior-year period |  | 100+% |  |  |  | 100+% |  |
Non-GAAP Financial Measure(1): |  |  |  |  |  |  |  |
% Change in operating income from the prior-year period adjusting for the impact of goodwill and other intangible asset impairments and the change in fair value of acquisition-related stock options |  | 100+% |  |  |  | 100+% |  |

(1)See “Reconciliations of Non-GAAP Financial Measures” beginning on page 58 for reconciliations between non-GAAP financial measures and the most directly comparable U.S. GAAP measures.
Reported operating results increased in The Americas for the three months ended March 31, 2022, primarily reflecting higher operating results from North America of approximately $251 million, primarily due to the increase in net sales, higher intercompany royalty income primarily from growth in our travel retail business and $60 million of income related to the change in fair value of acquisition-related stock options relating to the increase in our investment in DECIEM during the fiscal 2021 fourth quarter, partially offset by an unfavorable year-over-year impact of other intangible asset impairments relating to GLAMGLOW of $11 million.
Reported operating results increased in The Americas for the nine months ended March 31, 2022, primarily reflecting higher operating results from North America of approximately $776 million, primarily due to the increase in net sales, higher intercompany royalty income primarily from growth in our travel retail business, favorable year-over-year impact of goodwill and other intangible asset impairments relating to GLAMGLOW of $70 million and $58 million of acquisition-related stock option income relating to the increase in our investment in DECIEM during the fiscal 2021 fourth quarter. Partially offsetting these increases in operating income were higher advertising and promotional activities, primarily to support strategic investments in digital advertising and social media spending and in-store promotions given the increase in brick-and-mortar traffic, and increases in selling expense due to the brick-and-mortar and makeup recovery compared to the prior-year.
Europe, the Middle East & Africa

|  | Three Months Ended March 31 |  | Nine Months Ended March 31
($ in millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021
As Reported: |  |  |  |  |  |  |  |
Operating income |  | $ | 281 |  |  | $ | 361 |  |  | $ | 1,366 |  |  | $ | 1,429 |
$ Change from prior-year period |  | (80) |  |  |  |  | (63) |  |  |
% Change from prior-year period |  | (22) | % |  |  |  | (4) | % |  |
Non-GAAP Financial Measure(1): |  |  |  |  |  |  |  |
% Change in operating income from the prior-year period adjusting for long-lived asset impairments and changes in contingent consideration |  | (29) | % |  |  |  | (6) | % |  |

(1)See “Reconciliations of Non-GAAP Financial Measures” beginning on page 58 for reconciliations between non-GAAP financial measures and the most directly comparable U.S. GAAP measures.
55

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
Reported operating income decreased in Europe, the Middle East & Africa for the three and nine months ended March 31, 2022, primarily driven by lower results from our travel retail business and the United Kingdom, combined, of approximately $121 million and $162 million, respectively. In both periods, operating income decreased in our travel retail business reflecting the (i) increase in intercompany royalty expense to The Americas primarily due to the growth of our travel retail business and (ii) higher shipping costs due to the increase in net sales volume and shipping rates. Also contributing to the decrease in operating income from our travel retail business was higher advertising and promotional activity primarily to support strategic investments in key areas of growth (primarily hero products and the skin care product category), as well as to capture the current-year increase in airport traffic. These higher expenses were partially offset by the increase in net sales. Operating income decreased in the United Kingdom in both periods, led by higher selling and store operations costs as more brick-and-mortar locations were open compared to the prior-year, partially offset by an increase in net sales.
Partially offsetting these decreases in operating income for the three and nine months ended March 31, 2022 were higher results from several affiliates across the region, reflecting the brick-and-mortar recovery, compared to the prior-year periods.
Asia/Pacific

|  | Three Months Ended March 31 |  | Nine Months Ended March 31
($ in millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021
As Reported: |  |  |  |  |  |  |  |
Operating income |  | $ | 72 |  |  | $ | 245 |  |  | $ | 725 |  |  | $ | 890 |
$ Change from prior-year period |  | (173) |  |  |  |  | (165) |  |  |
% Change from prior-year period |  | (71) | % |  |  |  | (19) | % |  |
Non-GAAP Financial Measure(1): |  |  |  |  |  |  |  |
% Change in operating income from the prior-year period adjusting for other intangible asset impairments |  | 13 | % |  |  |  | 4 | % |  |

(1)See “Reconciliations of Non-GAAP Financial Measures” beginning on page 58 for reconciliations between non-GAAP financial measures and the most directly comparable U.S. GAAP measures.
Reported operating income decreased in Asia/Pacific for the three and nine months ended December 31. 2021, reflecting the current year other intangible asset impairment relating to Dr. Jart+ of $205 million, partially offset by increases in operating results from other affiliates across the region due to the progression towards recovery.
INTEREST AND INVESTMENT INCOME

|  | Three Months Ended March 31 |  | Nine Months Ended March 31
(In millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021
Interest expense |  | $ | 41 |  |  | $ | 43 |  |  | $ | 125 |  |  | $ | 131 |
Interest income and investment income, net |  | $ | 5 |  |  | $ | 9 |  |  | $ | 19 |  |  | $ | 40 |

Interest income and investment income, net decreased primarily due to equity method investment income recognized in the prior-year period relating to our previously held equity method investment in DECIEM.
56

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
PROVISION FOR INCOME TAXES
The provision for income taxes represents U.S. federal, foreign, state and local income taxes. The effective rate differs from the federal statutory rate primarily due to the effect of state and local income taxes, the tax impact of share-based compensation, the taxation of foreign income and income tax reserve adjustments, which represent changes in our net liability for unrecognized tax benefits including tax settlements and lapses of the applicable statutes of limitations. Our effective tax rate will change from quarter-to-quarter based on recurring and non-recurring factors including the geographical mix of earnings, enacted tax legislation, state and local income taxes, tax reserve adjustments, the tax impact of share-based compensation, the interaction of various global tax strategies and the impact from certain acquisitions. In addition, changes in judgment from the evaluation of new information resulting in the recognition, derecognition or remeasurement of a tax position taken in a prior annual period are recognized separately in the quarter of change.

| Three Months Ended March 31 |  | Nine Months Ended March 31
| 2022 |  | 2021 |  | 2022 |  | 2021
Effective rate for income taxes | 18.5 | % |  | 21.0 | % |  | 21.1 | % |  | 18.5 | %
Basis-point change from the prior-year period | (250) |  |  |  |  | 260 |  |  |

The effective tax rate for the three and nine months ended March 31, 2021 included the retroactive impact relating to fiscal 2020 and 2019 of the U.S. government issuance of final global intangible low-taxed income (“GILTI”) tax regulations in July 2020 under the Tax Cuts and Jobs Act that provide for a high-tax exception to the GILTI tax. The impact of the final issuance of GILTI tax regulations with respect to fiscal 2020 and 2019 was recognized as a discrete item in the provision for income taxes in the second and third quarters of fiscal 2021 and resulted in reductions of 30 basis points and 220 basis points to the effective tax rates for the three and nine months ended March 31, 2021, respectively.
For the three months ended March 31, 2022, the decrease in the effective tax rate was primarily attributable to a lower effective tax rate on the Company's foreign operations, partially offset by a decrease in excess tax benefits associated with stock-based compensation arrangements.
For the nine months ended March 31, 2022, the increase in the effective tax rate was primarily attributable to a higher effective tax rate on the Company’s foreign operations, which includes the retroactive impact of the final GILTI tax regulations recognized in the prior period. Also contributing to the increase was a decrease in excess tax benefits associated with stock-based compensation arrangements.
NET EARNINGS ATTRIBUTABLE TO THE ESTÉE LAUDER COMPANIES INC.

|  | Three Months Ended March 31 |  | Nine Months Ended March 31
($ in millions, except per share data) |  | 2022 |  | 2021 |  | 2022 |  | 2021
As Reported: |  |  |  |  |  |  |  |
Net earnings attributable to The Estée Lauder Companies Inc. |  | $ | 558 |  |  | $ | 456 |  |  | $ | 2,338 |  |  | $ | 1,852 |
$ Change from prior-year period |  | 102 |  |  |  |  | 486 |  |  |
% Change from prior-year period |  | 22 | % |  |  |  | 26 | % |  |
Diluted net earnings per common share |  | $ | 1.53 |  |  | $ | 1.24 |  |  | $ | 6.39 |  |  | $ | 5.03 |
% Change from prior-year period |  | 24 | % |  |  |  | 27 | % |  |
Non-GAAP Financial Measure(1): |  |  |  |  |  |  |  |
% Change in diluted net earnings per common share from the prior-year period adjusting for the impact of charges associated with restructuring and other activities, goodwill, other intangible and long-lived asset impairments, the change in fair value of acquisition-related stock options and changes in fair value of contingent consideration |  | 17 | % |  |  |  | 20 | % |  |

(1)See “Reconciliations of Non-GAAP Financial Measures” below for reconciliations between non-GAAP financial measures and the most directly comparable U.S. GAAP measures.
57

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
RECONCILIATIONS OF NON-GAAP FINANCIAL MEASURES
We use certain non-GAAP financial measures, among other financial measures, to evaluate our operating performance, which represent the manner in which we conduct and view our business. Management believes that excluding certain items that are not comparable from period to period, or do not reflect the Company’s underlying ongoing business, provides transparency for such items and helps investors and others compare and analyze our operating performance from period to period. In the future, we expect to incur charges or adjustments similar in nature to those presented below; however, the impact to the Company’s results in a given period may be highly variable and difficult to predict. Our non-GAAP financial measures may not be comparable to similarly titled measures used by, or determined in a manner consistent with, other companies. While we consider the non-GAAP measures useful in analyzing our results, they are not intended to replace, or act as a substitute for, any presentation included in the consolidated financial statements prepared in conformity with U.S. GAAP. The following tables present Net sales, Operating income and Diluted net earnings per common share adjusted to exclude the impact of charges associated with restructuring and other activities; goodwill, other intangible and long-lived asset impairments; the changes in fair value of contingent consideration; the change in fair value of acquisition-related stock options; and the effects of foreign currency translation.
The following tables provide reconciliations between these non-GAAP financial measures and the most directly comparable U.S. GAAP measures.

($ in millions, except per share data) |  | Three Months Ended March 31 |  | Variance |  | % Change |  | % Change in constant currency
| 2022 |  | 2021 |  |  |
Net sales, as reported |  | $ | 4,245 |  |  | $ | 3,864 |  |  | $ | 381 |  |  | 10 | % |  | 11 | %
Returns associated with restructuring and other activities |  | 1 |  |  | 10 |  |  | (9) |  |  |  |  |
Net sales, as adjusted |  | $ | 4,246 |  |  | $ | 3,874 |  |  | $ | 372 |  |  | 10 | % |  | 11 | %
Operating income, as reported |  | $ | 738 |  |  | $ | 616 |  |  | $ | 122 |  |  | 20 | % |  | 18 | %
Charges associated with restructuring and other activities |  | 23 |  |  | 145 |  |  | (122) |  |  |  |  |
Other intangible and long-lived asset impairments |  | 216 |  |  | 33 |  |  | 183 |  |  |  |  |
Change in fair value of acquisition-related stock options |  | (60) |  |  | — |  |  | (60) |  |  |  |  |
Operating income, as adjusted |  | $ | 917 |  |  | $ | 794 |  |  | $ | 123 |  |  | 15 | % |  | 16 | %
Diluted net earnings per common share, as reported |  | $ | 1.53 |  |  | $ | 1.24 |  |  | $ | .29 |  |  | 24 | % |  | 22 | %
Charges associated with restructuring and other activities |  | .05 |  |  | .31 |  |  | (.26) |  |  |  |  |
Other intangible and long-lived asset impairments |  | .45 |  |  | .07 |  |  | .38 |  |  |  |  |
Change in fair value of acquisition-related stock options (less portion attributable to redeemable noncontrolling interest) |  | (.13) |  |  | — |  |  | (.13) |  |  |  |  |
Diluted net earnings per common share, as adjusted |  | $ | 1.90 |  |  | $ | 1.62 |  |  | $ | .28 |  |  | 17 | % |  | 18 | %

58

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.

($ in millions, except per share data) |  | Nine Months Ended March 31 |  | Variance |  | % Change |  | % Change in constant currency
| 2022 |  | 2021 |  |  |
Net sales, as reported |  | $ | 14,176 |  |  | $ | 12,279 |  |  | $ | 1,897 |  |  | 15 | % |  | 15 | %
Returns associated with restructuring and other activities |  | 3 |  |  | 10 |  |  | (7) |  |  |  |  |
Net sales, as adjusted |  | $ | 14,179 |  |  | $ | 12,289 |  |  | $ | 1,890 |  |  | 15 | % |  | 15 | %
Operating income, as reported |  | $ | 3,091 |  |  | $ | 2,384 |  |  | $ | 707 |  |  | 30 | % |  | 28 | %
Charges associated with restructuring and other activities |  | 44 |  |  | 191 |  |  | (147) |  |  |  |  |
Goodwill, other intangible and long-lived asset impairments |  | 216 |  |  | 114 |  |  | 102 |  |  |  |  |
Changes in fair value of contingent consideration |  | — |  |  | (2) |  |  | 2 |  |  |  |  |
Change in fair value of acquisition-related stock options |  | (58) |  |  | — |  |  | (58) |  |  |  |  |
Operating income, as adjusted |  | $ | 3,293 |  |  | $ | 2,687 |  |  | $ | 606 |  |  | 23 | % |  | 22 | %
Diluted net earnings per common share, as reported |  | $ | 6.39 |  |  | $ | 5.03 |  |  | $ | 1.36 |  |  | 27 | % |  | 25 | %
Charges associated with restructuring and other activities |  | .09 |  |  | .41 |  |  | (.32) |  |  |  |  |
Goodwill, other intangible and long-lived asset impairments |  | .45 |  |  | .25 |  |  | .20 |  |  |  |  |
Changes in fair value of contingent consideration |  | — |  |  | (.01) |  |  | .01 |  |  |  |  |
Change in fair value of acquisition-related stock options (less portion attributable to redeemable noncontrolling interest) |  | (.13) |  |  | — |  |  | (.13) |  |  |  |  |
Diluted net earnings per common share, as adjusted |  | $ | 6.80 |  |  | $ | 5.68 |  |  | $ | 1.12 |  |  | 20 | % |  | 19 | %

As diluted net earnings per common share, as adjusted, is used as a measure of the Company’s performance, we consider the impact of current and deferred income taxes when calculating the per-share impact of each of the reconciling items.
59

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
The following tables reconcile the change in net sales by product category and geographic region, as reported, to the change in net sales excluding the effects of foreign currency translation:

|  | As Reported |  | Impact of foreign currency translation |  | Variance, in constant currency |  | % Change, as reported |  | % Change, in constant currency
|  | Three Months Ended March 31 |  |  |  |  |  |
($ in millions) |  | 2022 |  | 2021 |  | Variance |  |  |  |
By Product Category: |  |  |  |  |  |  |  |  |  |  |  |  |  |
Skin Care |  | $ | 2,395 |  |  | $ | 2,259 |  |  | $ | 136 |  |  | $ | 16 |  |  | $ | 152 |  |  | 6 | % |  | 7 | %
Makeup |  | 1,114 |  |  | 1,018 |  |  | 96 |  |  | 19 |  |  | 115 |  |  | 9 |  |  | 11 |
Fragrance |  | 579 |  |  | 454 |  |  | 125 |  |  | 14 |  |  | 139 |  |  | 28 |  |  | 31 |
Hair Care |  | 147 |  |  | 128 |  |  | 19 |  |  | 3 |  |  | 22 |  |  | 15 |  |  | 17 |
Other |  | 11 |  |  | 15 |  |  | (4) |  |  | — |  |  | (4) |  |  | (27) |  |  | (27) |
|  | 4,246 |  |  | 3,874 |  |  | 372 |  |  | 52 |  |  | 424 |  |  | 10 |  |  | 11 |
Returns associated with restructuring and other activities |  | (1) |  |  | (10) |  |  | 9 |  |  | (1) |  |  | 8 |  |  |  |  |
Total |  | $ | 4,245 |  |  | $ | 3,864 |  |  | $ | 381 |  |  | $ | 51 |  |  | $ | 432 |  |  | 10 | % |  | 11 | %
By Region: |  |  |  |  |  |  |  |  |  |  |  |  |  |
The Americas |  | $ | 1,053 |  |  | $ | 916 |  |  | $ | 137 |  |  | $ | (6) |  |  | $ | 131 |  |  | 15 | % |  | 14 | %
Europe, the Middle East & Africa |  | 1,990 |  |  | 1,706 |  |  | 284 |  |  | 47 |  |  | 331 |  |  | 17 |  |  | 19 |
Asia/Pacific |  | 1,203 |  |  | 1,252 |  |  | (49) |  |  | 11 |  |  | (38) |  |  | (4) |  |  | (3) |
|  | 4,246 |  |  | 3,874 |  |  | 372 |  |  | 52 |  |  | 424 |  |  | 10 |  |  | 11 |
Returns associated with restructuring and other activities |  | (1) |  |  | (10) |  |  | 9 |  |  | (1) |  |  | 8 |  |  |  |  |
Total |  | $ | 4,245 |  |  | $ | 3,864 |  |  | $ | 381 |  |  | $ | 51 |  |  | $ | 432 |  |  | 10 | % |  | 11 | %

60

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.

|  | As Reported |  | Impact of foreign currency translation |  | Variance, in constant currency |  | % Change, as reported |  | % Change, in constant currency
|  | Nine Months Ended March 31 |  |  |  |  |  |
($ in millions) |  | 2022 |  | 2021 |  | Variance |  |  |  |
By Product Category: |  |  |  |  |  |  |  |  |  |  |  |  |  |
Skin Care |  | $ | 8,003 |  |  | $ | 7,113 |  |  | $ | 890 |  |  | $ | (57) |  |  | $ | 833 |  |  | 13 | % |  | 12 | %
Makeup |  | 3,674 |  |  | 3,243 |  |  | 431 |  |  | 14 |  |  | 445 |  |  | 13 |  |  | 14 |
Fragrance |  | 1,987 |  |  | 1,478 |  |  | 509 |  |  | 8 |  |  | 517 |  |  | 34 |  |  | 35 |
Hair Care |  | 475 |  |  | 418 |  |  | 57 |  |  | 3 |  |  | 60 |  |  | 14 |  |  | 14 |
Other |  | 40 |  |  | 37 |  |  | 3 |  |  | — |  |  | 3 |  |  | 8 |  |  | 8 |
|  | 14,179 |  |  | 12,289 |  |  | 1,890 |  |  | (32) |  |  | 1,858 |  |  | 15 |  |  | 15 |
Returns associated with restructuring and other activities |  | (3) |  |  | (10) |  |  | 7 |  |  | (1) |  |  | 6 |  |  |  |  |
Total |  | $ | 14,176 |  |  | $ | 12,279 |  |  | $ | 1,897 |  |  | $ | (33) |  |  | $ | 1,864 |  |  | 15 | % |  | 15 | %
By Region: |  |  |  |  |  |  |  |  |  |  |  |  |  |
The Americas |  | $ | 3,547 |  |  | $ | 2,837 |  |  | $ | 710 |  |  | $ | (13) |  |  | $ | 697 |  |  | 25 | % |  | 25 | %
Europe, the Middle East & Africa |  | 6,201 |  |  | 5,276 |  |  | 925 |  |  | 45 |  |  | 970 |  |  | 18 |  |  | 18 |
Asia/Pacific |  | 4,431 |  |  | 4,176 |  |  | 255 |  |  | (64) |  |  | 191 |  |  | 6 |  |  | 5 |
|  | 14,179 |  |  | 12,289 |  |  | 1,890 |  |  | (32) |  |  | 1,858 |  |  | 15 |  |  | 15 |
Returns associated with restructuring and other activities |  | (3) |  |  | (10) |  |  | 7 |  |  | (1) |  |  | 6 |  |  |  |  |
Total |  | $ | 14,176 |  |  | $ | 12,279 |  |  | $ | 1,897 |  |  | $ | (33) |  |  | $ | 1,864 |  |  | 15 | % |  | 15 | %

61

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
The following tables reconcile the change in operating results by product category and geographic region, as reported, to the change in operating income excluding the impact of goodwill, other intangible and long-lived asset impairments and changes in fair value of contingent consideration:

|  | As Reported |  | Add: Changes in Other intangible and long-lived asset impairments |  | Add: Changes in fair value of contingent consideration |  | Add: Change in fair value of acquisition-related stock options |  | Variance, as adjusted |  | % Change, as reported |  | % Change, as adjusted
|  | Three Months Ended March 31 |  |  |  |  |  |  |  |
($ in millions) |  | 2022 |  | 2021 |  | Variance |  |  |  |  |  |
By Product Category: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Skin Care |  | $ | 667 |  |  | $ | 804 |  |  | $ | (137) |  |  | $ | 216 |  |  | $ | — |  |  | $ | (58) |  |  | $ | 21 |  |  | (17) | % |  | 3 | %
Makeup |  | 7 |  |  | (72) |  |  | 79 |  |  | (24) |  |  | — |  |  | (2) |  |  | 53 |  |  | 100+ |  | 100+
Fragrance |  | 105 |  |  | 47 |  |  | 58 |  |  | (9) |  |  | — |  |  | — |  |  | 49 |  |  | 100+ |  | 88 |
Hair Care |  | (18) |  |  | (17) |  |  | (1) |  |  | — |  |  | — |  |  | — |  |  | (1) |  |  | (6) |  |  | (6) |
Other |  | — |  |  | (1) |  |  | 1 |  |  | — |  |  | — |  |  | — |  |  | 1 |  |  | 100+ |  | 100 |
|  | 761 |  |  | 761 |  |  | — |  |  | $ | 183 |  |  | $ | — |  |  | $ | (60) |  |  | $ | 123 |  |  | — | % |  | 15 | %
Charges associated with restructuring and other activities |  | (23) |  |  | (145) |  |  | 122 |  |  |  |  |  |  |  |  |  |  |  |  |
Total |  | $ | 738 |  |  | $ | 616 |  |  | $ | 122 |  |  |  |  |  |  |  |  |  |  |  |  |
By Region: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
The Americas |  | $ | 408 |  |  | $ | 155 |  |  | $ | 253 |  |  | $ | 11 |  |  | — |  |  | $ | (60) |  |  | $ | 204 |  |  | 100+% |  | 100+%
Europe, the Middle East & Africa |  | 281 |  |  | 361 |  |  | (80) |  |  | (33) |  |  | — |  |  | — |  |  | (113) |  |  | (22) |  |  | (29) |
Asia/Pacific |  | 72 |  |  | 245 |  |  | (173) |  |  | 205 |  |  | — |  |  | — |  |  | 32 |  |  | (71) |  |  | 13 |
|  | 761 |  |  | 761 |  |  | — |  |  | $ | 183 |  |  | $ | — |  |  | $ | (60) |  |  | $ | 123 |  |  | — | % |  | 15 | %
Charges associated with restructuring and other activities |  | (23) |  |  | (145) |  |  | 122 |  |  |  |  |  |  |  |  |  |  |  |  |
Total |  | $ | 738 |  |  | $ | 616 |  |  | $ | 122 |  |  |  |  |  |  |  |  |  |  |  |  |

62

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.

|  | As Reported |  | Add: Changes in Goodwill, other intangible and long-lived asset impairments |  | Add: Changes in fair value of contingent consideration |  | Add: Change in fair value of acquisition-related stock options |  | Variance, as adjusted |  | % Change, as reported |  | % Change, as adjusted
|  | Nine Months Ended March 31 |  |  |  |  |  |  |  |
($ in millions) |  | 2022 |  | 2021 |  | Variance |  |  |  |  |  |
By Product Category: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Skin Care |  | $ | 2,466 |  |  | $ | 2,453 |  |  | $ | 13 |  |  | $ | 135 |  |  |  |  | $ | (56) |  |  | $ | 92 |  |  | 1 | % |  | 4 | %
Makeup |  | 228 |  |  | (115) |  |  | 343 |  |  | (24) |  |  | — |  |  | (2) |  |  | 317 |  |  | 100+ |  | 100+
Fragrance |  | 446 |  |  | 248 |  |  | 198 |  |  | (9) |  |  | 2 |  |  | — |  |  | 191 |  |  | 80 |  |  | 75 |
Hair Care |  | (8) |  |  | (10) |  |  | 2 |  |  | — |  |  | — |  |  | — |  |  | 2 |  |  | 20 |  |  | 20
Other |  | 3 |  |  | (1) |  |  | 4 |  |  | — |  |  | — |  |  | — |  |  | 4 |  |  | 100+ |  | 100+
|  | 3,135 |  |  | 2,575 |  |  | 560 |  |  | $ | 102 |  |  | $ | 2 |  |  | $ | (58) |  |  | $ | 606 |  |  | 22 | % |  | 23 | %
Charges associated with restructuring and other activities |  | (44) |  |  | (191) |  |  | 147 |  |  |  |  |  |  |  |  |  |  |  |  |
Total |  | $ | 3,091 |  |  | $ | 2,384 |  |  | $ | 707 |  |  |  |  |  |  |  |  |  |  |  |  |
By Region: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
The Americas |  | $ | 1,044 |  |  | $ | 256 |  |  | $ | 788 |  |  | $ | (70) |  |  | $ | — |  |  | $ | (58) |  |  | $ | 660 |  |  | 100+% |  | 100+%
Europe, the Middle East & Africa |  | 1,366 |  |  | 1,429 |  |  | (63) |  |  | (33) |  |  | 2 |  |  | — |  |  | (94) |  |  | (4) |  |  | (6) |
Asia/Pacific |  | 725 |  |  | 890 |  |  | (165) |  |  | 205 |  |  | — |  |  | — |  |  | 40 |  |  | (19) |  |  | 4 |
|  | 3,135 |  |  | 2,575 |  |  | 560 |  |  | $ | 102 |  |  | $ | 2 |  |  | $ | (58) |  |  | $ | 606 |  |  | 22 | % |  | 23 | %
Charges associated with restructuring and other activities |  | (44) |  |  | (191) |  |  | 147 |  |  |  |  |  |  |  |  |  |  |  |  |
Total |  | $ | 3,091 |  |  | $ | 2,384 |  |  | $ | 707 |  |  |  |  |  |  |  |  |  |  |  |  |

FINANCIAL CONDITION
LIQUIDITY AND CAPITAL RESOURCES
Overview
Our principal sources of funds historically have been cash flows from operations, borrowings pursuant to our commercial paper program, borrowings from the issuance of long-term debt and committed and uncommitted credit lines provided by banks and other lenders in the United States and abroad. At March 31, 2022, we had cash and cash equivalents of $3,836 million compared with $4,958 million at June 30, 2021. Our cash and cash equivalents are maintained at a number of financial institutions. To mitigate the risk of uninsured balances, we select financial institutions based on their credit ratings and financial strength, and we perform ongoing evaluations of these institutions to limit our concentration risk exposure.
Based on past performance and current expectations, we believe that cash on hand, cash generated from operations, available credit lines and access to credit markets will be adequate to support seasonal working capital needs, currently planned business operations, information technology enhancements, capital expenditures, acquisitions, dividends, stock repurchases, restructuring initiatives, commitments and other contractual obligations on both a near-term and long-term basis.
The Tax Cuts and Jobs Act (“TCJA”) resulted in the Transition Tax on unrepatriated earnings of our foreign subsidiaries and changed the tax law in ways that present opportunities to repatriate cash without additional U.S. federal income tax. As a result, we changed our indefinite reinvestment assertion related to certain foreign earnings, and we continue to analyze the indefinite reinvestment assertion on our remaining applicable foreign earnings. We do not believe that continuing to reinvest our foreign earnings impairs our ability to meet our domestic debt or working capital obligations. If these reinvested earnings were repatriated into the United States as dividends, we would be subject to state income taxes and applicable foreign taxes in certain jurisdictions.
The effects of inflation have not been significant to our overall operating results in recent years, however we are mindful of increasing inflationary pressures. Generally, we have been able to introduce new products at higher prices, increase prices and implement other operating efficiencies to sufficiently offset cost increases.
63

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
Credit Ratings
Changes in our credit ratings will likely result in changes in our borrowing costs. Our credit ratings also impact the cost of our revolving credit facility. Downgrades in our credit ratings may reduce our ability to issue commercial paper and/or long-term debt and would likely increase the relative costs of borrowing. A credit rating is not a recommendation to buy, sell, or hold securities, is subject to revision or withdrawal at any time by the assigning rating organization, and should be evaluated independently of any other rating. As of April 26, 2022, our long-term debt is rated A+ with a stable outlook by Standard & Poor’s and A1 with a stable outlook by Moody’s.
Debt
At March 31, 2022, our outstanding borrowings were as follows:

($ in millions) |  | Long-term Debt |  | Current Debt |  | Total Debt
3.125% Senior Notes, due December 1, 2049 (“2049 Senior Notes”) (1), (13) |  | $ | 636 |  |  | $ | — |  |  | $ | 636 |
4.15% Senior Notes, due March 15, 2047 (“2047 Senior Notes”) (2), (13) |  | 494 |  |  | — |  |  | 494 |
4.375% Senior Notes, due June 15, 2045 (“2045 Senior Notes”) (3), (13) |  | 455 |  |  | — |  |  | 455 |
3.70% Senior Notes, due August 15, 2042 (“2042 Senior Notes”) (4), (13) |  | 247 |  |  | — |  |  | 247 |
6.00% Senior Notes, due May 15, 2037 (“2037 Senior Notes”) (5), (13) |  | 294 |  |  | — |  |  | 294 |
5.75% Senior Notes, due October 15, 2033 (“2033 Senior Notes”) (6) |  | 197 |  |  | — |  |  | 197 |
1.950% Senior Notes, due March 15, 2031 ("2031 Senior Notes") (7), (13) |  | 574 |  |  | — |  |  | 574 |
2.600% Senior Notes, due April 15, 2030 ("2030 Senior Notes") (8), (13) |  | 643 |  |  | — |  |  | 643 |
2.375% Senior Notes, due December 1, 2029 (“2029 Senior Notes”) (9), (13) |  | 642 |  |  | — |  |  | 642 |
3.15% Senior Notes, due March 15, 2027 (“2027 Senior Notes”) (10), (13) |  | 498 |  |  | — |  |  | 498 |
2.00% Senior Notes, due December 1, 2024 (“2024 Senior Notes”) (11), (13) |  | 497 |  |  | — |  |  | 497 |
2.35% Senior Notes, due August 15, 2022 (“2022 Senior Notes”) (12), (13) |  | — |  |  | 251 |  |  | 251 |
Other long-term borrowings |  | 11 |  |  | — |  |  | 11 |
Other current borrowings |  | — |  |  | 18 |  |  | 18 |
|  | $ | 5,188 |  |  | $ | 269 |  |  | $ | 5,457 |

(1)Consists of $650 million principal, unamortized debt discount of $7 million and debt issuance costs of $7 million.
(2)Consists of $500 million principal, unamortized debt discount of $1 million and debt issuance costs of $5 million.
(3)Consists of $450 million principal, net unamortized debt premium of $9 million and debt issuance costs of $4 million.
(4)Consists of $250 million principal, unamortized debt discount of $1 million and debt issuance costs of $2 million.
(5)Consists of $300 million principal, unamortized debt discount of $3 million and debt issuance costs of $3 million.
(6)Consists of $200 million principal, unamortized debt discount of $2 million and debt issuance costs of $1 million.
(7)Consists of $600 million, principal, unamortized debt discount of $4 million, debt issuance costs of $4 million and a $18 million loss to reflect the fair value of interest rate swaps.
(8)Consists of $700 million principal, unamortized debt discount of $1 million, debt issuance costs of $3 million and a $53 million loss to reflect the fair value of interest rate swaps.
(9)Consists of $650 million principal, unamortized debt discount of $5 million and debt issuance costs of $3 million.
(10)Consists of $500 million principal and debt issuance costs of $2 million.
(11)Consists of $500 million principal, unamortized debt discount of $2 million and debt issuance costs of $1 million.
(12)Consists of $250 million principal and a $1 million gain to reflect the fair value of interest rate swaps.
(13)The Senior Notes contain certain customary incurrence–based covenants, including limitations on indebtedness secured by liens.
Total debt as a percent of total capitalization (excluding noncontrolling interests) was 47% and 48% at March 31, 2022 and June 30, 2021, respectively.
64

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
Cash Flows

|  | Nine Months Ended March 31
(In millions) |  | 2022 |  | 2021
Net cash flows provided by operating activities |  | $ | 1,969 |  |  | $ | 2,777 |
Net cash flows used for investing activities |  | $ | (563) |  |  | $ | (577) |
Net cash flows used for financing activities |  | $ | (2,516) |  |  | $ | (862) |

The change in net cash flows from operating activities primarily reflected higher working capital needs to support growth compared to the prior-year period and actions taken to mitigate global supply chain challenges, as well as higher cash paid for taxes. These changes were partially offset by higher earnings before taxes, excluding non-cash items.
The change in net cash flows used for investing activities primarily reflected an increase in capital expenditures, primarily driven by increased investments for a new manufacturing facility in Japan, online capabilities and information technology enhancements, as well as investments to support the reopening of our offices located around the world where COVID-19 cases subsided. Partially offsetting this increase is a favorable impact from the settlement of net investment hedges, which has a corresponding unfavorable impact that is reflected in the change in working capital noted above.
The change in net cash flows used for financing activities primarily reflected an increase relating to higher treasury stock repurchases and proceeds from the issuance of long-term debt, net in the prior-year period, partially offset by the repayment of short-term debt made in the prior-year period.
Dividends
For a summary of quarterly cash dividends declared per share on our Class A and Class B Common Stock during the nine months ended March 31, 2022, see Notes to Consolidated Financial Statements, Note 12 – Equity and Redeemable Noncontrolling Interest.
Pension and Post-retirement Plan Funding
There have been no significant changes to our pension and post-retirement funding as discussed in our Annual Report on Form 10-K for the fiscal year ended June 30, 2021.
Commitments, Contractual Obligations and Contingencies
There have been no significant changes to our commitments and contractual obligations as discussed in our Annual Report on Form 10-K for the fiscal year ended June 30, 2021. For a discussion of contingencies, see Notes to Consolidated Financial Statements, Note 9 – Contingencies.
Derivative Financial Instruments and Hedging Activities
For a discussion of our derivative financial instruments and hedging activities, see Notes to Consolidated Financial Statements, Note 5 – Derivative Financial Instruments.
Foreign Exchange Risk Management
For a discussion of foreign exchange risk management, see Notes to Consolidated Financial Statements, Note 5 – Derivative Financial Instruments (Cash Flow Hedges, Net Investment Hedges).
Credit Risk
For a discussion of credit risk, see Notes to Consolidated Financial Statements, Note 5 – Derivative Financial Instruments (Credit Risk).
65

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
Market Risk
We address certain financial exposures through a controlled program of market risk management that includes the use of foreign currency forward contracts to reduce the effects of fluctuating foreign currency exchange rates and to mitigate the change in fair value of specific assets and liabilities on the balance sheet. To perform a sensitivity analysis of our foreign currency forward contracts, we assess the change in fair values from the impact of hypothetical changes in foreign currency exchange rates. A hypothetical 10% weakening of the U.S. dollar against the foreign exchange rates for the currencies in our portfolio would have resulted in a net decrease in the fair value of our portfolio of approximately $258 million and $218 million as of March 31, 2022 and June 30, 2021, respectively. This potential change does not consider our underlying foreign currency exposures.
In addition, we enter into interest rate derivatives to manage the effects of interest rate movements on our aggregate liability portfolio, including future debt issuances. Based on a hypothetical 100 basis point increase in interest rates, the estimated fair value of our interest rate derivatives would decrease by approximately $41 million and $83 million as of March 31, 2022 and June 30, 2021, respectively.
Our sensitivity analysis represents an estimate of reasonably possible net losses that would be recognized on our portfolio of derivative financial instruments assuming hypothetical movements in future market rates and is not necessarily indicative of actual results, which may or may not occur. It does not represent the maximum possible loss or any expected loss that may occur, since actual future gains and losses will differ from those estimated, based upon actual fluctuations in market rates, operating exposures, and the timing thereof, and changes in our portfolio of derivative financial instruments during the year. We believe, however, that any such loss incurred would be offset by the effects of market rate movements on the respective underlying transactions for which the derivative financial instrument was intended.
OFF-BALANCE SHEET ARRANGEMENTS
We do not maintain any off-balance sheet arrangements, transactions, obligations or other relationships with unconsolidated entities that would be expected to have a material current or future effect upon our financial condition or results of operations.
CRITICAL ACCOUNTING POLICIES
As disclosed in our Annual Report on Form 10-K for the fiscal year ended June 30, 2021, the discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in conformity with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the amounts of assets, liabilities, revenues and expenses reported in those financial statements. These estimates and assumptions can be subjective and complex, and consequently, actual results could differ from those estimates. Our most critical accounting policies relate to goodwill, other intangible assets and long-lived assets, income taxes and business combinations. Since June 30, 2021, there have been no significant changes to the assumptions and estimates related to our critical accounting policies.
RECENTLY ISSUED ACCOUNTING STANDARDS
For a discussion regarding the impact of accounting standards that were recently issued but not yet effective, on the Company’s consolidated financial statements, see Notes to Consolidated Financial Statements, Note 1 – Summary of Significant Accounting Policies.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION
We and our representatives from time to time make written or oral forward-looking statements, including in this and other filings with the Securities and Exchange Commission, in our press releases and in our reports to stockholders, which may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may address our expectations regarding sales, earnings or other future financial performance and liquidity, other performance measures, product introductions, entry into new geographic regions, information technology initiatives, new methods of sale, our long-term strategy, restructuring and other charges and resulting cost savings, and future operations or operating results. These statements may contain words like “expect,” “will,” “will likely result,” “would,” “believe,” “estimate,” “planned,” “plans,” “intends,” “may,” “should,” “could,” “anticipate,” “estimate,” “project,” “projected,” “forecast,” and “forecasted” or similar expressions. Although we believe that our expectations are based on reasonable assumptions within the bounds of our knowledge of our business and operations, actual results may differ materially from our expectations. Factors that could cause actual results to differ from expectations include, without limitation:
66

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
(1)increased competitive activity from companies in the skin care, makeup, fragrance and hair care businesses;
(2)our ability to develop, produce and market new products on which future operating results may depend and to successfully address challenges in our business;
(3)consolidations, restructurings, bankruptcies and reorganizations in the retail industry causing a decrease in the number of stores that sell our products, an increase in the ownership concentration within the retail industry, ownership of retailers by our competitors or ownership of competitors by our customers that are retailers and our inability to collect receivables;
(4)destocking and tighter working capital management by retailers;
(5)the success, or changes in timing or scope, of new product launches and the success, or changes in timing or scope, of advertising, sampling and merchandising programs;
(6)shifts in the preferences of consumers as to where and how they shop;
(7)social, political and economic risks to our foreign or domestic manufacturing, distribution and retail operations, including changes in foreign investment and trade policies and regulations of the host countries and of the United States;
(8)changes in the laws, regulations and policies (including the interpretations and enforcement thereof) that affect, or will affect, our business, including those relating to our products or distribution networks, changes in accounting standards, tax laws and regulations, environmental or climate change laws, regulations or accords, trade rules and customs regulations, and the outcome and expense of legal or regulatory proceedings, and any action we may take as a result;
(9)foreign currency fluctuations affecting our results of operations and the value of our foreign assets, the relative prices at which we and our foreign competitors sell products in the same markets and our operating and manufacturing costs outside of the United States;
(10)changes in global or local conditions, including those due to volatility in the global credit and equity markets, natural or man-made disasters, real or perceived epidemics, supply chain challenges, inflation, or increased energy costs, that could affect consumer purchasing, the willingness or ability of consumers to travel and/or purchase our products while traveling, the financial strength of our customers, suppliers or other contract counterparties, our operations, the cost and availability of capital which we may need for new equipment, facilities or acquisitions, the returns that we are able to generate on our pension assets and the resulting impact on funding obligations, the cost and availability of raw materials and the assumptions underlying our critical accounting estimates;
(11)impacts attributable to the COVID-19 pandemic, including disruptions to our global business;
(12)shipment delays, commodity pricing, depletion of inventory and increased production costs resulting from disruptions of operations at any of the facilities that manufacture our products or at our distribution or inventory centers, including disruptions that may be caused by the implementation of information technology initiatives, or by restructurings;
(13)real estate rates and availability, which may affect our ability to increase or maintain the number of retail locations at which we sell our products and the costs associated with our other facilities;
(14)changes in product mix to products which are less profitable;
(15)our ability to acquire, develop or implement new information and distribution technologies and initiatives on a timely basis and within our cost estimates and our ability to maintain continuous operations of such systems and the security of data and other information that may be stored in such systems or other systems or media;
(16)our ability to capitalize on opportunities for improved efficiency, such as publicly-announced strategies and restructuring and cost-savings initiatives, and to integrate acquired businesses and realize value therefrom;
67

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
(17)consequences attributable to local or international conflicts around the world, as well as from any terrorist action, retaliation and the threat of further action or retaliation;
(18)the timing and impact of acquisitions, investments and divestitures; and
(19)additional factors as described in our filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the fiscal year ended June 30, 2021.
We assume no responsibility to update forward-looking statements made herein or otherwise.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
The information required by this item is set forth in Item 2 of this Quarterly Report on Form 10-Q under the caption Liquidity and Capital Resources - Market Risk and is incorporated herein by reference.
Item 4. Controls and Procedures.
Our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission and to ensure that information required to be disclosed is accumulated and communicated to management, including our principal executive and financial officers, to allow timely decisions regarding disclosure. The Chief Executive Officer and the Chief Financial Officer, with assistance from other members of management, have reviewed the effectiveness of our disclosure controls and procedures as of March 31, 2022 and, based on their evaluation, have concluded that the disclosure controls and procedures were effective as of such date.
As part of our review of internal control over financial reporting, we make changes to systems and processes to improve such controls and increase efficiencies, including from the impacts of COVID-19, while ensuring that we maintain an effective internal control environment. There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the third quarter of fiscal 2022 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
PART II. OTHER INFORMATION
Item 1. Legal Proceedings.
For a discussion of legal proceedings, see Notes to Consolidated Financial Statements, Note 9 – Contingencies.
68

Table of Contents
THE ESTÉE LAUDER COMPANIES INC.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Share Repurchase Program
We are authorized by the Board of Directors to repurchase shares of our Class A Common Stock in the open market or in privately negotiated transactions, depending on market conditions and other factors. The following table provides information relating to our repurchase of Class A Common Stock during the referenced periods:

Period |  | Total Number of Shares Purchased(1) |  | Average Price Paid Per Share |  | Total Number of Shares Purchased as Part of Publicly Announced Program |  | Maximum Number of Shares that May Yet Be Purchased Under the Program(2)
January 2022 |  | 845,738 |  | $ | 325.44 |  |  | 838,246 |  | 28,006,703
February 2022 |  | 365,988 |  | 303.78 |  |  | 365,988 |  | 27,640,715
March 2022 |  | 673,197 |  | 273.06 |  |  | 673,161 |  | 26,967,554
|  | 1,884,923 |  | 302.53 |  |  | 1,877,395 |  |

(1)Includes shares that were repurchased by the Company to satisfy tax withholding obligations upon the payout of certain stock-based compensation arrangements.
(2)The Board of Directors has authorized the current repurchase program for up to 80.0 million shares. The total amount was last increased by the Board on October 31, 2018. Our repurchase program does not have an expiration date.
Subsequent to March 31, 2022 and as of April 26, 2022, we purchased approximately 0.6 million additional shares of our Class A Common Stock for $154 million pursuant to our share repurchase program.
Item 6. Exhibits.

Exhibit Number |  | Description
10.1 |  | Amendment to amended and restated The Estée Lauder Companies Retirement Growth Account Plan, effective as of May 31, 2022 (SEC File No. 1-14064).†
31.1 |  | Certification pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (CEO).
31.2 |  | Certification pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (CFO).
32.1 |  | Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (CEO). (furnished)
32.2 |  | Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (CFO). (furnished)
101.1 |  | The following materials from The Estée Lauder Companies Inc.’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022 are formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the Consolidated Statements of Earnings, (ii) the Consolidated Statements of Comprehensive Income, (iii) the Consolidated Balance Sheets, (iv) the Consolidated Statements of Cash Flows and (v) Notes to Consolidated Financial Statements
104 |  | The cover page from The Estée Lauder Companies Inc.’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022 is formatted in iXBRL
*Incorporated herein by reference.
† Exhibit is a management contract or compensatory plan or arrangement.

69

Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

| THE ESTÉE LAUDER COMPANIES INC.
| By: | /s/ TRACEY T. TRAVIS
Date: May 3, 2022 |  | Tracey T. Travis
|  | Executive Vice President and Chief Financial Officer
|  | (Principal Financial and Accounting Officer)

70